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Oesophageal adenocarcinoma is an aggressive malignancy and is associated with extremely 
poor rates of survival.  Its only known precursor is Barrett’s oesophagus, which is a metaplasia 
that occurs in the lower oesophagus in response to gastro-oesophageal reflux.  Despite a 
number of recent advances, such as the introduction of neoadjuvant therapy and minimally 
invasive techniques, there has only been a modest improvement in overall survival over the 
last few decades.  One factor that has contributed to this is the limited availability of well-
validated, clinically relevant models for research purposes.  Therefore, the aim of this thesis, 
was to develop novel preclinical models for the study of Barrett’s carcinogenesis. 
 
Central to this thesis was the optimisation of the patient-derived tumour xenograft model.  
This is a model in which immunodeficient mice are used as hosts in order to culture pieces of 
human tumour.  Once established, the model provides a perpetual source of tumour tissue.  
Unfortunately, they have been difficult to establish in oesophageal adenocarcinoma using 
conventional techniques.  Through the use of a novel intramuscular transplantation 
technique, the efficiency of the model has been greatly improved.  Validation has also 
confirmed that the majority of derived xenografts are representative of the original patient 
tumour.  Importantly, however, validation also confirmed that a subset had undergone 
lymphomagenic transformation and were no longer representative of the original tumour.   
 
Following on from the success of the intramuscular xenograft technique, the model was 
subsequently used as a source of tissue for the generation of much needed cell lines.  Using 
small pieces of xenograft tissue, rather than single cell suspensions, a robust technique was 
established for the generation of cell lines.  In doing so, a cell line was established that had 
both metastatic and non-metastatic clones, making it a valuable tool for cancer research.  
Finally, the intramuscular transplantation technique was also used to successfully culture both 
normal human oesophageal tissue and metaplastic tissue.  Validation of this model also 
confirmed that the cultured tissue recapitulated the human disease process.  
 
In addition to the development and validation of multiple novel models for the study of 
Barrett’s carcinogenesis, this thesis also begins to explore how these models can be used to 
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Oesophageal cancer is an extremely aggressive cancer and is associated with very poor 
survival.  Worldwide, it is the eighth most common cancer and the sixth leading cause of 
cancer related death, posing a significant health burden (Ferlay, Shin, Bray, Forman, Mathers 
et al., 2010).  There are two main subtypes of oesophageal caner; oesophageal squamous cell 
carcinoma (SCC) and oesophageal adenocarcinoma (OAC).  Despite key differences with 
respect to risk factor profiles, tumour distribution and responses to therapy, both subtypes 
are treated in a similar fashion.  Whilst the incidence of SCC predominates in developing 
countries, OAC has recently superseded SCC as the most common subtype in the developed 
world (Pohl & Welch, 2005).  In order to fully understand this disease process, a clear 
knowledge of the structure, function and development of the normal human oesophagus is 
required. 
 
1.2 The structure and function of the human oesophagus 
 
The oesophagus is a muscular tube that forms the upper part of the gastrointestinal tract, 
connecting the oral cavity to the stomach (Sinnatamby, 2011).  Embryologically, it is a foregut 
structure that is derived from the endoderm.  From above, it is bordered by the 
cricopharyngeus muscle, which forms the upper oesophageal sphincter.  Its function is to co-
ordinate the swallow reflex and prevent the passage of ingested contents into the respiratory 
tract.  From below, it is bordered by the lower oesophageal sphincter, which functions to 
protect the lower oesophagus from the reflux of gastric acid and bile.  Throughout its course, 
the oesophagus traverses the neck and thoracic cavity before reaching the abdomen, where 
it joins the stomach at the gastroesophageal junction.  Its main function is to facilitate the 
passage of ingested contents via a coordinated series of peristaltic contractions.  This process 
requires a complex interaction between both the central nervous system and the myenteric 
plexus and involves both sensory and motor nerves (Paterson, 2006).  At rest, the oesophagus 
is a flat structure, however, with the passage of a bolus, it is able to distend. 
 22 
 
The wall of the oesophagus consists of four separate layers.  The mucosa, consisting of a non-
keratinised stratified squamous epithelium, forms the innermost layer.  The main function of 
this epithelial layer is to protect the underlying tissues from the noxious effects of both 
gastroduodenal refluxate and ingested substances.  This is achieved through the presence of 
an apical cell membrane and tight intercellular junctions (Orlando, 1998). It is also important 
to note, however, that from an embryological perspective, the oesophagus is initially lined by 
a pseudostratified layer of ciliated columnar epithelium before transitioning to a stratified 
squamous epithelium after the fourth month of gestation (Kuo & Urma, 2006).  Regeneration 
of this epithelium occurs within its basal layer and newly formed cells migrate to the luminal 
surface over a period of approximately three weeks, becoming terminally differentiated.   As 
the epithelium interdigitates with the underlying supportive connective tissue, a series of 
papillary regions are formed.  Immediately below the basal layer, the mucosa also consists of 
a thin layer of supportive tissue, known as the lamina propria as well as the muscularis mucosa 
(Figure  1-1).  The second layer consists of the submucosa, which contains a rich plexus of both 
blood vessels and nerves as well as submucosal glands (SMG), which are connected via ducts 
to the lumen.  These glands produce both mucus and bicarbonate and have an important role 
in both lubricating the oesophagus and protecting it against the effect of acid refluxate 
(Orlando, 1998). The varied distribution of these glands is shown in Figure  1-2.  Deep to this 
is the muscularis propria, consisting of an inner circular layer and an outer longitudinal layer 
that function together to produce a peristaltic wave.  In the upper oesophagus, this layer is 
composed of striated muscle, whereas in the lower oesophagus, it is composed entirely of 







Figure  1-1 Structure of normal human oesophageal epithelium 
A haematoxylin and eosin (H&E) section of normal human oesophagus demonstrating both 
mucosal and submucosal layers (a).  Within the submucosa is a SMG.  Scale bar represents 
200μm.  A magnified view of the region of interest demonstrating the features of the epithelial 
layer (b).  Within this section is a papillary zone (P), a basal layer (B) and more differentiated 
squamous cells (Sq) in the suprabasal layers.  Within the lamina propria there is a capillary 





Figure  1-2 The distribution of submucosal glands within the human oesophagus 
A diagram demonstrating the distribution of SMGs within two separate human oesophagi (A 
and B).  Image from Goetsch E. The structure of the mammalian esophagus. Am J Anat 
1910;10:34. 
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1.3 Pathophysiology of gastro-oesophageal reflux disease 
 
There are a number of anti-reflux mechanisms that exist in order to protect the oesophagus.  
These include mechanisms that are both intrinsic and extrinsic to the oesophagus.  Intrinsic 
factors include the lower oesophageal sphincter (LOS) with its associated high-pressure zone, 
the presence of both apical cell membranes and tight intercellular junctions that function 
together to create a protective epithelial layer as well as the secretion of both mucus and 
bicarbonate secretion from the SMGs.  The LOS is one of the main contributors to the anti-
reflux mechanism and is composed of specialised smooth muscle that has a high resting tone 
and is located within the wall of the distal oesophagus (Findlay & Maynard, 2019).  Unlike 
other sphincters, such as the pylorus, the LOS is an anatomically discrete structure. 
 
Extrinsic factors include the diaphragmatic sphincter, the presence of an intra-abdominal 
portion of oesophagus, the ‘angle of His’, and the phreno-oesophageal ligament (Sinnatamby, 
2011).  The diaphragmatic sphincter is formed by right crural fibres which wrap around the 
distal oesophagus as it passes into the abdominal cavity, acting like a pinchcock clamp.  The 
phreno-oesophageal ligament is layer of fascia that connects the gastro-oesophageal junction 
to the diaphragm and is important in maintaining the ‘angle of His’ and an intra-abdominal 
length of oesophagus.  The ‘angle of His’ is the acute angle formed between the distal 
oesophagus and the gastric cardia.  Such an angulation contributes to anti-reflux mechanisms 
by creating a flap valve effect.  An intra-abdominal portion of oesophagus is also mechanically 
advantageous as it exposes the distal oesophagus to the positive pressure of the abdomen, as 
opposed to the negative pressure of the thorax.  This leads to compression of the distal 
oesophagus.  Disruption to any of these mechanisms has the potential to lead to gastro-
duodeno-oesophageal reflux. 
 
The key noxious contents of gastro-duodeno-oesophageal reflux include acid, pepsin and bile.  
By disturbing the local pH-ion balance, acid has a direct injurious effect on the epithelium.  It 
also acts indirectly by activating pepsin, a proteolytic enzyme, leading to an impaired mucosal 
barrier.  In contrast, bile is able to pass directly into cells and disrupt cellular function by virtue 
of its lipophilic properties (Boeckxstaens & Rohof, 2014).  All of these processes eventually 
lead to tissue injury and the ensuing inflammatory response.   
 
 26 
The clinical entity describing the reflux of both gastric and duodenal secretions into the lower 
oesophagus is known as gastro-oesophageal reflux disease (GORD) and it is estimated to occur 
in up to 20% of the population (Boeckxstaens et al., 2014).  The clinical sequalae of GORD can 
be varied.  Short term exposure to refluxate typically results in oesophagitis.  In contrast, 
chronic exposure can result in structural changes to the lower oesophagus, ranging from 
peptic stricture formation to the development of intestinal-type metaplasia known as 
Barrett’s oesophagus (BO), which is thought to represent a protective mechanism (Yachimski, 
2016).   
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1.4 Barrett’s oesophagus 
1.4.1 Definition and clinical significance 
 
BO is the eponymous name describing the metaplasia that arises in the lower oesophagus in 
response to GORD.  In this process the normal stratified squamous epithelium of the lower 
oesophagus is replaced by columnar epithelium (Wang & Souza, 2011) (Figure  1-3).  It occurs 
in approximately 5% of the population and is clinically significant as it is the only known 
precursor lesion for OAC, conferring between a 30 to 100-fold increased risk (Streitz, 1994).  
This typically arises through a sequence of metaplasia followed by dysplasia.  For patients with 
non-dysplastic BO, the rate of progression to either high grade dysplasia or OAC is between 1 
to 3 / 1000 patients per year (Whiteman & Kendall, 2016).  For those with low grade dysplasia, 




Figure  1-3 The development of BO 
Barrett’s metaplasia occurs in a stepwise fashion.  In the initial phase GORD leads to 
inflammation in the lower oesophagus.  This then triggers a process of metaplasia whereby 
the stratified squamous epithelium is replaced by columnar epithelium.  Gradually specialised 
intestinal epithelium forms following the development of mucus producing goblet cells (light 








The diagnosis of BO requires an upper gastrointestinal endoscopic examination in order to 
detect the presence of a columnar-lined oesophagus extending more than 1cm proximal to 
the GOJ.  Columnar-lined oesophageal mucosa appears salmon-pink in colour compared to 
the much paler appearance of stratified squamous epithelium (Figure  1-4).    Unfortunately, 
high costs prohibit the use of upper gastrointestinal endoscopy as a diagnostic tool for 
screening purposes (Barbiere & Lyratzopoulos, 2009).  However, this may change with the 
development of less invasive and more cost-effective detection modalities (Offman & 
Fitzgerald, 2017).  Whilst there is no evidence for screening at a population level, a more 
targeted approach to screening may also be possible as researchers seek to better understand 
those at risk of BO through epidemiological studies (Thrift, Kendall, Pandeya, Vaughan, 
Whiteman et al., 2012).  However, clinicians need to be cognizant of the fact that not all 
patients with either GORD or BO are symptomatic.  In fact, the population prevalence of 
individuals with BO but without reflux symptoms is in the order of 1.2% (Ong, Lao-Sirieix, & 
Fitzgerald, 2010).  This explains why a significant proportion of cases of OAC are diagnosed at 
an advanced stage and in patients who are not on surveillance programs (Cooper, Kou, & 
Chak, 2009; Keld & Ang, 2011). 
 
Figure  1-4 Endoscopic appearance of the lower oesophagus 
Image ‘a’ demonstrates the normal appearance of the lower oesophagus.   The top of the 
gastric folds (G) indicate the GOJ.  Image ‘b’ demonstrates a segment of BO arising proximally 
from the GOJ.  The salmon pink appearance of the Barrett’s segment (B) is easily identified.  
This is in contrast to the pale appearance of the normal oesophageal epithelium (N).  Images 




1.4.2 Current management 
 
Once an endoscopic diagnosis of BO is made, confirmation is obtained via histological 
examination.  According to both the Australian and American guidelines, this requires the 
presence of intestinal metaplasia, characterised by the presence of mucus secreting goblet 
cells (Whiteman et al., 2016).  British guidelines, however, only require evidence of a columnar 
lined oesophagus (Tan, di Pietro, & Fitzgerald, 2017). 
 
Once the presence of BO is confirmed, patients are stratified based on the length of the BO 
segment and the presence of dysplasia.  The length of the BO segment is measured from the 
GOJ, to its most proximal extension.  Australian guidelines state that patients with non-
dysplastic BO should undergo surveillance, with the interval being determined by the length 
of the BO segment.  Patients with short segments (< 3cm) should undergo endoscopic 
assessment every three to five years, whereas those with long segments (>3cm) should be 
assessed every two to three years.  Patients with low-grade dysplasia, on the otherhand, 
should undergo endoscopic surveillance every six months irrespective of the length of the BO 
segment.  If a diagnosis of high-grade dysplasia is made, patients should be referred to a 
tertiary centre for endoscopic treatment. (Whiteman, Appleyard, Bahin, Bobryshev, Bourke 
et al., 2015).  Unfortunately, there are a number of issues with surveillance programs.  Firstly, 
there is generally poor adherence to recommended guidelines.  Secondly, there is a significant 
amount of sampling error and inter-observer variability associated with the detection of 
dysplastic foci.  This is because the lesions are usually flat and indistinguishable from the 
surrounding metaplasia (Ong et al., 2010).  In an attempt to overcome these difficulties and 
improve the endoscopic detection of both pre-malignant and malignant lesions, a consensus 
statement has recently been published by a number of leading endoscopists, stating that 
narrow band imaging with magnification should be used in conjunction with standard white 
light endoscopy to enhance the image during endoscopy (Chiu, Uedo, Singh, Gotoda, Ng et 
al., 2019).  In an attempt to further stratify patients with dysplastic foci, researchers are 
focusing on the development of biomarkers that will aid in predicting those patients who are 
most likely to progress to OAC (Frankell, Jammula, Li, Contino, Killcoyne et al., 2019). 
In patients diagnosed with dysplastic BO, confirmation is required by a second expert 
pathologist.  For low grade dysplasia, management consists of either more intensive 
surveillance or endoscopic treatment.  However, for high grade dysplasia, endoscopic 
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treatment must be offered.  The main principles of endoscopic management involve resecting 
dysplastic foci and ablating remaining non-dysplastic segments.  Patients undergoing 
endoscopic treatment are also required to undergo treatment for GORD.  This is to enable the 
oesophageal epithelium to regenerate in the absence of reflux.  This is usually achieved by 
either pharmacologically or surgically by means of fundoplication (Whiteman et al., 2016). 
1.4.3 Current theories regarding the pathogenesis of BO 
 
Current theories suggest that the development of BO is due to a complex interplay between 
environmental exposures, molecular genetics and cellular interactions.  Unfortunately, the 
exact mechanisms responsible for the development of BO at both the cellular and molecular 
level are poorly understood.  As a result, a number of different theories regarding the 
pathogenesis of BO exist, especially regarding Barrett’s cell of origin.  These theories are 
explored in the following sections.  
1.4.3.1 Barrett’s cell of origin 
 
Given the embryological basis of oesophageal development, it seems highly plausible that the 
Barrett’s cell of origin resides in a niche intrinsic to the oesophagus.  For this to occur, cells 
native to the oesophagus must go through the process of either transdifferentiation or 
transcommitment.  Transdifferentiation is the process whereby a phenotypic switch occurs 
between one differentiated cell type to another, typically involving cell types that were 
present during embryogenesis (Tosh & Slack, 2002).  This theory, however, fails to explain the 
ability of Barrett’s tissue to regenerate, as, by definition, differentiated cells lack the ability to 
self-renew (Shackleton, 2010).  Transdifferentiation also fails to explain how separate clones 
within a segment of BO are able to expand, a phenomenon that has been reported to occur 
quite frequently (Evans & McDonald, 2016; Nicholson, Graham, Simpson, Humphries, Burch 
et al., 2012).  However, both of these observations can be explained by the transcommitment 
model, as, in this model, the phenotypic switch occurs at the resident stem or progenitor cell 
level (Kapoor, Agrawal, & Mittal, 2015).   
 
Within the human oesophagus, a number of potential stem cell niches exist, that could 
potentially harbour the Barrett’s cell of origin.  These include the interpapillary basal layer as 
well as the SMG and its associated duct (Nicholson et al., 2012; Seery & Watt, 2000).  In 
support of this theory is the observation that human Barrett’s mucosa occurs in continuity 
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with oesophageal gland ducts (Coad, Woodman, Warner, Barr, Wright et al., 2005).  This 
theory is further supported by experimental work conducted using a canine model, which, like 
the human, also contain SMGs (Gillen, Keeling, Byrne, West, & Hennessy, 1988).  In the study 
by Gillen et al. (1988), the effects of acid and bile on regenerating oesophageal mucosa was 
tested.  Results revealed the formation of a columnar epithelium in response to acid and bile 
exposure in regions of the lower oesophagus that had been denuded.  As the epithelium was 
denuded in such a fashion as to prevent the migration of cells from gastro-oesophageal 
junction and gastric cardia, the authors concluded that the columnar cells originated from a 
source intrinsic to the oesophagus.  Like the human, the columnar epithelium was also found 
to be in continuity with SMGs.  More recently, an in vitro study that generated organoids from 
porcine SMGs, demonstrated that SMGs had the potential to generate both squamous and 
ductal phenotypes (von Furstenberg, Li, Stolarchuk, Feder, Campbell et al., 2017). 
 
A number of other purported theories suggest that the Barrett’s cell of origin may in fact 
reside at the gastro-oesophageal junction.  However, a key criticism of all of these theories, is 
that they are based on the findings from rodent models and not humans.  As there are a 
number of differences between the rodent and human oesophagus, this makes it difficult to 
interpret findings from one species to another.  Key differences include the absence of SMGs 
and the presence of a keratinised stratified squamous epithelial layer lining the oesophagus.  
The squamo-columnar junction is also located in the forestomach rather than the true GOJ 
(Read, Krishnadath, Clemons, & Phillips, 2018).   
 
In a study by Wang et al. (2011), a p63 knockout mouse was used to model human BO.  As 
p63 is essential for the development of all stratified epithelial tissues, its loss inhibits the 
transition from columnar to stratified squamous epithelium that occurs within the 
oesophagus during embryogenesis, resulting in a Barrett’s like phenotype.  However, a 
limitation of this model is that it is represents a defect of embryogenesis and not true 
metaplasia.  Extrapolating the findings from this model, the authors then identified a 
population of residual embryonic cells at the squamocolumnar junction (SCJ) in both wild-type 
mice and human samples which they claim have the potential to repopulate the oesophagus 
following injury.  However, these claims are not supported by any functional study. 
 
Stem cells residing at the gastric cardia have also been implicated in the pathogenesis of BO.  
In a study by Quante et al. (2012), a transgenic mouse model was used that overexpressed 
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the inflammatory cytokine IL-1β in stratified squamous epithelia.  This was selected in order 
to replicate the inflammatory response that occurs in GORD, one of the key risk factors for 
the development of BO.  The development of metaplasia and adenocarcinoma was further 
enhanced by exposure to bile acids and nitrosamines.  In this model, metaplasia and 
adenocarcinoma formation was localised to the SCJ and, through lineage tracing, was found 
to have originated from leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5+) 
cells residing in the adjacent gastric cardia.  These results suggest that gastric intestinal 
metaplasia is being modelled rather than BO. 
 
More recently Jiang et al. (2017) published evidence of a multi-layered epithelium at the SCJ 
or transition zone in both mice and humans.  These cells were   found to be p63+Krt5+Krt7+ 
and following ectopic expression of caudal-related homeobox transcription factor 2 (CDX2), 
transformed into a Barrett’s like phenotype within the confines of the transitional zone.  No 
effect was seen within normal squamous regions.  However, a criticism of this study is that 
the ectopic expression of CDX2 could be considered to be an artificial effect.  A similar result 
has also been reported in another study, whereby the intestinalisation of p63+Krt5+ cells was 
artificially induced following transfection with the CDX2 gene (Mari, Milano, Parikh, Straub, 
Everts et al., 2014). 
 
An alternative theory is that circulating bone marrow progenitor cells contribute to the 
development of BO.  In a study by Sarosi et al. (2008), female rats were irradiated with lethal 
dose of radiation and then rescued via a tail vein injection of bone marrow cells obtained from 
male rats.  In order to induce metaplasia, rats then underwent an oesophagoduodenostomy.  
Subsequent analysis of both normal and metaplastic tissue confirmed the presence of Y 
chromosomes.  Although the authors claim that these cells were contributing to the formation 
of metaplasia, it is more likely that they represent an inflammatory cell infiltrate. 
 
1.4.3.2 Key molecular pathways 
 
Three major pathways have been suggested to play a role in the development of BO 
(Clemons, Koh, & Phillips, 2014). The Notch and the caudal-related homeobox transcription 
factor (CDX) pathways are important regulators of intestinal differentiation.  They have been 
shown to be upregulated after bile and acid exposure in squamous cells and to drive 
upregulation of intestinal and BO specific genes, such as mucin2 and cytokeratin (CK) 20 
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(Clemons, Koh, et al., 2014).  As such, it is not surprising that they are aberrantly expressed 
in BO tissues. Surprisingly, however, overexpression of CDX2 in the mouse oesophagus under 
the cytokeratin 14 (CK14) promoter failed to induce columnar metaplasia, suggesting that 
CDX2 alone is insufficient to induce columnar metaplasia (Kong, Crissey, Funakoshi, Kreindler, 
& Lynch, 2011).  
 
The Sonic Hedgehog (Shh) pathway and its downstream effectors bone morphogenetic 
protein 4 (BMP4) and SOX9 have been gaining recent interest as putative drivers of 
metaplasia. Shh signalling is also an important pathway for gut development (Krishnadath, 
2007). Shh signalling is mediated by two membrane-bound receptors: patched (Ptch) and 
smoothened (Smo). Binding to Patch1 leads to activation of a cytoplasmic protein complex 
containing Gli transcription factors and to the activation of pathway targets such as BMP4 
and SOX9 (Wang, Clemons, Miyashita, Dupuy, Zhang et al., 2010).  Both Shh (Wang et al., 
2010) and BMP4 (Milano, van Baal, Buttar, Rygiel, de Kort et al., 2007; van Baal, Milana, 
Rygiel, Sondermeijer, Spek et al., 2008) are highly expressed in BO. Bile and acid have been 
shown to activate expression of Shh in epithelial cells, both in vitro and in vivo (Sun, Wang, 
Gai, Song, Jia et al., 2015; Wang et al., 2010). This epithelial Shh acts in a paracrine manner 
on mesenchymal cells and induces BMP4 secretion (Wang et al., 2010). Interestingly, 
epithelial cells also secrete BMP4 after direct contact to acid and bile salts (Zhou, Sun, Wang, 
Wang, Wang et al., 2009). Both mesenchymal-derived and epithelial-derived BMP4 acts on 
epithelial cells, as shown by the high expression of BMP4 targets such as ID2 in the epithelia 
of BO (van Baal, Milana, et al., 2008; van Baal, Rygiel, Milano, Anderson, Bergman et al., 
2008). An important set of in vitro and in vivo experiments evaluated the significance of BMP4 
signalling on epithelial cells in the development of BO. Exposure to BMP4 induced striking 
morphological changes on squamous epithelial cells and a shift in the cytokeratin expression 
pattern, in which the expression of CK10 and CK13 decreased and that of CK7 and CK20 was 
upregulated (Milano et al., 2007). RNA analysis of BMP4-treated squamous cells confirmed 
their transformation into a columnar type of cells, but not an increase in the expression of 
intestinal epithelial markers. Similarly, ectopic expression of BMP4 in the mouse oesophagus 
under the control of the CK14 promoter induced columnar differentiation but did not lead to 
intestinal metaplasia (Mari et al., 2014). It was only when CDX2 was also overexpressed in 
squamous cells, that BMP4 stimulation could induce the expression of both columnar and 
intestinal genes (Mari et al., 2014).   Further, chromatin immunoprecipitation experiments 
on human BO cells, confirmed, at the molecular level, that both CDX2 and phosphorylated 
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SMAD (the transcription factor for BMP4) bind to the mucin 2 gene promoter. Importantly, 
using a surgical mouse model of BO the exact sequence in which these markers appear during 
the development of non-intestinal to intestinal metaplasia were identified (Mari et al., 2014). 
In this model it was shown that activation of the BMP4/pSMAD pathway is an early event, 
whereas CDX2 and MUC2 expression appear late during the development of intestinal 
metaplasia. Together, these experiments have therefore demonstrated an important role of 
the BMP4/CDX2 pathway in the development of columnar and intestinal metaplasia, 
rendering this pathway highly attractive as a therapeutic target for Barrett’s metaplasia. 
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1.5 Oesophageal adenocarcinoma 
1.5.1 Background  
 
In Australia, the current 5-year survival rate for OAC is approximately 16%, which is only a 
modest improvement from the level of 10% that was recorded 25 years ago (Cancer Council 
Victoria, 2011).  This is despite extensive research efforts and changes to clinical management 
over this period.  Such changes have included improvements to endoscopic technologies to 
better identify early cancers, staging techniques, endoscopic resection, the introduction of 
neoadjuvant therapy, the development of less invasive surgical techniques, the establishment 
of centralised cancer services and the improved management of post-operative complications 
(Kleinberg, 2013; Rouvelas & Lagergren, 2010; van Hagen, Hulshof, van Lanschot, Steyerberg, 
van Berge Henegouwen et al., 2012; Zehetner, DeMeester, Hagen, Ayazi, Augustin et al., 
2011). 
 
The incidence of OAC has also risen more than six-fold over the last four decades, which is 
more than any other solid cancer over that same period (Pohl et al., 2005).    Through 
population-based studies, obesity and GORD have been identified as two of the strongest risk 
factors for the development of OAC (Thrift, Pandeya, & Whiteman, 2012).  It is widely 
accepted that the rising prevalence of these risk factors is contributing to the steep rise in 
incidence seen in OAC. 
1.5.2 Clinical presentation and management 
 
The majority of patients that present with OAC have either advanced locoregional or 
metastatic disease.  These patients typically present with dysphagia.  However, they may also 
present with iron deficiency anaemia secondary to a bleeding tumour.  Only approximately 
25% of patients present with localised disease with fewer than 15% being detected via 
Barrett’s surveillance programs (Rubenstein & Shaheen, 2015).   
. 
The current management of OAC varies according to the stage of disease, patient fitness and 
institutional practices.  The treatment of early cancers that are confined to either the mucosa 
or superficial sub-mucosa are typically based on endoscopic approaches, such as either 
endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) (Rubenstein 
et al., 2015).  The 5-year survival rate for patients who present in this early stage has been 
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reported to be as high as 90% (Keld et al., 2011).  For patients with locally advanced disease, 
treatment consists of either neoadjuvant chemotherapy (combination of cytotoxic and 
antimetabolite agents) or chemoradiotherapy followed by surgery with curative intent.  This 
is based on the results from three seminal publications.  These include the  MAGIC trial, the 
CROSS study and, more recently, the FLOT study (Al-Batran, Hofheinz, Pauligk, Kopp, Haag et 
al., 2016; Cunningham, Allum, Stenning, Thompson, Van de Velde et al., 2006; van Hagen et 
al., 2012).  In the MAGIC trial, which compared the combination of peri-operative 
chemotherapy in the form of epirubicin, cisplatin and fluorouracil (ECF) in combination with 
surgery versus surgery alone for resectable gastroesophageal cancers, results revealed a 5-
year survival of 36 percent in the combined chemotherapy and surgery group versus 23 
percent in the surgery alone group (Cunningham et al., 2006).  In the CROSS study, the added 
effect of radiotherapy was assessed.  This resulted in improved R0 resection rates and a 5-
year survival of 49.4 months in the group receiving chemoradiotherapy in conjunction with 
surgery versus 24 months for the group that received surgery alone (van Hagen et al., 2012).  
More recently, the combination of perioperative docetaxel, oxaliplatin, leucovorin and 
fluorouracil (FLOT) was compared to perioperative  ECF (Al-Batran et al., 2016).  Results 
revealed that higher proportions of patients treated with perioperative FLOT achieved a 
complete pathological response compared to those treated with ECF (16% vs 6%; p=0.02). 
Unfortunately, the majority of patients present with disease in its later stages with between 
50 to 60% having distant metastasis at the time of diagnosis (Howlader, Noone, Krapcho, 
Garshell, Miller et al., 2015; Tejani & Burtness, 2012).  For these patients, palliation is the only 
option.  This consists of various combinations of chemotherapy, radiotherapy, endoscopic 
stenting and comfort measures (Rubenstein et al., 2015).   
 
1.5.3 Current theories regarding the pathogenesis of oesophageal adenocarcinoma 
 
Given that the 5-year survival rate for patients with OAC that are treated with curative intent 
is less than 45% (Weaver, Ross-Innes, & Fitzgerald, 2014), alternative treatment strategies are 
urgently needed.  As the hallmark features of OAC are its rising incidence, late presentation 
and resistance to treatment, research efforts should focus on risk factor modification, 
improved screening to enable earlier detection and the development of improved treatment 
options.  However, in order to identify novel therapeutic targets, a greater understanding of 
both the genetic and cellular events involved in the pathogenesis of OAC is required.  Such 
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knowledge may even help to better identify patients who need more intensive treatment and 
surveillance. 
1.5.3.1 Key genetic events 
 
A number of key discoveries into the genetic landscape of both BO and OAC have been 
identified through the use of genome-wide analyses in two recently published studies (Nones, 
Waddell, Wayte, Patch, Bailey et al., 2014; Weaver, Ross-Innes, Shannon, Lynch, Forshew et 
al., 2014).  In the study by Nones et al. (2014) a combination of whole-genome sequencing, 
single-nucleotide polymorphism arrays and copy number analyses revealed that catastrophic 
genomic events were frequent in OAC.  This was reportedly due to a recently discovered 
process known chromothripsis (Zhang, Spektor, Cornils, Francis, Jackson et al., 2015), which 
was found to have occurred in 32% of cases.  In this process, a limited number of 
chromosomes become fragmented before reforming haphazardly, thereby creating multiple 
mutations within a single cell cycle.  This process, previously unrecognised in OAC, explains 
the mechanism behind the marked heterogeneity seen in OAC.  This theory can also be used 
to explain the rapid genomic evolution the occurs in OAC as well as the broad range of 
oncogenes that it encompasses. 
 
In the study by Weaver et al. (2014), OAC samples from a cohort of 112 patients were 
sequenced in order to determine commonly mutated genes.  In an attempt to determine the 
order of mutations in the Barrett’s carcinogenesis sequence, samples were also sequenced 
from a separate cohort of patients with BO from two separate disease points.  These included 
non-dysplastic BO and BO with associated high-grade dysplasia.  One of the key findings of 
this study was that the majority of recurrently mutated genes were found to be present in 
only a small proportion of patients.  Surprisingly, the most frequently mutated genes 
identified in the OAC cohort were also found to be present at a similar frequency in the non-
dysplastic BO samples.  Of these mutations, the only ones that were found to have occurred 
in a disease stage specific manner were p53 and SMAD4, with the p53 mutation marking the 
transition from non-dysplastic BO to BO with high-grade dysplasia, and SMAD4 marking the 
transition between high-grade dysplasia and early OAC.  Unfortunately, the utility of SMAD4 




1.5.3.2 Model of cancer cell propagation 
 
Disease recurrence is one of the main factors contributing to the high mortality rate 
associated with OAC.  This is due to the presence of residual cancer cells with tumorigenic 
potential.  In the case of OAC, it is unknown if all cells have this potential or only a small sub-
population.  If it is only a small sub-population, it is likely that OAC follows the cancer stem 
cell (CSC) model.  Conversely, if all cells have equal tumorigenic potential, then it seems likely 
that OAC follows the model of clonal evolution.  Although not a defining feature, CSCs have 
also been shown to exhibit chemoresistance properties, as demonstrated by the cluster of 
differentiation (CD) 133+ population of cells within glioblastoma (Liu, Yuan, Zeng, Tunici, Ng 
et al., 2006).  Possible explanations for this include enhanced DNA damage repair 
mechanisms, impaired apoptosis and more efficient drug efflux (Dean, Fojo, & Bates, 2005; 
Grotenhuis, Wijnhoven, & van Lanschot, 2012).  Being able to identify such a population within 
OAC may help in the development of more targeted therapies. 
Based on the fact that CSC populations have already been identified in a number of other solid 
cancers, including breast, brain and colon cancer (Grotenhuis et al., 2012), research efforts 
have focused on identifying a CSC population within OAC.  As a result, a range of candidate 
markers have already been tested.  These have included CD24, CD29, CD34, CD44, CD133, 
CD166, EpCAM, ! -catenin, Musashi-1, leucine-rich-repeat-containing G-protein-coupled 
receptor 5 (Lgr5) and the α6bri/CD71dim cell population (Becker, Huang, & Mashimo, 2010; 
Bobryshev, Freeman, Botelho, Tran, Levert-Mignon et al., 2010; Grotenhuis, Dinjens, 
Wijnhoven, Sonneveld, Sacchetti et al., 2010; Zhao, Quaroni, & Casson, 2012).  Despite these 
efforts, a true CSC population within OAC is yet to be identified. 
 
However, before further research is undertaken in this area, initial research efforts should 
focus on trying to identify the model of cancer cell propagation that OAC follows.  Only if the 
frequency of tumour initiating cell (TIC) within OAC is found to be low, should efforts be made 
to identify a potential CSC population.   
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1.6 Preclinical models for the study of Barrett’s carcinogenesis 
 
Despite recent advances in the management of both BO and OAC over the last few decades, 
there has only been an incremental improvement with respect to the overall survival rate for 
this disease (Cancer Council Victoria, 2011).  For there to be a significant improvement in 
survival rates, novel treatments need to be developed.  However, the limited availability of 
suitable preclinical models has proven to be a significant barrier to progress (Liu, Duong, 
Phillips, & Clemons, 2016).  Two common models currently used in cancer research include 
the cancer cell line and the xenograft model (Hidalgo, Amant, Biankin, Budinska, Byrne et al., 
2014; Mullard, 2018). 
 
Cancer cell lines are typically established following the digestion of pieces of primary tumour 
followed by an extended period of in vitro culture.  By definition, they are clonal populations 
of cells and lack the heterogeneity that is typical of most cancers (Mullard, 2018).  Despite this 
limitation, cancer cell lines are an extremely versatile and commonly used model.  They enable 
a high throughput of invitro assays, ranging from drug screens to mechanistic studies. 
Unfortunately, a robust technique for the establishment of cell lines has not been established.  
This is of particular concern in OAC, as there are only six bona fide cell lines derived from 
Barrett’s associated adenocarcinomas (Boonstra, Tilanus, & Dinjens, 2015).   
 
Another commonly used preclinical cancer model is the xenograft model.  Traditionally, these 
have been generated following the injection of established cancer cell lines into 
immunodeficient mice (Dodbiba, Teichman, Fleet, Thai, Sun et al., 2013b).  However, more 
recently, the patient-derived tumour xenograft (PDTX) model has gained popularity (Hidalgo 
et al., 2014).  In this model, tissue pieces are transplanted into an immunodeficient host.  
Following successful engraftment, tumours are then serially passaged through multiple 
generations until multiple cohorts are established.  They are thought to be superior to 
conventional cell line models as they better recapitulate tumour heterogeneity and contain 
elements of human stroma (Hidalgo et al., 2014).  There are many potential applications of 
the PDTX model, however, they are most commonly used for drug target validation (Tentler, 
Tan, Weekes, Jimeno, Leong et al., 2012).  However, like the cell line model, PDTXs have also 
proven difficult to establish in OAC (J. J. Boonstra, R. van Marion, H. J. Douben, J. S. Lanchbury, 
K. M. Timms et al., 2012; de Both, Wijnhoven, Sleddens, Tilanus, & Dinjens, 2001; Dodbiba, 
Teichman, Fleet, Thai, Starmans et al., 2015; Dodbiba et al., 2013b). 
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A number of preclinical models have also been developed for the study of BO.  The following 
published review highlights the progress that has been made in the development of these 
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Introduction
Barrett’s esophagus (BE) is the eponym describing
the metaplastic process that occurs in the lower
esophagus in response to gastroesophageal reflux
(GER). BE is clinically significant because it is the
only known precursor lesion for esophageal adeno-
carcinoma (EAC), a cancer with an extremely poor
prognosis and an incidence that has risen more than
sixfold over the last four decades.1 Unfortunately,
the exact mechanisms responsible for both the ini-
tiation of BE and its progression to EAC are poorly
understood, and this has led to several key contro-
versies in the field. One of the main controversies
surrounds the location and identity of the Barrett’s
cell of origin.2,3 Current theories include cells that
are native to the esophagus (squamous cells, ductal
cells, and submucosal gland cells), cells located at
the squamocolumnar junction (SCJ) (transitional
basal cells and embryonic stem cells), cells from
the proximal stomach (gastric cardia), and even
bone marrow-derived cells.4 Another controversy,
closely entwined with the Barrett’s cell of origin,
is whether BE forms through a process of transd-
ifferentiation (transformation of one differentiated
cell type to another) or transcommitment (repro-
gramming at the stem or progenitor cell level).3
Several controversies regarding the pathogenesis of
Barrett’s carcinogenesis also exist at the molecular
genetic level. Examples include the component of
refluxate responsible for the initiation of the meta-
plastic process,5 as well as the sequence of muta-
tions and epigenetic changes required for neoplastic
progression.6,7
Current treatments for BE consist of endoscop-
ically resecting or ablating metaplastic segments
using a combination of either endoscopic submu-
cosal dissection, endoscopic mucosal resection, or
radiofrequency ablation.8 These treatments aim to
denude portions of the esophagus, which in the
absence of the GER, undergo repair with neosqua-
mous epithelium.8 Unfortunately, these techniques
can lead to both recurrent Barrett’s9 and buried
Barrett’s,10 making ongoing surveillance and treat-
ment challenging. These techniques can also lead
to complications, such as perforation, stricture for-
mation, and bleeding. In a recent systematic review,
assessing the safety of endoscopic treatments for
both BE and early EAC, the rates of perforation,
stricture formation, and bleeding were 33.5%, 7.5%,
and 1.3%, respectively.11 There is currently no phar-
macotherapy that targets the molecular drivers of
doi: 10.1111/nyas.13916
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BE, either for the prevention or treatment of the
disease.
To develop improved therapies to treat BE, a
greater understanding of the disease processes at
the molecular genetic level is required. However, for
therapeutic development to occur, improved pre-
clinical models are required for mechanistic studies
and testing of novel therapies.12 The ideal model
for the study of Barrett’s carcinogenesis should be
manipulable, reproducible, and three-dimensional
and should allow for environmental exposures. As
BE is likely due to a complex interaction between dif-
ferent cell types,13 the ideal model should include a
full complement of epithelial, stromal, and inflam-
matory cells.14 The epithelial component should
include cells from the esophagus (including sub-
mucosal glands and ductal cells), stomach, and gas-
troesophageal junction. Through such an approach,
all potential sources of the BE cell of origin should
be included. The ideal model also needs to undergo
strict validation to confirm that it recapitulates the
human disease process and can model the progres-
sion from the BE cell of origin to columnar epithe-
lia to adenocarcinoma (AC). Our review highlights
the progress made in the development of preclinical
models for the study of BE.
Methodology
A PubMed search was performed for publication
dates from January 1950 to March 2018 using a
combination of the following terms: Barrett’s esoph-
agus, preclinical model, reflux model, animal model,
transgenic model, cell line, organotypic model, and
organoid model. Articles were limited to those pub-
lished in English. A manual search of citations for
relevant articles was also performed. Both original
articles and review articles were included.
In vivo models
While a number of key discoveries have been pub-
lished from a range of different preclinical models
of BE, there have also been a number of conflict-
ing results. These conflicting results were observed
because there is no single preclinical model that
offers the ideal system with which to study Barrett’s
carcinogenesis.15 While attempts have been made
to develop an in vivo Barrett’s model from sev-
eral different species, research efforts have mainly
focused on murine and canine models. To generate
both the Barrett’s phenotype and EAC within these
animal models, a number of modifications have
been attempted. These include the surgical induc-
tion of different types of reflux, genetic modifica-
tion, and exposure to different forms of exogenous
carcinogens.16–19
Research in this field was originally focused on
reflux esophagitis and the columnar lined esopha-
gus (CLE). During this early period, several studies
were performed using canine models to investigate
the effects of various refluxates on the esophagus. An
advantage of this model is that both the canine and
human esophagi contain submucosal glands.15 In a
landmark study by Bremner et al., dogs were ran-
domized to one of three groups following stripping
of the lower esophageal mucosa. These included
a surgically induced reflux group, a gastric hyper-
secretion group, and a control group.20 The results
indicated that neo-epithelialization occurred via a
columnar epithelium in the reflux group, whereas
a squamous epithelium predominated in those ani-
mals with a competent lower esophageal sphinc-
ter. From these results, the authors concluded that
the CLE is an acquired condition formed from the
migration of columnar cells from either a gastric or
a junctional origin. In 1988, Gillen et al. published a
similar study to that performed by Bremner et al.21
However, in that study using a canine model, the
lower esophageal mucosa was denuded in a certain
manner to create a squamous barrier to any migrat-
ing gastric or junctional cells. Similar to Bremner,
the authors observed the formation of a columnar
epithelium in the presence of acid reflux, both on
its own and in combination with bile (but not bile
on its own). From these results, they also concluded
that BE is an acquired condition. However, unlike
Bremner, the authors concluded that the columnar
cells originate from a source intrinsic to the esoph-
agus, such as the submucosal gland. These results
were further supported by canine studies conducted
by Li et al., who concluded that the regenerating
epithelium was in continuity with the ducts of the
esophageal glands.22
Two of the seminal studies assessing the effect of
refluxate composition on the esophagus were Fer-
guson et al. in 195023 and Redo et al. in 1959.24
Ferguson et al. demonstrated that either the com-
bination of acid and pepsin or bile on its own
is capable of causing esophagitis. However, when
the lower esophagus is perfused with acid on its
own, no effect is seen. In the study by Redo et al.,
140 Ann. N.Y. Acad. Sci. 1434 (2018) 139–148 C⃝ 2018 New York Academy of Sciences.
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canine esophagi were perfused with different types
of refluxate over a seven-and-a-half-hour period.
The refluxates included gastric juice, hydrochloric
acid, pepsin, and bile, which were collected from a
patient with a duodenal fistula. The results were con-
sistent with those obtained by Ferguson et al., sug-
gesting that acid–pepsin activity is responsible for
ulceration of the esophagus. However, in this study,
no effect was seen with bile reflux. These results
contradicted earlier observations made by Barrett
regarding the destructive effects of bile. In his 1954
paper, Barrett described the severe esophagitis expe-
rienced by one patient following a total gastrectomy
and esophagoduodenostomy.25
To further investigate the effects of reflux com-
position on the development of esophagitis, Lev-
rat et al. devised a surgically induced reflux model
in the rat.16 This study followed on from previous
work investigating reflux esophagitis in the rat fol-
lowing total gastrectomy.26,27 In Levrat et al.’s study,
six different types of anastomosis were fashioned to
induce different types of reflux. These consisted of
an esophagojejunostomy with different combina-
tions of gastrectomy and pancreaticobiliary diver-
sion. The different approaches enabled the study
of gastric, biliary, and pancreatic secretions both in
isolation and combination. The results suggested
that bile was the key injurious factor and that gas-
tric secretions alone had little effect. Despite key
anatomical and histological differences between the
murine and human esophagus, such as the presence
of a keratinized squamous epithelium within the
esophagus, an SCJ located within the forestomach,
and the absence of esophageal submucosal glands
(ESMGs),15 this paper served to popularize the
murine model and formed the basis from which sev-
eral later surgical reflux models were generated.28–35
Once the association between the CLE and
EAC became apparent, research shifted from
investigating reflux esophagitis to the more clin-
ically important metaplasia–dysplasia–carcinoma
sequence. Given the complexities involved in such
a disease process and its long natural time course,
researchers have gone to great efforts to generate
a suitable animal model. Potential advantages of
animal models include the ability to adjust for the
known risk factors, such as sex and obesity.15 These
models also have the ability to mount an inflam-
matory response, which is likely to be one of the
key early steps in the pathogenesis of BE.36 Such
a model could allow investigation into each of the
various stages of the malignant transformation and
provide the opportunity to test both preventative
and treatment strategies in a controlled fashion.37
Unfortunately, despite many attempts over the last
two to three decades, the ideal animal model to study
Barrett’s carcinogenesis has not been identified. This
is largely due to animals rarely developing a natural
BE phenotype.15 In fact, there have only been three
reported cases of animals developing spontaneous
BE, two of which were in dogs38,39 and one in a
baboon.40 Of the two cases reported in dogs, one
also progressed to EAC.38 Despite both the dog and
baboon developing BE spontaneously, they failed
to become popular as preclinical models because
they are resource intensive and can take up to
30 months to develop BE41 and 60 months to
develop EAC.15
Despite its limitations, the bulk of the research
has been conducted using the surgically induced
reflux murine model to determine if both BE and
EAC will develop under augmented conditions. In
early studies, the added effect of carcinogen admin-
istration was tested in combination with the sur-
gical induction of reflux.19,42–44 The results from
these studies revealed that reflux on its own could
induce esophagitis, metaplasia, and cancer forma-
tion. However, the rates increased with carcinogen
exposure. Clark et al.19 reported that esophagitis
occurred in 97%, metaplasia in 10%, dysplasia in
8%, and cancer in 3% of the cases. However, unlike
humans, the cancers were squamous cell carcino-
mas and not ACs. When combined with carcinogen
exposure, these rates increased to 99% for esophagi-
tis, 13% for metaplasia, and 57% for carcinoma. In
this setting, both squamous cell carcinomas and ACs
developed at a ratio of approximately two to one.
The requirement for carcinogen exposure to pro-
duce ACs of the distal esophagus was challenged in
later studies.45–47 Fein et al. reported AC formation
without the need for carcinogen.47 In this series, all
animals exposed to duodenal reflux demonstrated
evidence of severe esophagitis, 87% had evidence of
a columnar lined distal esophagus, and 48% had AC
of the anastomotic site. Goldstein et al. also reported
AC formation in the absence of carcinogen. In their
study, a higher rate of AC formation (73%) was
achieved simply by correcting the iron deficiency
anemia that occurs following the surgical induc-
tion of reflux.46 This rate was not affected by the
141Ann. N.Y. Acad. Sci. 1434 (2018) 139–148 C⃝ 2018 New York Academy of Sciences.
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administration of carcinogen, which promoted the
formation of squamous cell carcinomas instead.
To extrapolate the results from animal models to
the human disease process, it is essential that models
undergo rigorous validation.30 Unfortunately, the
results from multiple studies aiming to validate the
surgically induced reflux model have varied, leaving
two fundamental issues unresolved. The first issue
is whether the CLE seen within the model is truly
metaplastic or simply is the migration of epithelial
cells from below the anastomosis. The research sup-
porting the metaplasia hypothesis has provided evi-
dence that the CLE within the model shares similar
morphology, mucin profile, and markers of differ-
entiation (CK7, CK20, Das-1, villin, and pS2/TFF1)
to BE.48 Further studies have also been performed
comparing the trefoil factor (TFF) gene expression
profile between the CLE and jejunum distal to the
anastomosis, as TFF has previously been validated
as a marker capable of discriminating between BE
and small intestine.49 The results revealed a statis-
tically significant higher expression of TFF-1 and
TFF-2 within the CLE compared with that in the
jejunum.34 Gronnier et al. later confirmed these
results.30 However, they also identified Brunner’s
glands within the columnar lined esophageal seg-
ment. Because these glands normally reside within
the submucosa of the first part of the duodenum,
this raised the possibility that duodenal tissue may
have been mechanically introduced into the distal
esophagus, suggesting that both mechanisms may
be occurring.30 Buskens et al. also suggested that
the ectopic glandular tissue could be implanted into
the esophageal submucosa following an anastomo-
sis, leading to AC formation.37
The second unresolved issue is whether the ACs
that develop within the model are representative of
those seen in humans. With respect to the histol-
ogy and invasive potential of these tumors, most
studies have reported the development of well-
differentiated mucinous tumors at the level of the
anastomosis.35,37,50 Microscopically, these tumors
appear to originate from the submucosa and extend
to the external surface, lacking any mucosal involve-
ment. They also exhibit a benign phenotype with no
evidence of either local or distant dissemination.37,50
This phenotype is in vast contrast to most human
ACs, which display varying degrees of differen-
tiation, arise from the mucosa, and frequently
metastasize.48 In contrast to these findings, Su et al.
reported that 12 out of 14 cases of the EAC in their
series demonstrated evidence of invasion into mus-
cle, adventitia, and adjacent organs, although these
findings were not readily apparent in the published
images.48 Gronnier et al. also described the pres-
ence of distant lung and liver metastases from their
series in previously unreported data detailed in a
letter to the editor.51 In an attempt to validate these
tumors at the molecular level, Su et al. demonstrated
that the immunohistochemical expression of tumor
markers p53 and COX2 within the reflux-induced
ACs was comparable to that of human controls.48 In
contrast, Buskens et al. reported that p53 immuno-
histochemistry was not associated with malignant
transformation within the model.37
Transgenic models
Although the exact mechanisms responsible for the
development of BE and its subsequent progression
to EAC remain unknown, it is likely that the disease
involves a complex interplay between molecular and
genetic events, cellular interactions, and environ-
mental exposures. Given these complexities, numer-
ous genes and signaling pathways have been impli-
cated in its pathogenesis. Examples include genes
involved in intestinal differentiation, such as the
homeobox genes CDX1 and CDX2, and signaling
pathways involved in both esophageal embryogene-
sis and intestinal development, including bone mor-
phogenetic protein 4, sonic hedgehog (Shh), Notch,
and WNT.18,52,53 With the advent of the genetic-
ally engineered mouse models, a unique opportu-
nity was presented to test the functional effect of
individual genetic alterations in a controlled setting.
Unfortunately, despite initial optimism, geneti-
cally engineered mouse models still have signifi-
cant limitations. First, these models still possess all
the same limitations of mouse models that have
previously been discussed. Second, the anticipated
phenotype is not always achieved.54 This is espe-
cially relevant for complex disease processes, such as
Barrett’s carcinogenesis, where multiple factors are
involved in disease pathogenesis. In this instance, the
addition of reflux may be required to generate the
desired phenotype, as demonstrated by Fein et al.55
Both factors make it difficult to interpret the results
and relate them to the human disease process.
Despite these shortcomings, several key stud-
ies have attempted to investigate the fundamental
questions related to the pathogenesis of BE using
142 Ann. N.Y. Acad. Sci. 1434 (2018) 139–148 C⃝ 2018 New York Academy of Sciences.
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transgenic models. Such areas include the cell of
origin of BE and the role of inflammation and sig-
naling pathways in the pathogenesis of BE.
In a study by Quante et al., a transgenic
mouse model was used to assess the effect of
esophageal inflammation on the Barrett’s car-
cinogenesis sequence.17 In this model, interleukin
(IL)-1!, a proinflammatory cytokine upstream of
IL-6 and TNF-", was overexpressed. This led to a
Barrett’s-like metaplasia at the SCJ, representative of
the human disease. Through lineage tracing exper-
iments, the authors also concluded that the meta-
plasia was due to the migration of Lgr5+ cells from
the gastric cardia.17
Another signaling pathway implicated in the
pathogenesis of BE is the Hedgehog pathway,
which drives the development of the CLE during
embryogenesis.36 To test if the reactivation of this
pathway is sufficient to induce a columnar pheno-
type in the adult esophagus, Wang et al. used a
conditional Shh transgenic model.18 Following
transduction, esophageal epithelial cells were cocul-
tured with fibroblasts within an ex-vivo trans-
plantable culture system. While Shh expression
failed to generate an overt columnar epithelium
in this model, it did lead to the expression of the
columnar markers cytokeratin 8/18 and Sox9.
In a study addressing the cell of origin of BE,
Wang et al. elected to use the p63-deficient mouse
in an attempt to model the damage caused by
reflux.56 As p63 is required for the self-renewal
of stem cells within stratified epithelium, these
mice fail to generate stratified epithelial tissues
and can only survive in utero. By assessing the
embryonic tissue, the authors claimed that these
mice generated Barrett’s-like metaplasia, consistent
with the human disease and that the columnar cells
originate from residual embryonic cells located
at the SCJ.56 However, a criticism of this study is
that the authors were simply studying a defect of
embryogenesis rather than true metaplasia and
that their conclusions may not be valid. More
recently, however, Jiang et al. have challenged these
findings.57 Jiang et al. were the first group to identify
a transitional zone at the SCJ in both humans and
mice. This transitional zone is characterized by
basal cells that express both squamous (p63, KRT5)
and columnar (KRT7) markers and suprabasal cells
that only express columnar markers. Lineage trac-
ing confirmed that these KRT7 positive suprabasal
cells originated from the basal layer of the tran-
sitional epithelium. Using a mouse model that
was genetically engineered to express the intestinal
transcription factor CDX2, this transitional zone
was shown to expand. This led to a gradual decrease
in squamous markers and an increase in columnar
markers, typical of the human disease process.
Genetically engineered mouse models have also
been combined with surgically induced reflux mod-
els in an attempt to investigate the role of both can-
didate genes and environmental exposures within
a controlled system. However, it was precedent on
the successful generation of the reflux model within
the mouse. The first report of such a model was in
1999 by Fein et al.55 In this study, a total gastrectomy
was performed in conjunction with an esophagoje-
junostomy on the wild type, p53 gene knockout or
APC-mutated mice. The results revealed that both
p53 loss and APC-mutation were associated with
the formation of a CLE, whereas only p53 loss was
associated with progression to AC. Xu et al. later
conducted further work assessing the feasibility of
the surgically induced reflux model in mice.58 In that
study, the authors reported an extremely low oper-
ative mortality rate of only 7.5%. Consistent with
earlier studies conducted in rats, both CLEs and
carcinomas were evident. The carcinomas were pre-
dominantly either squamous or adenosquamous,
and their rate of formation increased significantly
with additional carcinogen administration. Raggi
et al. also conducted similar work assessing the
suitability of the mouse model.33 However, they
reported a much higher incidence of AC formation
without the need for carcinogen. Given the steep
learning curve and difficulties associated with oper-
ating on small animals,33 an alternative technique
has been developed that employs micromagnets to
induce fistula formation.59
In vitro models
In vitro models are tools in which cells are cultured
and studied outside of their native environment.
To study BE, cells are typically derived from either
the normal esophagus or regions of BE. However,
as cells derived from freshly digested tissue tend to
have a finite life span, the majority of research has
focused on cells that have been immortalized. The
successful culture of cells also requires the estab-
lishment of an artificial environment that attempts
to recreate the in vivo conditions. Examples include
143Ann. N.Y. Acad. Sci. 1434 (2018) 139–148 C⃝ 2018 New York Academy of Sciences.
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the simple two-dimensional culture of cells on plas-
tic to more complex coculture systems that recreate
a three-dimensional environment. More recently,
organoid models have gained popularity in the field
of Barrett’s carcinogenesis.
Cell lines
In addition to established cancer cell lines, a num-
ber of immortalized epithelial cell lines have been
generated from both normal esophageal tissue and
BE, creating the potential to study multiple stages of
the metaplasia-carcinoma sequence in the in vitro
setting. The first such cell line, HET-1A, was devel-
oped in 1991.60 In this study, normal esophageal
tissue was collected at autopsy and cultured under
serum-free conditions using an explant technique.
Epithelial cells were then immortalized following
transfection with viral genes (simian virus 40 large
T-antigen).60 An alternative technique for cell
immortalization is via the expression of hTERT,
the catalytic subunit of telomerase.61 hTERT acts
to maintain the lengths of the telomeres, which are
protective structures at the end of chromosomes.
Under normal conditions, telomeres undergo
shortening with each cell division and, once a
critical length is reached, trigger a permanent cell
cycle arrest.61 Using this technique, numerous
normal esophageal and Barrett’s cell lines have been
created.15,61 As an extension of the simple in vitro
culture of established cell lines, numerous studies
have augmented the culture conditions through the
addition of both acid and bile salts.62,63 While there
are no standardized culture conditions, the addition
of acid and bile salts has been demonstrated to
induce BE-specific molecules.62
Unfortunately, established cell lines are clonal,
and the identity of their progenitor cell is
unknown, limiting their use in the study of Bar-
rett’s carcinogenesis.15 In theory, for a cell line to be
of value in the study of Barrett’s carcinogenesis, it
needs to be derived from the Barrett’s cell of origin,
which could include any number of sources, such as
squamous cells, ductal cells, cells from the ESMG,
transitional cells, or gastric cardia cells.4
As the stroma has been reported to play a crucial
role in the pathogenesis of BE,18 in vitro assays based
purely on epithelial cell lines may also be ignoring
key interactions with the microenvironment. In an
attempt to overcome this limitation, the more com-
plex organotypic model was developed.
Organotypic models
The organotypic assay was originally published in
1983 and was developed to better recapitulate the in
vivo conditions of epithelial cells. Through the use of
a collagen basal layer and an air–liquid interface, it
was demonstrated that cultured skin keratinocytes
could form a three-dimensional polarized epithe-
lium both in vitro and in vivo using a transplantable
culture system.64 However, it took another 20 years
before a group led by Rustgi adapted this model for
the study of esophageal epithelium.65 In this study,
the model was modified to include the seeding of
fibroblasts within the collagen matrix before it was
subsequently used to assess the effect of epidermal
growth factor receptor overexpression on epithe-
lial homeostasis. Over the course of the following
decade, Rustgi authored numerous other studies
based on this model, including both methodologi-
cal and mechanistic studies.12,66–70 Using this model,
researchers have attempted to investigate the factors
related to the pathogenesis of the columnar meta-
plasia seen in BE. These factors include signaling
pathways and transcription factors, such as WNT
and COX2,71 CDX1 and c-MYC,69 in addition to
the role of acid exposure.12 Although these stud-
ies reported an upregulation of intestinal markers
and varying degrees of mucin production, an overt
Barrett’s phenotype, consisting of a single layer of
columnar cells, was not achieved. The organotypic
model has also been used as a tool to promote the in
vitro differentiation of intestinal stem cells.72 This
characteristic is thought to be the result of enhanced
oxygen delivery to the cells and occurs because the
thin film of media used within the model provides
only a minimal barrier for gas diffusion.73
In addition to the culture of normal keratinocytes,
the organotypic model can also be used to culture
cancer cells. To investigate the role of the stroma
on the invasiveness of EAC, Underwood et al. cul-
tured the established cancer cell lines Flo-1 and
OE33 in combination with either normal or cancer-
associated fibroblasts.74 The results from this study
revealed an increase in tumor cell invasion in the
presence of cancer-associated fibroblasts, partly due
to the matricellular protein periostin.
Organoid models
Organoids are complex structures that resemble
their tissue of origin and are grown in vitro from
individual stem cells.75 Sato et al. first described the
144 Ann. N.Y. Acad. Sci. 1434 (2018) 139–148 C⃝ 2018 New York Academy of Sciences.
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– Ability to test the functional effect of
different genes and exposures in a
controlled setting
– Fails to demonstrate a natural BE phenotype without significant
manipulation
– Key anatomic and histologic differences with respect to the human
(absence of ESMG, presence of a keratinized squamous epithelium,
and SCJ located in the forestomach)
– Expected phenotype is not always achieved
– Tumors tend to demonstrate a phenotype different from that of
human tumors (benign appearance, submucosal, increased rate of
ESCC, mucinous, and fail to metastasize)
– Technically difficult to generate surgically induced reflux models
Canine – Presence of ESMG
– Reported to develop a natural BE and
EAC phenotype
– Can be combined with a surgically
induced reflux model
– Large animal and requires significant resources
– Length of time to develop BE and EAC (up to 5 years)
– Unable to be genetically manipulated
In vitro
Cell lines – Cost
– Reproducibility




– Typically require established or immortalized cell lines
Organotypic – Three dimensional
– Can assess the effect of cell interactions
– Manipulable
– Lacks other essential cellular elements (e.g., stromal and
inflammatory cells)
– Unable to generate a true BE phenotype
Organoid – Reproducible
– Three dimensional
– Ongoing tissue resource
– Lacks other essential cellular elements (e.g., stromal and
inflammatory cells)
– Unable to culture human squamous organoids
ESMG, esophageal submucosal gland; SCJ, squamocolumnar junction; BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma;
ESCC, esophageal squamous cell carcinoma.
model in their seminal paper entitled “Long-term
expansion of epithelial organoids from human
colon, adenoma, AC, and Barrett’s epithelium.”76
The key to the development of this model was the
identification of the essential factors required for
stem cell maintenance. These factors include R-
spondin (WNT agonist), Noggin (BMP inhibitor),
epidermal growth factor, and Matrigel to recreate
the laminin-rich crypt microenvironment.76
The great power of this model is that it can
reconstitute a complete Barrett’s phenotype from
individual stem cells obtained from fresh biop-
sies, negating the use of established cell lines for
preclinical studies. As organoids provide an ongo-
ing tissue resource, there is also great potential to
establish organoid biobanks for sharing of resources
among researchers and replication of results. Com-
pared with cell lines, organoids also provide a
much better model of the molecular and genetic
diversity seen within the human disease. Unfortu-
nately, while squamous organoids derived from the
murine esophagus have been readily cultured using
this model,76,77 researchers have failed to develop
a reproducible technique for the culture of squa-
mous organoids derived from the human esoph-
agus. However, encouragingly, researchers have
recently optimized the generation of squamous
organoids from the porcine ESMG.78 Given the his-
tological similarities with the human esophagus,
efforts should now be made to generate squamous
organoids from the human esophagus using similar
techniques.
Summary
This review highlights the range of preclinical mod-
els that have been used for the study of Barrett’s
carcinogenesis (summarized in Table 1). It also
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identifies a number of key discoveries that have been
made using these model systems. While the recently
developed organoid models show great promise, it
is clear that the ideal model for the study of Barrett’s
carcinogenesis is lacking. Thus, the choice of model
system needs to be tailored to the hypothesis being
investigated. Researchers may even find it prudent
to use multiple models when answering a research
question. For example, the organoid model may be
used as a screening tool to assess potential com-
pounds before progressing to animal models and,
if successful, further progressing into clinical trials.
Hopefully, such an approach will lead to improved
patient outcomes.
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In summary, OAC is devastating malignancy and is associated with a significant health burden.  
Whilst some progress has been made over recent years in regard to improving patient 
outcomes, the survival rates are still poor.  It is clear that a greater understanding of the 
factors responsible for the both initiation of BO and its progression to OAC are required for 
continued improvements to be made.  However, a key barrier to research has been the 
paucity of well-validated preclinical models that recapitulate the human disease process.  The 
main aim of this thesis is to both develop and validate additional preclinical models for the 
study of Barrett’s carcinogenesis, in the hope that this will enable a greater understanding of 
disease biology and lead to improved treatment options.  Central to this is the optimisation of 
the PDTX model, a model that is used extensively in cancer research, as well as exploring many 








Severe combined immunodeficiency (SCID), Non-obese diabetic / severe combined 
immunodeficiency (NOD SCID) and NOD/SCID interleukin-2 receptor gamma chain knockout 
(NSG) mice were all used for the primary establishment of PDTX.  Only NSG mice were used 
for cell injection xenografts.  Mice were obtained from either the Animal Resource Centre 
(Canning Vale, Western Australia), the Walter & Eliza Hall Institute (Melbourne, Victoria) or 
bred internally at The Peter MacCallum Cancer Centre (Melbourne, Victoria).  The Animal 
Experimentation Ethics Committee at The Peter MacCallum Cancer Centre approved all 
animal studies.  Mice were housed in filter cages and received standard pellet feed and water 
whilst being kept on a 12-hour day / 12-hour night cycle. 
 
2.1.2 Human Tissue 
 
The Human Research Ethics Committee at The Peter MacCallum Cancer Centre provided the 
initial approval for the collection of human tissue for research purposes.  Following this, both 
the St Vincent’s Hospital in Melbourne and Cabrini Hospital in Malvern were recruited as 
additional tissue collection sites.  This required the approval from the research ethics 
committee at both sites following the submission of an amended human research ethics 
committee (HREC) form, site specific assessment (SSA) form, patient information and consent 
form (PICF) and research collaborative agreement.  The PICF has been included in appendix 1. 
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Table 2-1 General chemicals and reagents 
Reagent Description / Supplier 
0.9% NaCl Pfizer, NSW, Australia 
5-fluorouracil Hospira, Victoria, Australia 
Alcian blue stain (1% w/v Alcian blue, 8GX in 3% v/v acetic acid, pH 2.5) Sigma-Aldrich, St. Louis, MI, USA  
Anaesthetic solution (normal saline with ketamine (10mg/mL) and xylazine (2mg/mL))  
Fluorescence-activated cell sorting (FACS) Blocking Buffer (PBS-/- supplemented with 2% BSA and 2% FCS) 
 
5% w/v skim milk, 0.1% v/v Tween 20 in Tris-buffered saline)  
Bromo-2’-deoxyuridine (BrdU) Sigma-Aldrich 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Calcein / cell dissociation solution Thermo Fisher Scientific, Waltham, MA, USA 
Chlorhexidine gluconate (2% v/v/) / isopropyl alcohol (70% v/v) Perrigo, WA, Australia 
Cisplatin Hospira 
Collagenase A Roche Diagnostics, Mannheim, Germany 
Dispase II Roche Diagnostics 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 




Reagent Description / Supplier 
Dulbecco's Modified Eagle Media (DMEM) Life Technologies, Victoria, Australia 
EpiGROTM (basal medium supplemented with L-glutamine (6mM), EpiFactor P (0.40%), Epinephrine (1.0μM), 
rh TGF-a (0.5ng/mL), hydrocortisone hemisuccinate (100ng/mL), rh Insulin (5μg/mL) & Apo-Transferrin 
(5μg/mL)) 
Merck Millipore, Burlington, MA, USA 
EpilifeTM (Serum free basal medium with propriety supplements formulated for the culture of keratinocytes) Invitrogen, Carlsbad, CA, USA  
Foetal calf serum (FCS) Gibco, Dublin, Ireland 
Fluorodeoxyglucose [18F]FDG Provided by the Nuclear Medicine 
department at PMCC 
Freezing solution (FCS + 10% DMSO) 
 
Gentamicin Sigma-Aldrich 
Hanks buffered salt solution without CaCl2 or MgCl2 (HBSS -/-) Thermo Fisher Scientific, Waltham, MA, 
USA 
Human intestinal stem cell (HISC) medium  (DMEM/F12 supplemented with 1xB27, recombinant R-spondin 







Reagent Description / Supplier 
Isofluorane AbbVie, NSW, Australia 
Ketamine Parnell Laboratories, NSW, Australia 
Labelling buffer (PBS-/- supplemented with 2% BSA) 
 
Luciferase / enhanced green fluorescent protein (eGFP) vector Gift from the Shackleton Laboratory 
Luciferin Promega, Madison, WI, USA 
Matrigel® (354234) BD Biosciences, Franklin Lakes, NJ, USA 
MCDB 153 Sigma-Aldrich 
Normal buffered formalin (NBF) Perrigo 
Nuclear fast red (0.1% Nuclear fast red in 5% w/v aluminium sulphate)  
Tissue dissociation solution (HBSS supplemented with 6mg/ml Dispase II and 3 mg/ml of Collagenase A) 
 
OPSITE Spray Smith & Nephew, Victoria, Australia 
Penicillin Gibco 
Phosphatase Inhibitor (PhosphoSTOP) Roche 
Protease Inhibitor (Complete ULTRA) Roche 
Dulbeco’s phosphate buffered solution without CaCl2 or MgCl2 (PBS -/-) Gibco 
PBS++ (PBS-/- supplemented with penicillin 200 U/ml & streptomycin 200 μg/ml) 
 




Reagent Description / Supplier 
Propidium Iodide Thermo Fisher Scientific 
Western Blot Rinsing Buffer (0.1% v/v Tween 20 in Tris-buffered saline)  
RIPA Buffer (1 mmol/L EDTA; 1% v/v NP40; 0.5% w/v sodium deoxycholate; 0.1% v/v SDS; 50 mmol/L sodium 
fluoride; 1 mmol/L sodium pyrophosphate in PBS) 
Sigma-Aldrich 
RPMI 1640 Life Technologies 
Sequebrene Sigma-Aldrich 
Skim milk (5% w/v) Fonterra, Victoria, Australia 
Soybean Trypsin Inhibitor (0.5mg/ml) Life Technologies 
Streptomycin Bayer, Leverkusen, Germany 
Trypsin 0.05% Gibco 
Trypsin 0.25%-EDTA Life Technologies 
Tris-buffered saline BDH, Poole, UK 





Table 2-2 Antibodies used for immunohistochemical analyses 
 
Antibody Cat. No. Concentration Supplier 
AE1/AE3 NCL-L 1:200 Leica Biosystems, Victoria, Australia 
Anti-BrdU 347580 1:100 BD Transduction Laboratories, Franklin Lakes, NJ, USA 
Anti-human mitochondrial antibody MAB1273 1:500 Merck Millipore, Billerica, MA, USA 
CD20 760-2531 0.3!g/ml Ventana Roche, Tucson, AZ, USA 
CD45 M0701 1:200 DakoCytomation, Glostrup, Denmark 
CDX2 235R-16 1:200 Cell Marque, Rocklin, CA, USA 
Cleaved caspase-3 9661S 1:300 Cell Signaling Technology, Danvers, MA, USA 
CK5 305R-16 1:50 Cell Marque  
CK7 POV-TL 12/30 1:50 DakoCytomation 
CK19 RCK108 1:100 DakoCytomation 
HMW 334M-85 1:200 Cell Marque 
Ki67 790-4286 2!g/ml Ventana Roche 
MLH1 NCL-L 1:50 Leica Biosystems 
MUC2 15334 1:50 Santa Cruz Biotech 
MUC5AC MRQ-18 1:100 Cell Marque 
p40 AC13066C 1:100 Biocare Medical, Pacheco, CA, USA 
p63 m7317 1:100 DakoCytomation 
PMS2 760-5094 1!g/ml Ventana Roche 
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Table 2-3 Antibodies used for the FACS sorting of xenograft-derived cells 
 




Antibody Cat. No. Concentration Supplier 
Human EpCAM/TROP1 - Fluorescein isothiocynate (FITC) AB9601F 1:5 R&D Systems, Minneapolis, MN, USA 
Human leukocyte antigen (HLA) - FITC BD 555552 1:5 BD Transduction Laboratories 
Mouse IgG2B – FITC (EpCAM isotype control) IC0041F 1:5 R&D Systems 
Mouse IgG1 – FITC (HLA isotype control) BD 555909 1:50 BD Transduction Laboratories 
Antibody Origin Dilution Clone Supplier 
Primary     
DAPI  1:1,000 D1306 Thermo Fisher Scientific 
CD44 Rabbit 1:100 157107 Abcam, Cambridge, MA, USA 
CD133 Rabbit 1:100 OAAI00379 Aviva Systems Biologicals, San Diego, CA, USA 
Lgr5 Rabbit 1:100 75732 Abcam 
Secondary     
488 IgG (green) Donkey 
(anti-rabbit) 
1:1000 A21206 Invitrogen, Waltham, MA, USA 
594 IgG (red) Donkey 
(anti-rabbit) 
1:1000 A21207 Invitrogen 
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Table 2-5 Antibodies used for the western blot analysis of xenograft-derived cells 
Antibody Origin Clone Supplier 
Anti E-cadherin Rabbit EP700Y Abcam 
Anti N-cadherin Mouse 32/N-Cadherin BD Transduction Laboratories 
Anti-GAPDH Mouse 6C5 Abcam 
Anti-Vimentin Rabbit R28 Cell Signaling Technology 
Anti-rabbit Swine P0217 Dako 
Anti-mouse Goat P0447 Dako 
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Table 2-6 Equipment for mice preparation and experiments 
Description Supplier 
Scales  
Ear clippers  
Heat pad  
LACRI-LUBEÒ  Allergan, NSW, Australia 
0.5mL 29-gauge insulin syringe  
 
Table 2-7 Equipment and surgical instruments 
Category Contents 





Sutures • 3/0 vicryl on a reverse cutting needle 
• 4/0 vicryl rapide on a reverse cutting needle 
• 5/0 prolene on a reverse cutting needle 
Instruments • Needle holders 
• Plain or Debakey forceps 
• Adson forceps 
• Iris scissors 
• Baby Metzenbaum scissors 
• Scalpel blade holder 
• Scalpel blade 
 
Table 2-8 Special equipment for tissue processing and both in vivo and in vitro cell culture 
Description Supplier 
Amicon Ultra 15 (Cat. No. UFC900308) Merck Millipore 
Hat chamber culture system (Cat. No. 30268) Renner KG, Dannstadt, Germany 
McIlwain tissue chopper Mickle laboratory Engineering, Surrey, UK 
ProGripTM mesh Medtronic, Dublin, Ireland 
T25 collagen coated cell culture flask (Cat No. 
354534) 
BD Transduction Laboratories 
Terasaki plate BD Transduction Laboratories 
 
 61 
Table 2-9 Description and culture conditions of established cell lines 
Cell line Type Media 
HET-1A (Stoner, Kaighn, Reddel, Resau, Bowman et al., 
1991) 
Immortalised cell line derived from normal oesophageal 
squamous epithelium 
MCDB 153 
BAR-T (Jaiswal, Morales, Feagins, Gandia, Zhang et al., 2007) Immortalised cell line derived from BO MCDB 153 




2.2.1 Mechanical and enzymatic digestion of primary tumour 
 
Primary tissue was both mechanically and enzymatically digested as previously described 
(Clemons, Do, Fennell, Deb, Fellowes et al., 2014).  Following dissection from a surgical 
specimen, tumour tissue was placed in PBS+++ and kept on ice until further processing.  Under 
aseptic conditions and within the confines of a cell culture hood, tumour tissue was placed on 
a petri dish and chopped into a slurry using a number 23 scalpel blade.  The slurry was then 
incubated overnight in 6mg/ml of Dispase II.  Following this, the suspension was centrifuged 
at 1,500 rpm and the pellet re-suspended in pre-warmed 0.25% trypsin-EDTA solution for 5 
minutes at room temperature.  The trypsin solution was then neutralised using 0.5mg/ml of 
soybean trypsin inhibitor and the suspension passed through a 70μm cell strainer.  The filtrate 
was then centrifuged at 1,500 rpm and the pellet re-suspended in DMEM supplemented with 
20%FCS.  The cell solution was then plated and cultured at 37oC and 5% oxygen.  Media was 
changed three times per week. 
2.2.2 Positron-emission tomography Imaging 
 
For assessment of [18F]FDG positron-emission tomography (PET) avidity, mice bearing first 
generation xenografts were first anesthetized using isofluorane and then imaged using the 
Philips Mosaic small animal PET scanner, 90 minutes after receiving 14.8 MBq of [18F]FDG via 
unilateral tail vein injection. 
2.2.3 Mechanical and enzymatic digestion of patient-derived tumour xenografts 
 
Viable xenograft tissue was digested using a modification of the Civenni technique (Civenni, 
Walter, Kobert, Mihic-Probst, Zipser et al., 2011).  Xenografts were initially chopped into small 
pieces using a scalpel and then passed through a mechanical tissue chopper multiple times in 
order to yield a fine slurry.  After processing, the slurry was collected in PBS++, briefly vortexed 
and then centrifuged at 1,500 rpm for five minutes.  Following aspiration of the supernatant, 
the cell slurry was then re-suspended in tissue dissociation solution at a concentration of 10ml 
per gram of tissue.  This was then placed in a 37oC water bath for 45 minutes, with tituration 
every 5 minutes.  After 45 minutes of enzymatic dissociation, the entire solution was 
centrifuged at 1,500 rpm for 5 minutes.  The supernatant was then aspirated, and the cell 
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pellet resuspended in RPMI supplemented with 10% FCS in order to neutralize the tissue 
dissociation solution.  After vortexing, the suspension was then passed through a 40μm cell 
strainer in order to yield a single cell solution. 
 
2.2.4 Sphere formation assay 
 
Cells were collected in Eppendorf tubes following FACS sorting.  Eppendorf tubes were then 
centrifuged at 1500 r.p.m. for 5 minutes.  Following this, the supernatant was aspirated and 
cell pellets resuspended in 25μL of Matrigel.  The Matrigel / cell suspension was then seeded 
into individual wells of a 48 well plate and the Matrigel then allowed to polymerise at 37oC for 
ten minutes.  Following polymerization, 250uL of HISC media was then added to each well. 
2.2.5 eGFP transduction of established cell lines 
 
Established cell lines are lifted and split into a six-well tissue culture plate at a seeding density 
of 2×105 cells per well.  Once the cells were approximately 50% confluent, the old media was 
aspirated and the cells washed with PBS-/-.  500μl of eGFP/luciferase lentivirus, 250 μl of 
media and 0.75μl of sequebrene were then added to each well.  The plate was then gently 
rocked to ensure an even distribution of virus and linker molecule.  A spin inoculation was 
subsequently performed by placing the multi-well plate in a centrifuge at 2500 rpm for 30 
minutes at 30oC.  The cells were then incubated for 12 hours before the media was changed.  
Following a period of passaging, the cells were lifted and filtered using a 40μm filter in order 
to form a single cell suspension.  These cells were then sorted via FACS based on GFP 
expression.  Matched non-transduced cells were used as an isotype control.   
 
2.2.6 FACS sorting of both freshly isolated xenograft derived cells and cultured cells 
 
FACS sorting of both freshly isolated xenograft cells and established xenograft derived cell 
lines was performed using the BD FACSAria II System.  Sorting was performed based on the 
expression of epithelial cell adhesion molecules (EpCAM), human leucocyte antigen (HLA) and 
eGFP expression.  Details of the antibodies used for FACS are provided in Table 2-3.  Following 
the formation of a single cell suspension, cells were resuspended in blocking buffer and 
incubated for 20 minutes at 4oC.  A cell count was then performed, and cells resuspended in 
labelling buffer at a concentration of 106 cells/10µl.  Primary antibodies, including isotype 
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controls, were applied for one hour and incubated at 4oC on a rotating mixer.   Cells were then 
washed twice with labelling buffer.  Unstained cells were kept aside for calibration and 
viability testing using PI at a concentration of 1:200.  For sorting based on eGFP expression, 
matched non-transduced cells were used as controls.  The following table details both of the 
primary antibodies that were used including concentrations and isotype controls.  Cells were 
then sorted on the basis of viability and either FITC or eGFP expression. 
2.2.7 Cytospin preparation 
 
Following FACS sorting, single cells were collected into Eppendorf tubes.  Following collection, 
the final volume of FACS buffer was adjusted in order to yield a final concentration of 5×105 
cells per ml.  Slides were then labelled and 200µl of cell solution added to each of the cytospin 
chambers.  Slides were then centrifuged at 250 r.p.m. for ten minutes.  Cytospin preparations 
were then immediately fixed in acetone for ten minutes before being allowed to air dry.  Slides 
were then stored at -30oC prior to being stained.  
 
2.2.8 Immunohistochemical assessment 
 
Immunohistochemical analysis was used to assess for the presence of human cells through 
the use of an antibody that reacts with human mitochondria.  These were performed on 
cytospin preparations in addition to formalin-fixed paraffin-embedded (FFPE) sections of 
PDTX and cell injection xenografts.  For FFPE samples the tissue was sectioned into 4μm slices 
and baked onto superfrost plus slides at 60oC for one hour.  FFPE sections were then dewaxed 
using xylene and then rehydrated in ethanol.  Antigen retrieval was then performed by boiling 
the slides for three minutes at a temperature of 125oC within a pressure cooker.   Slides were 
then cooled in tap water before being blocked using the Dako peroxidase blocking system for 
five minutes.   After washing with Tris-Buffered Saline with 0.1% Tween 20 (TBST), slides were 
then blocked using 10% BSA for one hour.  The primary antibody was then applied and left to 
incubate for one hour at room temperature or overnight at 4oC.  A secondary antibody, 
conjugated with HRP, was then applied and incubated for 45 minutes at room temperature. 
DAB staining was then performed, and the slides washed with water.  Following antibody 
incubation, slides were washed three times with TBST.  
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Immunohistochemical (IHC) staining against the proteins CDX2, MUC5AC, AE1/AE3, HMW, 
p63, CK5, p40, MLH1, PMS2 and CD45 was performed by the Department of Pathology at the 
Peter MacCallum Cancer Centre using an automated staining machine.  All IHC staining was 
performed in conjunction with positive and negative controls.  Details of the antibodies used 
for IHC analyses are provided in Table 2-2. 
2.2.9 Alcian blue staining 
Tissue sections were stained with Alcian blue for 30 minutes at room temperature before 
being rinsed in distilled water for two minutes.  Following this, sections were then counter 
stained with nuclear fast red for five minutes before being rinsed in distilled water.  Sections 
were then dehydrated in 95% alcohol followed by two changes in absolute alcohol.  
2.2.10 DNA extraction and sequencing 
 
DNA was extracted from both FFPE and snap frozen tissue in addition to cells in culture using 
the DNeasy Blood and Tissue kit (QIAGEN) as per the manufacturer’s protocol.  
 
2.2.10.1 Targeted oncogene panel 
 
Following DNA extraction, targeted sequencing across a panel of 48 known oncogenes (Table 
2-10) was performed by the Department of Pathology at the Peter MacCallum Cancer Centre 
using the Illumina TruSeq Amplicon Cancer Panel (Illumina, San Diego, CA, USA) as previously 
described (Clemons, Do, et al., 2014) . 




2.2.10.2 Short tandem repeat analysis 
 
Following extraction, DNA was submitted for short tandem repeat (STR) genotyping to either 
the Australian Genome Research Facility using the PowerPlex 16HS System (Promega) or the 
Victorian Centre for Functional Genomics using the Promega GenePrint 10 System (Promega). 
2.2.11 Tumorigenic assay 
 
Established cell lines were resuspended in a 1:1 mixture of serum free media and Matrigel at 
a concentration of 5×106 cells per 100μl.  After being anaesthetized with isoflurane, NOD-SCID 
IL-2RgKO (NSG) mice were then injected subcutaneously in the flank region with 5×106 cells.  
Mice were then closely monitored for tumor formation and culled according to guidelines 
once tumors reached the ethical limit of 1500 mm3, as calculated by the formula (length × 




2.2.12 Determining the tumour initiating cell frequency in the oesophageal PDTX model 
through the use of an extreme limiting dilution assay 
 
In order to determine the frequency of TIC within the PDTX model, an extreme limiting dilution 
assay (ELDA) was performed.  This involved performing a series of tumorigenic assays 
consisting of differing number of cells per injection, ranging from 5×106 to single cells.  Cell 
numbers per injection were established via serial dilution.  However, for single cell injections, 
cells were collected via FACS, having been sorted based on EpCAM, into individual wells of a 
Terasaki plate.  Individual cells were then resuspended in 100µl of serum free media and 
Matrigel in a 1:1 ratio.  The cell suspension was then pipetted into a 29-gauge insulin syringe 
and kept on ice until subcutaneously injected into the flank of an NSG mouse.  Mice were then 
closely monitored for tumor formation as previously described in section 2.2.11.  Once 
tumours were established, a calculation of TIC frequency was performed using ELDA online 
calculator provided by the Walter and Eliza Hall Institute of Medical Research, Melbourne 
(http://bioinf.wehi.edu.au/software/elda/). 
 
2.2.13 Assessment of metastatic burden 
 
Mice harbouring cell injection xenografts formed by eGFP/luciferase-transduced cells were 
imaged using the Xenogen IVIS 100 Imaging System (Caliper Life Science, Hopkinton, MA, 
USA).  Prior to imaging, mice were injected subcutaneously with 100μl of luciferin (20mg/ml) 
and subsequently anaesthetised using isoflurane for imaging.  Mice were imaged using a 60 
second exposure time.  For ex vivo imaging, harvested organs and tumours underwent a five-
minute exposure.   
2.2.14 Western blot analysis 
 
Cells were plated into a 10 cm tissue culture dishes cultured overnight.  Cells were then lysed 
at 4°C in RIPA buffer containing both phosphatase and protease inhibitors.  Protein 
concentrations were quantified against standard curves. Equivalent amounts of protein 
lysates were boiled and loaded into the wells of the SDS-PAGE gel.  The gel was then run at 80 
V for 20 minutes followed by 120 V for 60 minutes.  Proteins were then transferred to PVDF 
membranes.  Membranes were incubated for 1 h in blocking buffer and probed overnight at 
4°C with the primary antibody. Blots were washed three times in rinsing buffer for five 
minutes each, followed by incubation with peroxidase-conjugated secondary antibody (Dako) 
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for 2 h at room temperature. Proteins were visualised by ECL Plus Western blotting substrate 
kit (Thermo Fisher Scientific).  Blots were reprobed with anti-GAPDH antibodies to assess 
protein loading.  Table 2-5 provides a summary of the antibodies used.  
2.2.15 Migration assay 
 
For the migration assay a number of different chemoattractants were used including serum 
free media, media containing 10% FCS and both normal associated fibroblast (NAF) and cancer 
associated fibroblast (CAF) concentrated conditioned media.  Fibroblast conditioned media 
was established by culturing either NAFs or CAFs in DMEM with 10% FCS until they were 80% 
confluent.  Fibroblasts were then serum starved for 24 hours.  The conditioned serum free 
media was then collected and filtered through a 0.22µm.  The conditioned media was then 
concentrated using the Amicon Ultra 15 centrifugal filter by spinning at 3,100g for 25 minutes.  
In this process 15ml of conditioned media was concentrated to a final volume of 600µl.  
Protein levels were then measured. 
 
Established cell lines were cultured in T75 flasks until approximately 80% confluent.  Cells 
were then washed twice with PBS -/- before being serum starved overnight at 37oC and 5% 
CO2.  Cells were then lifted and resuspended in serum free media.  A cell count was then 
performed.  Migration assays were then set up using the 96 well High Throughput Screening 
8µm pore size apparatus (Corning Cat. No. 3374).  Well inserts were then plated with 5×104 
cells in 50µl of serum free media.  The lower reservoirs were filled with 150µl of varying 
chemoattractants.  Cells were then incubated for 24 hours.  A standard curve of cell number 
to relative fluorescent unit was then established as per the manufacturer’s protocol.   Inserts 
were then washed once and receiver wells twice with PBS -/-.   The insert tray was then placed 
into a separate receiver well containing 100µl of Calcein AM/CDS solution.  Plates were then 
incubated for one hour at 37oC.  Fluorescent readings were then recorded using the 
POLARStar OPTIMA multi-plate reader (BMG Labtech, Ortenberg, Germany) at an excitation 
wavelength of 485nm and emission wavelength of 520nm.  
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Chapter 3 Optimising the oesophageal patient-derived 
tumour xenograft model 
3.1 Introduction 
 
Xenograft models have proven to be valuable tools in the field of cancer research.    
Traditionally, xenografts have been created from the injection of established cell lines into 
immunodeficient host mice.  As this model can be easily manipulated, it has proven to be a 
powerful tool for mechanistic studies.  However, it does have limitations.  With respect to 
OAC, there are only twelve widely available, bona fide cell lines and not all of these are 
tumorigenic (Liu, Duong, et al., 2016).  Additionally, cell injection xenografts lack both the 
stromal elements and heterogeneity typically associated with OAC.  One model that 
overcomes these limitations and is currently being used quite extensively in other cancers is 
the PDTX model.  
 
In the PDTX model, fresh pieces of original patient tumour, denoted as F0, are divided into 
approximately 1-2mm3 and implanted into immunocompromised mice.  Typically, a 
heterotopic transplantation site, such as the subcutaneous space is used.  However, other 
sites, such as the renal capsule, have also been reported (Tentler et al., 2012).  Following 
successful engraftment, denoted as F1, the xenografts are then harvested, divided and 
implanted into a further cohort of immunocompromised mice.  This is known as the expansion 
phase and is denoted Fx (where x refers to the generation or passage number).  This process 
of serial transplantation continues indefinitely, or until the required numbers are reached for 
a specific experiment (Tentler et al., 2012) (Figure  3-1). 
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Figure  3-1 Xenograft models in cancer research 
A diagrammatic representation of the two main types of xenograft models used in cancer 
research.  On the left is the cell injection xenograft model (A).  In this model, in vitro cell lines 
are established from patient tumours.  These cell lines are then injected into an 
immunodeficient host mouse in order to form a xenograft.  Alternatively, in the PDTX model 
(B), pieces of original patient tumour, rather than established cell lines, are implanted.  
Xenografts are then passaged multiple times in order to generate the required number of 
cohorts.   
 
In order to verify that PDTX models recapitulate the human disease process they must 
undergo a strict process of validation (Decaudin, 2011).  Validation requires a comparison 
between the characteristics of both the original patient tumour and the derived xenograft.  
Characterisation should consist of histopathological, IHC and molecular evaluation, as 
assessed by an expert pathologist.  Genomic profiling is also recommended to ensure that 
genetic abnormalities present within the original tumour are also present within the 
preclinical model (Decaudin, 2011).   
PDTXs are commonly used as preclinical tools to assess potential therapeutic responses.  
However, this relies on the PDTX model having a high predictive value.  For this to occur, it 
must respond in a similar fashion to the original patient tumour.  Unfortunately, there is no 
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way of validating the model’s response to novel and untested treatments.  In this situation, it 
needs to be assumed that the results seen in the preclinical setting will be translated to the 
clinical setting. 
Another challenge that is especially relevant in the field of OAC involves modelling the marked 
genetic diversity that exists within the disease, as a significant proportion of OACs develop 
catastrophic chromosomal events (Nones et al., 2014).  In order to overcome this limitation, 
repositories or ‘biobanks’ of PDTXs need to be established that incorporate a large range of 
mutations, especially those that are commonly mutated. 
In addition to its role in biomarker discovery and drug target validation, well-characterized 
PDTX models can also be used for many other purposes.  Examples include the study of 
metastasis, imaging assessments, angiogenesis and the identification of tumour initiating 
cells.  Additionally, with the development of orthotopic models comes the opportunity to 





Figure  3-2 Applications of the PDTX model in cancer research 
A diagrammatic representation of the multiple applications of the PDTX.  One of the PDTX 
model’s most popularized applications has been in the assessment of treatment responses and 
biomarker development.  Other applications include the investigation of disease biology, the 
assessment of imaging techniques and the generation of additional cell lines. 
 
Unfortunately, there has only been minimal success in generating PDTXs from OAC.  
Throughout the literature there have only been five studies that have reported the successful 
generation of PDTXs in OAC, with success rates ranging between 30 to 35% (J. J. Boonstra, R. 
van Marion, H. J. C. W. Douben, J. S. Lanchbury, K. M. Timms et al., 2012; de Both et al., 2001; 
Dodbiba, Teichman, Fleet, Thai, Sun et al., 2013a; El-Rifai, Harper, Cummings, Hyytinen, 
Frierson et al., 1998; Rumpel, Powell, & Moskaluk, 1999).  This is in stark contrast to many 
other tumour types and serves to highlight the need for an improved PDTX model in OAC 






Table 3-1 PDTX engraftment rates and cell line number across a range of different 
tumours. 
Cancer PDTX Engraftment Rate No. of Commercially Available Cell Lines 
PDAa 60% 20 
Lung 95% 200 
Breast 37% 84 
Prostate 90% 17 
Ovarian 95% 55 
Colorectal 40% 60 
Brain 96% 28 
OACb 35% 12 
 
aPDA, pancreatic ductal adenocarcinoma; bOAC, oesophageal adenocarcinoma 
 
("The European Collection of Authenticated Cell Cultures", 2019; Behrens, Walther, & Fichtner, 
2017; Cunningham & You, 2015; Gazdar, Girard, Lockwood, Lam, & Minna, 2010; Lengyel, 
Burdette, Kenny, Matei, Pilrose et al., 2014; Tentler et al., 2012). 
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3.2 Intramuscular transplantation improves engraftment rates for 
oesophageal patient-derived tumor xenografts  
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ABSTRACT
Background. Recently, there has been an increase in the
availability of targeted molecular therapies for cancer
treatment. The application of these approaches to esopha-
geal cancer, however, has been hampered by the relative
lack of appropriate models for preclinical testing. Patient-
derived tumor xenograft (PDTX) models are gaining
popularity for studying many cancers. Unfortunately, it has
proven difficult to generate xenografts from esophageal
cancer using these models. The purpose of this study was to
improve the engraftment efficiency of esophageal PDTXs.
Methods. Fresh pieces of esophageal tumors obtained
from endoscopic biopsies or resected specimens were
collected from 23 patients. The tumors were then coated in
Matrigel and transplanted in immunocompromised mice
subcutaneously (n = 6) and/or using a novel implantation
technique whereby the tumor is placed in a dorsal intra-
muscular pocket (n = 18). They are then monitored for
engraftment.
Results. With the novel intramuscular technique, suc-
cessful engraftment was achieved for all 18 patient tumors.
Among these PDTXs, 13 recapitulated the original patient
tumors with respect to degree of differentiation, molecular
and genetic profiles, and chemotherapeutic response.
Lymphomatous transformation was observed in the other
five PDTXs. Successful engraftment was achieved for only
one of six patient tumors using the classic subcutaneous
approach.
Discussion. We achieved a much higher engraftment rate
of PDTXs using our novel intramuscular transplant tech-
nique than has been reported in other published studies. It
is hoped that this advancement will help expedite the de-
velopment and testing of new therapies for esophageal
cancer.
Esophageal cancer is currently the eighth most common
cancer worldwide and has an extremely high case fatality
rate.1 Approximately 83 % of all cases occur in developing
countries, where squamous cell carcinoma (SCC) is the
main subtype.2 In the developed world, esophageal ade-
nocarcinoma poses the greater problem, as its incidence has
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risen more than sixfold over the last four decades.3 Cur-
rently, in the United States, only 17.5 % of all patients who
present with esophageal cancer survive more than 5 years.4
Alternative treatment strategies are needed to improve
disease outcomes. Progress is being hampered by a lack of
suitable preclinical models with which to study the disease
and test new therapies.
One model that has shown great promise in the field of
cancer research is the patient-derived tumor xenograft
(PDTX), in which the patient’s tumor tissue is grown and
expanded in immunocompromised mice. As these models
recapitulate the original patient tumors with respect to
histology, molecular and genetic profiles, and therapeutic
response, they are being increasingly used as preclinical
models for drug target validation and biomarker identifi-
cation.5 PDTXs also have the capacity to provide a
perpetual tissue bank, making them a valuable resource,
particularly for esophageal cancer, where the collection of
treatment-naive tissue is often limited to small endoscopic
biopsies obtained prior to neoadjuvant therapy.6 Unfortu-
nately, there has been limited success in generating
esophageal PDTXs, with success rates ranging between
30.0 and 38.5 %.7–13
Given the importance of the PDTX model to cancer
research, refinements that lead to improvements in en-
graftment efficiencies are of great benefit.14 One variable
with the potential to improve engraftment efficiency is the
transplantation site. Common sites for heterotopic trans-
plantation include subcutaneous (SC) and renal subcapsular
spaces.5 We hypothesized that an intramuscular (IM)
transplantation site might provide improved engraftment of




Scid, NOD scid, NOD-scid interleukin-2 (IL2) receptor
gamma chain knockout (NSG), and athymic nude mice
were obtained from either the Animal Resource Centre
(Canning Vale, Western Australia), or the Walter & Eliza
Hall Institute (Melbourne, Victoria), or they were bred
internally at the Peter MacCallum Cancer Centre (Mel-
bourne, Victoria). All mice were maintained and housed in
the animal facility of the Peter MacCallum Cancer Centre.
All experimental procedures involving animals were ap-
proved by the Peter MacCallum Cancer Centre Animal
Experimental Ethics Committee and conducted in accor-
dance with the National Health and Medical Research
Council (NHMRC) Australian Code for the Care and Use
of Animals for Scientific Purposes (8th edition, 2013).
Tissue Collection and Preparation
Patient tissue was collected from the Peter MacCallum
Cancer Centre, the Cabrini Medical Centre, and other
hospitals through the Victorian Cancer Biobank between
March 2012 and June 2014. The collection and use of
human tissue for this project was approved by the Ethics
Committee of the Peter MacCallum Cancer Centre and
carried out according to the NHMRC National Statement
On Ethical Conduct in Human Research (2007).
After obtaining informed consent, fresh samples of ei-
ther treatment-naive or posttreatment esophageal tumors
were collected from patients’ endoscopic biopsies or sur-
gical resection specimens. They were placed in chilled
phosphate-buffered saline (PBS) supplemented with peni-
cillin 200 U/ml and streptomycin 200 lg/ml (PBS??) and
kept on ice. Samples were divided into approximately
2 mm3 pieces, with any necrotic areas being discarded.
Representative fragments were also snap frozen for DNA/
RNA analysis or fixed in 10 % buffered formalin for his-
tological evaluation. The remaining tumor pieces were
placed in Matrigel (BD Biosciences, Franklin Lakes, NJ,
USA) and kept on ice until implantation. All specimens
were implanted within 90 min of collection.
Implantation and Monitoring
Mice were anesthetized via an intraperitoneal injection
of 100 ll of anesthetic solution (ketamine 10 mg/ml and
xylazine 2 mg/ml) per 10 g of body weight. The dorsum of
the mouse was shaved and prepared with a 2 % (v/v)
chlorhexidine gluconate/70 % (v/v) isopropyl alcohol so-
lution. Under aseptic conditions, a 15-mm midline incision
was made immediately caudal to the dorsal hump. Using
blunt dissection, a skin flap was raised and the skin re-
tracted laterally. For IM implantation, a superficial stay
suture was placed in the dorsal musculature immediately
caudal to the lowest rib using a 4/0 braided absorbable
suture. After tenting the muscle fibers, an IM pocket was
created using a combination of sharp and blunt dissection
until it was just large enough to accommodate the tumor
piece. The tumor piece coated in Matrigel was then placed
in the IM pocket prior to suture closing (Fig. S1). For SC
implantation, a tumor piece, similarly coated in Matrigel,
was implanted under the raised skin flap. One or two
separate transplantation sites were used per mouse. The
skin was closed using 3/0 braided absorbable suture. Mice
were closely monitored for tumor formation and culled
according to guidelines once tumors reached the ethical
limit of 1500 mm3 as calculated by the formula
(length 9 width2)/2 or at any sign of discomfort and/or
stress.
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Harvesting and Processing of PDTXs
PDTXs were carefully resected to ensure that the muscle
layer was dissected free. After débridement of any necrotic
areas, the PDTX was divided into 2 mm3 pieces and pro-
cessed as per the original tissue. For cryopreservation,
pieces were washed with PBS?? and then aliquoted into
cryovials (up to two per cryovial) containing 1 ml of fetal
calf serum containing 10 % (v/v) dimethylsulfoxide and
frozen to -80 !C at approximately -1 !C/min.
Histology and Immunohistochemistry
Sections of formalin-fixed paraffin-embedded tissue
from all of the original patient-derived tissues and the
PDTXs were stained with hematoxylin and eosin (H&E).
To confirm that the PDTXs were of human origin, im-
munohistochemistry was performed using an antibody
against the human mitochondrial antigen, MAB1273
(1:500) (Merck Millipore, Billerica, MA, USA). CK7
(1:50) (POV-TL 12/30; DakoCytomation, Glostrup, Den-
mark) and CK19 (1:100) (RCK108; DakoCytomation)
antibodies were used to confirm that adenocarcinomas
were from the esophagus or the gastroesophageal
junction.15
DNA Extraction and Sequencing
DNA from both the original patient sample and the
PDTXs was extracted from freshly frozen pieces of tissue
using the DNeasy Blood and Tissue kit (Qiagen, Hilden,
Germany) as per the recommended protocol. Targeted se-
quencing across a panel of 48 known oncogenes was then
performed using the Illumina TruSeq Amplicon Cancer
Panel as previously described.16
Therapeutic Response
For assessment of the chemotherapeutic response, a
single PDTX was divided and implanted into cohorts of up
to 18 mice using the IM technique. Athymic nude mice
were selected for this purpose because of the ease of tumor
detection and better tolerance of the chemotherapy.17,18
Once tumors reached a volume of 125 mm3, the mice were
randomized to receive either matched patient chemother-
apy [5-fluorouracil (5FU)/cisplatin] or the vehicle (0.9 %
NaCl) alone. Cisplatin (DBL) was suspended in 0.9 % (w/
v) NaCl and administered at a dose of 4 mg/kg via in-
traperitoneal injection on a weekly basis for 3 weeks. 5FU
(DBL) was suspended in 0.9 % NaCl and administered at
10 mg/kg via intraperitoneal injection on days 1 to 5 of a
14 day treatment cycle. This cycle was repeated twice.
Given the rapid systemic absorption of both cisplatin and
5FU from the peritoneal cavity, the intraperitoneal route
was chosen because of its ease of administration.19,20
RESULTS
Tumor samples from 23 patients were harvested from the
esophagus, gastroesophageal junction (GEJ), or peritoneum
(metastatic deposit from a primary GEJ tumor). They in-
cluded both adenocarcinoma and SCC. One to four tumor
pieces (mode = 2) from each patient were implanted.
Samples from four patients were lost because of the pre-
mature death of the host mice during the first month (i.e.,
before a tumor could become established) and were excluded
from further analysis. Of the remaining patients, samples
implanted using the IM technique had a per-implant success
rate of 65 % (24/37) and resulted in successful engraftment
of at least one implant from each of the 18 patients with this
method (Table 1). In comparison, the SC technique had a
per-implant success rate of only 9 % (1/11) and was asso-
ciated with successful engraftment ofjust one of the six
(16 %) patients (Table 1).
All engrafted tissues were subjected to thorough
histopathological analysis by an experienced histopathol-
ogist. All were demonstrated to be composed of human
tissue, as demonstrated by staining with anti-human mito-
chondrial antibody (Fig. 1a). Of the 18 engrafted lines, 13
were confirmed to be of epithelial origin and to have
maintained the same degree of differentiation (Fig. 1a) and
expression of molecular markers (Fig. 1b) as their parent
tumor. Thus, we were able to establish bona fide esopha-
geal PDTXs from 13 of 18 patients (72 %) using the IM
technique compared to just one from six patients using the
SC method.
Of the five IM xenografts that failed to recapitulate their
parent tumors, four were confirmed to be B cell lym-
phomas, and one was composed of a combination of both
epithelial and lymphoid cells (Fig. S2a). These lymphomas
stained strongly for Epstein-Barr virus (EBV) RNA (Fig.
S2d), indicating that latent EBV may be the driver of this
lymphomatous transformation. These five lymphoma lines
were also reproducibly metastatic in the mice, with ex-
tranodal dissemination frequently noted in the lung, liver,
and spleen (data not shown).
All of the validated esophageal PDTX lines have now
been passaged up to seven times. We have also been able to
reestablish four of the five esophageal PDTX lines fol-
lowing cryopreservation. All passages were performed in
NSG mice except for the failed cryopreserved sample,
which was implanted in NOD scid mice (Table 1).
Targeted sequencing of 48 known cancer-related genes
revealed the model to be relatively stable genetically. From
a single PDTX line (patient 1), the original tumor was
compared to seven PDTXs across three consecutive
Improved Engraftment of Esophageal PDTXs
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generations. Our results identified the presence of syn-
onymous variants in five genes (FGFR3, PDGFRA, EGFR,
RET, PTEN) and nonsynonymous variants in three genes
(HNF1A, TP53, STK11) in the parent tumor. These were
maintained in the original PDTX and subsequent passages,
with the exception of one-second generation PDTX in
which the STK11 variant was not detected.
Importantly, we confirmed that the therapeutic responses
observed in the patients are reproducible within the PDTX.
For example, patient 11, who had a poorly differentiated
SCC of the mid to lower esophagus, experienced a com-
plete response to a combination of chemotherapy (5FU and
cisplatin) and radiotherapy (50.4 Gy over 28 fractions).
This complete response was mirrored in the matching
PDTX (Fig. 2a). Similarly, patient 15, who underwent
treatment for a moderately differentiated adenocarcinoma
of the GEJ, demonstrated only a partial response to the
combination of chemotherapy (5FU and cisplatin) and ra-
diotherapy (50.4 Gy over 28 fractions), and this partial
response was mirrored in the matching PDTX (Fig. 2b).
DISCUSSION
We report a methodology for improved establishment of
PDTXs from esophageal tumors. Using this novel IM
technique, we were able to establish esophageal PDTX lines
from 13 of 18 patients. These results suggest that this IM
transplantation technique is more robust than the standard
SC approach for generating esophageal PDTXs. Given our
early success using the IM technique and the importance
placed on generating additional PDTX lines from the limited
quantity of tissue available, the majority of specimens in our
series were implanted using the IM technique. Hence, the
numbers were too low for a direct comparison of the ‘‘take’’
rate between the IM and SC techniques. Nevertheless, given
that the best reported engraftment rate across a range of
esophageal PDTX studies is only 38.5 %,7–13 the IM tech-
nique appears to be superior. Caution is needed when
making such a comparison, however, as the small numbers
mean that it is not possible to standardize for variables such
as ischemia time and tumor viability.
TABLE 1 Matched pathological features and engraftment results from implanted PDTXs
ID Site Type Grade Tissue source Therapy prior to implantation Techniquea Mouse strain Engraftment after
cryopreservationa
CT RT IM SC
1 GEJ AC Poor Resection Y N 1/4 0/2 SCID 2/2
2 GEJ AC Poor Resection Y Y 1/2 SCID 2/2
3 GEJ AC Mod Resection Y N 0/4 NOD SCID
4 Esophagus AC ? NE Mod Biopsy N N 2/2 NSG
5 Esophagus AC Mod–poor Biopsy N N 1/2 NOD SCID 0/1
6 Esophagus AC In situ Biopsy N N 1/2 0/1 NSG
7 Esophagus SCC Mod Biopsy N N 1/1 NSG
8 Esophagus AC Mod Biopsy N N 1/1 NSG
9 Esophagus AC Mod Biopsy N N 1/1b 0/1 NSG
10 Esophagus AC Mod Biopsy N N 2/2 1/2 NSG 1/1
11 Esophagus SCC Poor Biopsy N N 2/2 NSG
12 Esophagus SCC Mod Resection N N 1/1 NSG 1/1
13 PM from GEJ AC Mod–poor Resection N N 1/2 NSG
14 Esophagus AC Poor Resection Y N 1/3 NSG
15 GEJ AC Mod Biopsy N N 2/3 NSG
16 Esophageal AC Poor Resection N N 1/2c NSG
17 Esophageal SCC In situ Biopsy N N 1/1 0/1 NSG
18 Esophagus AC Mod Biopsy N N 1/2 NSG
19 Esophagus AC ? NE Poor Biopsy Y N 3/4 NSG
Lymphomatous transformation within engrafted tumor is indicated in bold
PDTXs patient-derived tumor xenografts, ID patient identification number, GEJ gastroesophageal junction, Mod moderate, PM peritoneal
metastasis, AC adenocarcinoma, NE neuroendocrine differentiation, SCC squamous cell carcinoma, CT chemotherapy, RT radiotherapy, IM
intramuscular, SC subcutaneous, Y yes, N no, no entry not attempted
a Fractions indicate the number of successful engraftments divided by the total number of implants
b Transformation occurred at the second passage
c Mixed epithelial component
M. Read et al.
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We postulate that the improved ‘‘take’’ rate observed
using the IM technique could possibly be attributed to the
greater blood supply in the transplant bed. Evidence for
this possibility can be extrapolated from a study of ectopic
transplantation of ovarian tissue.21 In that study, SC and IM
transplantation sites were compared through a series of
experiments involving xenografting normal rat ovarian
tissue into nude mice. Results showed that the SC trans-
plantation site exhibited pericyte loss and tissue damage,
whereas the IM site maintained its vascularity and
demonstrated tissue preservation.21 It is also well estab-
lished that there is greater autoregulatory control over
blood flow in muscle tissue than in cutaneous tissue.22 This
control ensures that the temperature within the transplant
bed remains relatively constant, protecting the tumor graft
against hypothermic insult.
We confirmed that the esophageal PDTXs in our series
are composed of human tissue and that they are
representative of the original patient’s tumor with respect
to degree of differentiation and the molecular and genetic
phenotypes. By assessing the response to standard che-
motherapy, we have also produced evidence that the
biology of the PDTX matches that of the original tumor.
This finding highlights the potential power of well-
validated PDTXs as preclinical tools for both biomarker
validation and selection of second-line therapies.
The feasibility of cryopreserving esophageal PDTXs
was also demonstrated in this study. This discovery has the
potential to lead to significant reductions in the resources
required to maintain perpetual PDTX biobanks. It also
gives researchers the ability to share PDTX resources more
readily with collaborators.
Researchers must also be cognizant of potential limita-
tions when using PDTX models. Overall, 5 of the initial 18
established xenografts (26 %) underwent lymphomatous
transformation. As it is not easy to distinguish poorly
FIG. 1 Patient-derived tumor
xenograft (PDTX) recapitulates
the original patient tumor. a
Hematoxylin and eosin (H & E)
staining (of the original tumor
and the PDTX) and
immunohistochemistry using an
anti-human mitochondrial
antibody (PDTX only) of a
poorly differentiated esophageal
adenocarcinoma (patient 1, top
panels) and an esophageal
squamous cell carcinoma
(patient 11, bottom panels). b H
& E staining and
immunohistochemistry using
CK7 and CK19 antibodies in a
gastroesophageal junctional
adenocarcinoma (patient 15, top
panels) and the corresponding
PDTX (bottom panels)




differentiated carcinomas from lymphomas by histology
alone, it is important that poorly differentiated PDTXs are
tested for the expression of lymphoma markers. Indeed, the
process of lymphomatous transformation in xenografts has
only recently been reported,7,23,24 and it can be as high as
68 %, as reported in one series.24 It is most likely that the
lymphomas arise through transformation of EBV-infected
B cells that have been transplanted with the tumor tissue
piece into a permissive environment. The situation is akin
to the development of lymphomas in immunodeficient
patients, putatively modeling an EBV-driven posttransplant
lymphoproliferative disorder.25 Given the high rate of EBV
infection in the general population, it seems likely that this
phenomenon has either been under-recognized or under-
reported in the literature.
CONCLUSIONS
We have demonstrated that an IM transplant technique
is associated with improved engraftment of esophageal
FIG. 2 Assessment of tumor biology. Pretreatment and posttreat-
ment 18F-fluorodeoxyglucose-positron emission tomography images
and the growth curves for the respective PDTX with and without
treatment with matched chemotherapy [cisplatin/5-fluouracil (5FU)]
from representative patients who had either a complete metabolic
response (a, patient 11) or a partial metabolic response (b, patient 15)
to neoadjuvant treatment (cisplatin/5FU). Results are shown as the
mean ± SEM. An unpaired t-test was performed on all data points
using GraphPad Prism 5.0. *p \ 0.05 for drug-treated tumors
compared to vehicle-treated tumors at the same time point. Arrows
indicate the sites of the primary tumors




PDTXs. Given the importance of the PDTX as a preclinical
tool, it is hoped that this refinement will lead to greater
understanding of cancer biology and improved therapies.
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3.2.1 Supplementary data 
 
 
Figure  3-3 Supplementary Figure 1 
Intramuscular (IM) implantation technique and PDTX formation. a After placement of a stay 
suture, a small IM pocket is created on the dorsum of the mouse that is just large enough to 
accommodate the tumour piece. b After implantation, the IM pocket is sutured closed with the 
implant evident immediately below the outer muscle fibres. c Gross view of an IM PDTX at the 





Figure  3-4 Supplementary Figure 2 
Identification and characterization of lymphomagenic transformation within a subset of 
established PDTXs. Immunohistochemistry using pan-cytokeratin AE1/AE3 (1:100) (NCL-L-
AE1/AE3; Novocastra/Leica Microsystems, Newcastle, UK), CD20 (1:200) (M7055, 
DakoCytomation; Dako, Glostrup, Denmark), and CD45 (1:200) (M0701, DakoCytomation) 
antibodies on the original patient tumor and the corresponding PDTX. The PDTX of patient 9 
(a) is negative for the pan-cytokeratin marker AE1/AE3 but positive for the common leukocyte 
antigen CD45 and the B-lymphocyte restricted antigen CD20, indicating that it is 
predominantly composed of human B cells. In comparison, the PDTX of patient 16 (b) exhibits 
a combination of epithelial cells (nests of AE1/AE3-positive cells) and lymphocytes. cFurther 
analysis via flow cytometry was performed as previously described (Craig FE, Foon 
KA. Blood 2008;222:3941–67) of single cells derived from PDTX 14 and confirmed that the 
lymphoid cells were CD19+ B cells (left plot). The abnormal B-cell population was then gated 
and is depicted on the FSC vs. SSC plot in blue (right plot), indicating that these cells are also 
large. d Right In situ hybridization for the Epstein Barr virus (EBV) (blue staining) was 
performed on sections of formalin-fixed paraffin-embedded PDTX using the INFORM EBER 
Probe and ISH iVIEW Blue Detection Kit (Ventana/Roche, Tucson, AZ, USA) as per the 
manufacturer’s protocol and counterstained with eosin (pink staining). Left EBV-positive 
nasopharyngeal carcinoma (positive control). Right Section from PDTX 9 (Read et al., 2016.  
Reproduced with permission). 
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3.3 A detailed description of the IM transplantation technique 
 
Tissue is obtained directly from a patient tumour (either from either a surgical resection 
specimen or endoscopic biopsy) in order to establish a first-generation PDTX.  For passaging 
of PDTXs, tissue can be either freshly harvested or derived from a freshly thawed specimen.  
Following collection, tumour tissue is placed in normal saline and kept on ice. Within a laminar 
flow hood, tissue is then prepared for transplantation.  Necrotic areas are debrided, and 
tumour tissue divided into 1 to 2 mm sized pieces (Figure  3-5).  Pieces are then placed in 
Matrigel (50 μL/tumour piece) and keep on ice until transplantation. 
 
 
Figure  3-5 Tissue pieces prior to transplant 
A photo demonstrating the size of tumour pieces required for transplantation. 
 
NSG mice are then anaesthetised via an intraperitoneal injection of anaesthetic solution 
(100μL/10g body weight).  A small area is then shaved over the dorsum of each mouse.  After 
being placed onto a sterile field, mice are then prepared with 2% chlorhexidine gluconate / 
70% isopropyl alcohol.  A small dorsal midline incision of approximately 15mm is then made 
using Metzembaum scissors at the level of the renal angle (immediately caudal to the dorsal 
hump) (Figure  3-6).  Stay sutures are then placed in the skin to aid with retraction (3/0 undyed 
vicryl).  On each side of the midline, a superficial suture is then placed into the dorsal 
musculature using 4/0 vicryl rapide.  Muscle fibres are then tented by pulling up on the suture 
and a small incision made in the tented muscle fibres using Iris scissors.  Using blunt dissection, 
a pocket is developed that is just large enough to accommodate a piece of tumour.  Care is 
taken to remain inside the muscle and not enter the retroperitoneum.  A tumour piece 
covered in Matrigel is then placed into the intramuscular pocket.  The opening is then closed 
with a single interrupted suture using 4/0 vicryl rapide.  The procedure is then repeated on 
the contralateral side if necessary.  Skin is closed with 3/0 undyed vicryl using two to three 




Figure  3-6 A Diagrammatic representation of the skin incision site 
A 15mm dorsal skin incision is made at the level of the renal angle 
 
Post transplantation, mice are housed on heat pads and monitored for any anaesthetic or 
procedure related complications.  Antibiotic water (dilute stock solution to 1:100) is 
administered for five days post procedure.  Mice are monitored weekly for signs of tumour 
development or distress.  Care needs to be taken when assessing for tumour formation as 
tumours have the potential to invade the retroperitoneum (i.e. grow ventrally rather than 
dorsally). 
 
Once tumour size reaches ethical limits, or mice display signs of suffering, mice are culled 
using CO2 inhalation.  After harvesting, PDTXs are debrided, with necrotic regions and host 
tissue being removed.  PDTX tissue is allocated as per the following flow chart (Figure  3-7).  
For cryopreservation, PDTX tissue is divided into 1-2mm pieces.  PDTX pieces are then placed 
into sterile cryo-tubes with 1mL of freezing solution (up to four PDTX pieces per tube).  Cryo-
tubes are then slowly cooled to -80oC. before being placed in liquid nitrogen storage.  Tissue 




Figure  3-7 A flowchart demonstrating how successfully generated PDTXs are processed 
Pieces of PDTXs can be used for serial passaging, cryopreservation and cell line generation.  
Tissue must also be kept for the purpose of validation.  This typically involves both 
histopathological and IHC assessment as well as genomic analysis. 
 
3.4 Establishment and validation of additional PDTX lines using the IM 
technique 
 
Following the publication of the IM PDTX technique (Read et al., 2016), additional PDTXs were 
established.  As a general rule, PDTX lines were maintained for at least four generations.  In 
order to save on both costs and resources, PDTX lines were then cryopreserved and re-
established when required.  The details of the complete PDTX biobank are provided in the 
table below. 
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Table 3-2 The complete table of matched pathological features and engraftment results from implanted PDTXs 
 
 
Abbreviations:  IM, intramuscular; SC, subcutaneous; GOJ, gastro-oesophageal junction; PM, peritoneal metastasis; AC, adenocarcinoma; NET, neuroendocrine 
tumour; SCC, squamous cell carcinoma; CT, chemotherapy; RT, radiotherapy; Y, yes; N, no; no entry, not attempted.  Colours: Green, successful; Yellow, 
lymphomagenic transformation; Red, unsuccessful. * Mixed epithelial component # Transformation occurred at second passage.  Entries in bold represent 
xenografts that were generated following the publication of the original series (Read et al., 2016).
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For the purpose of validation, a representative OAC (IS076, ID22) and oesophageal SCC 
(MA924, ID24) were selected from the PDTX biobank, for both H&E and IHC analysis.  In order 
to improve the efficiency of IHC staining across multiple different PDTX lines, and to ensure 
uniform staining across all samples, a tissue microarray (TMA) was created.  Details regarding 
the establishment of the PDTX TMA, including the layout of samples, is provided in Appendix 
2.  ID numbers correlate with those used in Table 3-2. 
 
For the selected OAC line, IS076 (ID 22), IHC staining for the intestinal markers MUC5AC and 
CDX2 is shown.  Results revealed the maintained degree of differentiation and expression of 
CDX2 and MUC5AC across both original patient tumour and derived PDTXs (Figure  3-8). 
 
Figure  3-8 An analysis of tissue architecture and IHC profile from the original patient 
tumour & PDTX from the IS076 line 
A comparison of tissue architecture and IHC profile across the original patient tumour and both 
first and second generations PDTXs for the IS076 line.  IHC markers include the intestinal 




For the selected SCC line, MA924 (ID 24), staining for the squamous markers p40, CK5, p63 
and high molecular weight (HMW) cytokeratin is shown (Figure  3-9).  Results revealed that 
the degree of differentiation and degree of keratinisation were maintained across the original 
patient tumour and both first and second generation PDTXs.  In addition, IHC analysis 
confirmed the maintained expression of squamous markers P63, P40, CK5 and HMW. 
 
Figure  3-9 A comparison of tissue architecture and IHC profile between the original 
patient tumour and PDTX from the oesophageal SCC line MA924 
H&E staining and a SCC specific immunohistochemistry panel consisting of p40, CK5, p63 and 
HMW of the original patient tumour (F0) and both first (F1) and second (F2) generations PDTXs 
of the oesophageal SCC line MA924.  Scale bars represent 100μm.  
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3.5 Characterisation of PDTX lines that underwent lymphomagenic 
transformation 
 
Validation of the PDTX model confirmed that approximately 20% (5/24) of engrafted 
xenografts had undergone lymphomagenic transformation.  Such transformation was usually 
evident at time of necropsy, as mice typically developed splenomegaly with associated 




Figure  3-10 A spleen harvested from a mouse bearing an PDTX that had undergone 
lymphomagenic transformation 
The spleen demonstrates evidence of splenomegaly.  The arrow indicates the demarcation 
between splenic tissue and tumour. 
 
In order to identify potential factors that may have contributed to this process, the clinical 
details and results of both IHC analyses and flow cytometric immunophenotyping of the 
relevant patients and PDTX lines were reviewed.  The full clinical details of each of the patients 
are provided in appendix 3 (as per the previous section, ID numbers are provided which 
reference Table 3-2).  However, an analysis of clinical details failed to identify a common 
causative factor, such as the subsequent development of a lymphoma in the patient or 






A histopathological and IHC analysis was performed on four of the PDTX lines suspected of 
undergoing lymphomagenic transformation, and their original patient tumours.  IHC markers 
included the pan cytokeratin AE1/AE3, the common leukocyte antigen CD45 and the pan B-
cell marker CD20 (Figure  3-11).  In addition, in situ hybridisation for the Epstein Barr virus 
(EBV) was also performed on the PDTX line AN595 (ID9) (Figure  3-12).  Analysis of original 
patient tumours revealed that they were all epithelial in origin, demonstrating strong staining 
for AE1/AE3.  However, within the tumours there was also evidence of a lymphocytic 
infiltration, with both CD45 and CD20 positive cells being identified.  Within two samples, 
entire aggregates were identified, consisting predominantly of CD20 positive B lymphocytes.  
In comparison, derived xenografts were characterised by a mass of undifferentiated tumour 
cells that were strongly positive for both CD45 and CD20, with very few AE1/AE3 positive 
epithelial cells being identified.  Results from the in situ hybridization for the EBV within one 







Figure  3-11  Histopathological and IHC analysis of PDTX lines suspected of undergoing 
lymphomagenic transformation 
Hematoxylin and eosin (H&E) and IHC analysis using antibodies against AE1/AE3 (pan 
cytokeratin), CD45 (common leukocyte antigen) and CD20 (B-cell marker) on both the original 
patient tumours (F0) and the corresponding PDTXs (F1/F3) of lines suspected of undergoing 





Figure  3-12 In situ hybridization for the Epstein Barr virus (EBV) within PDTX line AN959 
In situ hybridization for the Epstein Barr virus (EBV) is indicated by dark blue staining.  On the 
left is a positive control (EBV-positive nasopharyngeal carcinoma) and on the right is a FFPE 
section of a first-generation PDTX from the line AN959.  Scale bars represent 100μm. 
 
Flow cytometric immunophenotyping is a technique that is employed in order to diagnose 
haematological malignancies.  This is achieved by identifying abnormal cell populations from 
within a sample based on a number of parameters.  These parameters include cell size, 
granularity and cell surface marker expression.   Analysis of three of the PDTX lines suspected 
of undergoing lymphomagenic transformation was performed using a panel of previously 
validated markers (Craig & Foon, 2008).  These PDTX lines included GB975 (ID4), RF226 (ID14) 
and JA227 (ID16).  The results revealed the consistent presence of an abnormal B-cell 
population.  These cells tended to be large in size by light scatter properties and had exhibited 
evidence of light chain restriction.  Such a clonal proliferation is diagnostic of a CD5 negative, 






Figure  3-13 Flow cytometric analysis of PDTX lines suspected of undergoing lymphomagenic transformation 
A representative panel of FACS plots used to determine the immunophenotype of the PDTX lines JA227, RF226 and GB975.  Plots include forward (FSC) versus 





IHC and flow cytometric analysis confirmed that approximately 20% (5/24) of the oesophageal 
cancer PDTX lines that were generated in this study, using the IM technique, had transformed 
into diffuse large B-cell lymphomas of human origin.  However, it is important to note that 
this process is not unique to either oesophageal cancer or the IM transplantation technique, 
as there have been numerous other reports from PDTX series involving other cancer types of 
lymphomagenic transformation (Butler, Hou, Becker, Zanfagnin, Enderica-Gonzalez et al., 
2017; Chen, Ahmed, Adeyi, Dick, & Ghanekar, 2012; John, Yanagawa, Kohler, Craddock, 
Bandarchi-Chamkhaleh et al., 2012).  One study, involving the generation of prostate cancer 
PDTXs, even reported a lymphoma transformation rate of 80% (Wetterauer, Vlajnic, Schuler, 
Gsponer, Thalmann et al., 2015).  These studies typically employed heterotopic 
transplantation sites such as the subcutaneous and intraperitoneal spaces. 
 
In humans, the process of lymphomagenic transformation is commonly driven by the EBV 
infection of B cells (Vockerodt, Yap, Shannon-Lowe, Curley, Wei et al., 2015).  Testing of one 
of the transformed PDTX in this series by in situ hybridisation confirmed the presence of EBV, 
suggesting that the virus may also play a role in transformation in the xenograft setting.  This 
is consistent other studies that have investigated the same process (Butler et al., 2017; K. Chen 
et al., 2012).  As EBV infected B cells are normally under the control of the immune system 
through the action of antigen-specific T lymphocytes, both of these studies concluded that 
the transformation is most likely related to the culture of EBV infected B cells in an 
immunodeficient setting (Landais, Saulquin, & Houssaint, 2005).  Such a process is akin to the 
development of B-cell lymphomas post solid organ transplantation (Vockerodt et al., 2015).  
It may also explain why the rate of lymphomagenic transformation increases as the level of 
host immunity decreases (Choi, Lee, Kim, Sim, Kim et al., 2016).  In the study by Choi et al. 
(2016), 15 gastric cancer PDTXs were established from a total of 62 different patient samples.  
Of these 15 PDTXs, six were established in nude mice (which are deficient in T cells), and nine 
in NSG mice (which are deficient in T, B and natural killer cells).  In total, 5/15 of these PDTXs 
underwent lymphomagenic transformation, all of which occurred with NSG mice. 
 
In an attempt to prevent lymphomagenic transformation from occurring, it is necessary to 
understand if the process occurs entirely in the host mouse or begins in the patient. Although 
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rare, primary lymphoepithelial carcinomas of the oesophagus are a recognised entity (Terada, 
2013).  More common, however, in the clinical setting, is the process of EBV driven 
lymphomagenic transformation.  This typically occurs in immunocompromised patients, such 
as those with immunodeficiency disorders and in those receiving chemotherapy (Krishnan & 
Morgan, 2007).  However, upon review of the clinical histories and pathologies of all of the 
patients in this series, there was no evidence that any of the patients had lymphomas prior to 
implantation nor did they subsequently develop lymphomas. 
 
This phenomenon highlights an important limitation of the PDTX model and reinforces the 
need for strict validation.  Simply confirming that PDTXs are of human origin and share the 
same genomic profile as the original patient is not sufficient.  At a minimum, validation also 
needs to consist of both histopathological and IHC assessment, in order to confirm that the 
derived xenografts recapitulate the same degree of differentiation and molecular profile as 
the original tumour.  Relying on histopathological assessment alone has limitations, especially 
in the setting of poorly differentiated tumours, as it can be difficult to distinguish epithelial 
from non-epithelial tumours in this setting.  For this reason, an IHC analysis needs to be 
performed consisting of both epithelial and lymphoma markers.  If transformation is 
suspected, confirmation can be achieved via a flow cytometric analysis in order to confirm 
clonality (Craig et al., 2008). 
 
Researchers are also investigating techniques to prevent and even reverse this process once 
it has established.  Having identified lymphomagenic transformation in their series of ovarian 
cancer xenografts, Butler et al. (2017) trialled the administration of an anti-CD20 antibody at 
the time of implantation, which decreased the rate of lymphomagenic transformation 
decreased from 11.1% (13/117) to 1.88% (3/160). 
 
The discovery that oesophageal PDTXs are susceptible to lymphomagenic transformation has 
far reaching implications.  Given that preclinical drug validation is currently the most common 
application of the PDTX model, failure to recognise transformed PDTX lines could have 
significant downstream effects.  Clinical trials could either be commenced based on inaccurate 
preclinical data, or, more significantly, rejected when in fact the drug may have had a clinical 
effect.  Such a scenario has previously occurred in the field of OAC when a series of commonly 
used cell lines were misidentified (Boonstra, van Marion, Beer, Lin, Chaves et al., 2010).  In 
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this study, two mistakenly identified OAC cell lines were linked to over 100 publications and 
11 US patents.   
 
Whilst some researchers are slowly coming to the realisation that lymphomagenic 
transformation can occur, others have failed to be as diligent with PDTX validation.  An 
example is seen in a study by Wang et al. (2014).  In this study, oesophageal PDTX models 
were used to test the effect of Notch inhibition on tumour growth.  Although the authors 
reported positive preclinical results, they did not perform an adequate validation of their 
model.  They provided identical images of both the original patient tumour and PDTX, and 
subsequent images of the PDTX simply revealed evidence of a poorly differentiated carcinoma 
(Wang et al., 2014)(Figure  3-14). 
 
 
Figure  3-14 Poorly validated oesophageal PDTXs 
H&E sections form both the original patient tumour and PDTX.  Boxes outline regions of both 
primary tumour and PDTX that are an exact match (a). PDTXs treated with both vehicle and 
drug are shown in b.  H&E sections form both drug and vehicle treated PDTXs reveal a poorly 
differentiated tumour with no clear epithelial component (b).  Although the PDTXs shown in 
both a and b are all reportedly derived from the same line, they fail to demonstrate any 




3.6 Assessment of PET/FDG avidity within the PDTX model 
3.6.1 Background 
 
PET is a form of functional imaging that is commonly used in oncology.  It provides an adjunct 
to the anatomical information gained from computed tomography (CT).  It relies on the 
labelling of biologically important molecules with positron-emitting radionucleotides.  
Glucose is commonly used for this purpose in the form of fluorodeoxyglucose (FDG).  This is 
based on the observation that tissue hypoxia within tumours leads to up regulation of the 
GLUT1 glucose transporter (Jadvar, Alavi, & Gambhir, 2009; Li, Du, Ma, Postel, & Civelek, 
2014).  This in turn leads to an increased amount of glucose entering the tumour cells.  As the 
radionucleotide decays, radiation is emitted which is subsequently detected by a PET scanner.   
 
In the field of oncology, PET is commonly used as a tool to detect metastatic disease.  
However, for reasons that are largely unknown, only certain tumour types are FDG avid.  It is 
this FDG avidity which determines the clinical utility of the study.  For example, it has been 
validated in oesophageal but not gastric cancer (Kelloff, Hoffman, Johnson, Scher, Siegel et 
al., 2005).  In oesophageal cancer, FDG PET also has a role in measuring a tumour’s metabolic 
response to neoadjuvant therapy.  By comparing imaging pre and post neoadjuvant therapy, 
clinicians can determine if a tumour is a complete, partial or non-responder and alter 
treatment accordingly.  A key limitation of FDG PET however, relates to the size of tumours 
that can be detected.  Due to surrounding background activity, false-negatives are commonly 
found in lesions less than 7mm (Mahajan & Cook, 2016). 
 
Given the important role that FDG PET plays in oesophageal cancer, the final form of validation 
of the PDTX model involved comparing the FDG PET avidity of the primary patient tumour to 
that of the derived xenograft.  If these results correlate, it would provide further evidence that 
tumour biology is maintained between the original patient tumour and PDTX.  It would also 




The results of FDG PET imaging from two separate first generation PDTX lines are shown 
below, alongside the matched results from the FDG PET imaging of the original patient 
tumours (Figure  3-15 & Figure  3-16).  These lines include PL128 (ID18) & JB075 (ID19), both 
of which were derived from OAC.  Identification (ID) numbers are also provided which 
reference back to Table 3-2.  Unfortunately, validation of JB075 confirmed that it had 
undergone lymphomagenic transformation.  In neither case did the FDG avidity correlate with 
the result seen in the patient.   
 
  Figure  3-15 A comparison of FDG PET avidity between the original patient tumour and 
first-generation PDTX of the line PL128 (ID 18) 
An FDG PET image from patient PL128 (ID 18) in coronal section at time of diagnosis (a).  The 
corresponding FDG PET of the first-generation PDTX is shown in both sagittal (b) and 
transverse sections (c).  Both original patient tumour and PDTX are identified by red arrows.   
 
 
Figure  3-16 A comparison of FDG PET avidity between the original patient tumour and 
first-generation PDTX of the line JB075 (ID 19) 
An FDG PET image from patient JB075 (ID 19) in coronal section at time of diagnosis (a).  The 
corresponding FDG PET of the first-generation PDTX is shown in both sagittal (b) and 
transverse sections (c).  Both original patient tumour and PDTX are identified by red arrows.  





This is the first time that the FDG PET avidity of original patient tumours has been compared 
to first generation PDTXs in the setting of OAC.  Unfortunately, whilst the PDTX demonstrated 
some degree of avidity, there was no clear correlation with patient results.  These findings are 
consistent with other published series which assessed xenograft FDG PET from a range of 
other cancers (Apisarnthanarax, Alauddin, Mourtada, Ariga, Raju et al., 2006; Chen, Cheng, 
Walton, Wang, Ebi et al., 2012; Guerreschi, Scalbert, Qassemyar, Kluza, Ravasi et al., 2013; 
Moroz, Kochetkov, Cai, Wu, Shamis et al., 2011; Munk Jensen, Erichsen, Bjorkling, Madsen, 
Jensen et al., 2013).  However, it should be noted that the majority of published studies are 
based on cell line derived xenografts and not PDTXs. 
 
The poor correlation between the PDTX and the patient with respect to FDG PET imaging may 
be the result of an altered microenvironment.  As the PDTX resides in a more vascular 
microenvironment compared to their native site, they could potentially be receiving a greater 




3.7 Applications of the PDTX model   
 
3.7.1 PDTXs as a preclinical tool for molecular imaging studies 
 
As a proof of principle, an experiment was performed using a novel small molecular inhibitor 
labelled with a near-infrared (NIR) dye to determine the feasibility of imaging tumours in vivo.  
Such a technique forms the basis of ‘firefly’ or ‘real-time image-guided surgery’ and is 
currently being investigated in the treatment of brain, liver and prostate cancer (Cho, Jeon, 
Buch, Nag, Nasrallah et al., 2018; Contino, Eldridge, Secrier, Bower, Fels Elliott et al., 2016; 
Neuman, Eifler, Castanares, Chowdhury, Chen et al., 2015; Thursfield, Farrugia, Karahalios, & 
Giles, 2012; Tummers, Miller, Teraphongphom, van den Berg, Hasan et al., 2019).  In this 
example, the selected molecule is an inhibitor of the BMP pathway and was chosen as there 
is evidence suggesting that activation of the BMP pathway is required for the development of 
both BO and OAC (Calpe, Correia, Sancho-Serra Mdel, & Krishnadath, 2016; Calpe, Wagner, El 
Khattabi, Rutten, Zimberlin et al., 2015; Clemons, Phillips, & Lord, 2013; Milano et al., 2007). 
In this experiment, mice harbouring PDTXs with high BMP expression were injected with a 
labelled inhibitor via intraperitoneal injection up to 24 hours prior to being imaged. Results 
revealed the accurate localisation of the tumour, as seen on both in vivo and ex vivo imaging 
(Figure  3-17).  In OAC, such a technique could be used to indicate the extent of disease beyond 
the primary tumour.  This could include the presence of involved lymph nodes or malignant 
infiltration into surrounding stroma.  If successful, such an approach has the potential to have 
a huge impact in the surgical treatment of OAC, as it may lead to improved R0 resection 





Figure  3-17 NIR imaging of an oesophageal PDTX with high BMP expression 
A control mouse (non-tumour bearing) and mouse harboring an IM PDTX with high BMP 
expression were imaged 24 hours after the administration of a combined BMP2 and BMP4  
inhibitor labelled with a NIR dye (100 mcg via intraperitoneal injection) (panel a).  Ex vivo 
imaging is shown in panel b.  A representative section of the PDTX is shown in panel c, 




3.7.2 Using PDTXs to investigate the frequency of tumour initiating cell within OAC 
 
Some theories suggest that CSCs are responsible for disease recurrence and metastasis 
formation, as they tend to be resistant to both chemotherapy and radiotherapy owing to their 
quiescent state (Visvader & Lindeman, 2012).  If OAC is demonstrated to follow a CSC model, 
successfully targeting these CSCs may lead to the development of novel therapeutic strategies 
and significant survival improvements.  However, before trying to identify a specific OAC CSC 
population, the first step is to determine the frequency of tumour initiating cells from a range 
of different tumours.  This will give some indication as to whether OAC follows a CSC model, 
in which only a minority of cells have tumorigenic potential or follows a clonal evolution model 
in which all cells share an equal tumorigenic potential.  In order to assess this, a series of 
limiting dilution assays were performed across a range of different xenograft lines.  
An Extreme Limiting Dilation Assay (ELDA) was performed using four separate OAC PDTX lines.  
This included one poorly differentiated PDTX line and three moderately differentiated PDTX 
lines.  In total, 90 separate injections were performed resulting in the formation of 59 separate 
tumours (Table 3-3).  The number of cells per injection ranged from 5,000,000 to a single cell.  
Results revealed a TIC frequency of 1/296 (CI of 1/496 to 1/177) for the poorly differentiated 
PDTX line and 1/1258 (CI 1/3166 to 1/499) for the three moderately differentiated PDTX lines.  





Table 3-3 Results of the limiting dilution assay  
	
 
In theory, given that these results suggest that the tumour initiating cell frequency within OAC 
represents a relatively rare population, it is possible that OAC follows the CSC model.  
However, whilst the CSC model requires that the tumour-initiating cell fraction represent a 
rare population, a strict threshold does not exist.  Some studies have reported frequencies of 
CSCs ranging from <1% in acute myeloid leukaemia and liver cancer to 82% in acute 
lymphoblastic leukaemia (Rich, 2016).  In order to confirm these findings, additional limiting 
dilution assays need to be performed across a larger number of PDTX lines.  If OAC is proven 
to follow a CSC model, attempts should then be made to try and identify the specific CSC 
population.  Once identified, these populations need to undergo functional testing in order to 
confirm their stemness.  Such tests include tumorigenic and serial transplantation assays in 







This chapter highlights the significant progress that has been made with respect to optimising 
the oesophageal cancer PDTX model, through the development of an IM transplantation 
technique (Read et al., 2016).  By adopting such an approach, the successful engraftment rate 
of bona fide oesophageal PDTXs was approximately 78% (18/23).  This is in contrast to a 
success rate of 16.6% (1/6) using the standard subcutaneous approach.  Given the early 
success of the IM approach and the importance of generating PDTX models, the majority of 
samples were implanted using the IM technique, making it impossible to make a direct 
comparison between the two techniques.  However, considering that the best reported 
engraftment rate in the literature is only 33% using the subcutaneous technique, the IM 
approach is clearly superior (de Both et al., 2001; Dodbiba et al., 2013b).  Such a development 
is a significant advancement in the field of OAC, where a paucity of suitable preclinical models 
has hindered research (Liu, Duong, et al., 2016).  
 
Another highlight in this chapter was the successful re-establishment of PDTXs post 
cryopreservation (Read et al., 2016), a methodology for which had not been previously 
described.  Cryopreservation enables large repositories of PDTXs to be established, each with 
their unique mutational profile.  This has important implications for cancers like OAC, which 
have extremely high mutational burdens and means that PDTXs only need to be re-established 
when their specific mutational profile is required to be tested.  Other benefits include 
significant cost savings as well as the unnecessary passage of PDTXs.  Cryopreservation also 
allows this precious resource to be more readily shared amongst researchers. 
 
Another key finding in this chapter has been the importance of thorough validation, which is 
an essential step in ensuring that PDTXs recapitulate their original patient tumours and that 
results can be translated to the clinical setting.  Validation should ensure that PDTXs maintain 
the same degree of differentiation, expression of molecular markers and mutational profile 
as the original patient tumour.  If required, the response of PDTXs to standard chemotherapy 
should also be assessed. 
 
However, a limitation of the PDTX model that needs to be highlighted is lymphomagenic 
transformation.  Although previously recognised in the literature, the process was not widely 
reported.  Publishing these findings has served to increase awareness of this process 
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throughout the research community, as evidenced through citations in a number of other 
papers (Choi et al., 2016; Dieter, Giessler, Kriegsmann, Dubash, Mohrmann et al., 2017; 
Kalavska, Kucerova, Schmidtova, Toro, Kozovska et al., 2018).   
 
Optimising the PDTX model also has the potential to have marked impact on the preclinical 
development of novel therapies for oesophageal cancer, as seen from the preliminary results 
of BMP inhibition on a PDTX with high BMP expression.  Another example of the this can be 
seen in a study by Liu et al. (Liu, Read, Cullinane, Azar, Fennell et al., 2015).  In this study, the 
effect of a newly developed drug, APR-246 was assessed on a range of preclinical models of 
OAC.  Included in this were PDTX lines obtained from the biobank established in this chapter.  
As APR-246 is purported to act by restoring the function of mutated p53 back to its wild-type 
function, PDTX lines both with and without p53 mutations were used.  The use of PDTX models 
in this study directly contributed to the initiation of a clinical trial. 
 
The IM transplantation technique has also been successfully applied to other cancer types.  
Examples include its use in the CASCADE program, which is a rapid autopsy program designed 
to obtain metastatic deposits from patients with breast, ovarian, melanoma and prostate 
cancer (Alsop, Thorne, Sandhu, Hamilton, Mintoff et al., 2016).  Following collection, tissue is 
then either biobanked or xenografted.  Other tumours types using the technique include both 
gastric cancer and anal SCC, which has led to the generation of the first anal SCC PDTX biobank 
(Bernardi, 2017).   
 
The remainder of this thesis will explore multiple other novel applications of the PDTX model 
in the study of Barrett’s carcinogenesis. 
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Chapter 4 The generation and validation of xenograft derived 
oesophageal cancer cell lines 
4.1 Introduction 
 
Preclinical models are essential tools in cancer research, as they enable the study of disease 
biology and also provide a means to screen novel therapies.  Unfortunately, relevant models 
are lacking in the field of oesophageal cancer.  This research barrier explains, in part, why 
there have been very little improvements to the overall survival for oesophageal cancer over 
the last few decades.  Traditionally, cancer cell lines have been the most versatile and widely 
adopted preclinical model, as they are robust and enable the high throughput of experiments.  
Whilst there have been numerous publications describing the establishment and validation of 
SCC cell lines (Boonstra, van der Velden, Beerens, van Marion, Morita-Fujimura et al., 2007; 
Kuriya, Kitamura, Akaishi, Hirayama, Sekine et al., 1983; Nishihira, Hashimoto, Katayama, 
Mori, & Kuroki, 1993; Nishihira, Kasai, Mori, Watanabe, Kuriya et al., 1979; Shimada, Imamura, 
Wagata, Yamaguchi, & Tobe, 1992), there have been very few published adenocarcinoma cell 
lines.  In fact, there have only been 12 bona fide OAC cell lines reported in the literature.  
These include FLO-1 (Hughes, Nambu, Soldes, Hamstra, Rehemtulla et al., 1997), KYAE-1 (Kan, 
Shimada, Sato, Maeda, Kawabe et al., 2001), SK-GT-4 (Altorki, Schwartz, Blundell, Davis, 
Kelsen et al., 1993), JROECLl9 (OE19) and JROECL33 (OE33) (Rockett et al., 1997), JH-EsoAd1 
(Alvarez, Koorstra, Hong, Boonstra, Dinjens et al., 2008), OACM5.1 and OACP4CE (de Both et 
al., 2001), ESO26 and ESO51 (Boonstra et al., 2010), OANC1 (Clemons, Do, et al., 2014) and 
MFD-1 (Cowie, Garcia, Hayden, & Underwood, 2015; Garcia, Hayden, Cowie, Mellone, 
Derouet et al., 2015). Of these 12 cell lines, only six have been derived from patients with 









Table 4-1 Details of the six bona fide OAC cell lines that originated from a region of BO 
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The discrepancy between the numbers of SCC versus adenocarcinoma cell lines may be due 
to the fact that, historically, SCC was the most common form of oesophageal cancer and this 
coincided with the period that the majority of cell lines were established.  It has only been in 
recent years that OAC has taken over the incidence of SCC in the Western world (Pohl et al., 
2005).   
The limited availability of treatment naïve tissue has also hindered the development of 
oesophageal cancer cell lines.  This has been particularly so since the introduction of 
neoadjuvant therapy, which has now become the standard of care for locally advanced 
oesophageal tumours.  As resection specimens typically demonstrate some degree of 
therapeutic response, the viability of cells obtained from these sources is often reduced, 
leading to limited outgrowth of epithelial cells in vitro.  Access to treatment naïve tissue has 
mainly been limited to small endoscopic biopsies obtained prior to treatment.  Other issues 
to affect the in vitro growth of tumour cells include fibroblast outgrowth and the low 
adherence of freshly isolated tumour cells to plastic.  Unfortunately, a robust technique for 
the establishment of cell lines has not been published, with most authors adopting differing 
methods and a ‘trial and error’ type approach.  
It is also worth acknowledging that cell lines generated from tissue that has been treated with 
neoadjuvant therapy may not be representative of the original tumour, as neoadjuvant 
therapy has the potential to induce additional mutations within the tumour.   
Current cell lines also fail to model two clinically relevant aspects of disease biology.  The first 
is that they fail to model the genetic diversity observed in oesophageal cancer.  At the genetic 
level, oesophageal cancer, especially adenocarcinoma, is a highly unstable disease and is 
characterised by marked intra and inter tumour genetic heterogeneity.  A number of recently 
published studies using whole genome sequencing, have identified that this is due to the early 
loss of tumour suppressor genes, such as p53, which then lead to the rapid accumulation of 
catastrophic genetic events (Gregson, Bornschein, & Fitzgerald, 2016; Nones et al., 2014; 
Secrier, Li, de Silva, Eldridge, Contino et al., 2016).  In order to recapitulate such a vast genetic 
landscape and provide clinically relevant preclinical models, many more cell lines are required.  
The second is that the majority of currently available cell lines fail to metastasise in the in vivo 
setting.  This aspect of the disease is extremely important to model as it is leading cause of 
mortality for patients who present with the disease.  Typically, locoregional disease can be 
treated with a combination of surgery and perioperative chemotherapy and/or 
chemoradiotherapy.  However, once distant metastases have formed, treatment becomes 
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palliative.  Unfortunately, the only cell line that exists that reproducibly metastasises is a 
subclone of the FLO-1 cell line that was successfully isolated and cultured by Liu et al (Liu, 
Hoefnagel, Fisher, Krishnadath, Montgomery et al., 2016).  This cell line has been shown to be 
reproducibly metastatic when injected both subcutaneously and orthotopically. 
The aim of this chapter, therefore, was to develop additional OAC cell lines.  However, this is 
particularly challenging given the limited availability of treatment naïve OAC tissue.  As a 
result, oesophageal SCC tissue is also used throughout this chapter in order to both develop 






Numerous techniques were trialled in an attempt to generate additional oesophageal cancer 
cell lines.  These techniques involved using both primary tumour as well as the PDTX model as 
a source of tissue.  A flow diagram outlining these techniques in addition to the range of steps 
performed in order to validate successfully derived cell lines is shown in Figure  4-1.   
 
Figure  4-1 An outline of the techniques used for the generation and validation of addition 
cell lines. 
Red lines outline failed techniques whilst green lines outline techniques that were associated 
with the successful generation of cell lines.   
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4.2.1 Attempted cell line generation from primary tumour tissue 
 
Initial attempts at generating OAC cancer cell lines were performed using original patient 
tissue obtained from oesophageal resection specimens.  In total, attempts were made at 
generating cell lines from four separate patient tumours.  These tumours were mechanically 
and enzymatically digested, as described in section 2.2.1, and placed into culture.  Short-term 
culture of these digested tumours revealed a large amount of floating cellular debris with only 
the occasional adherent cell.  These adherent cells assumed a fibroblast-like morphology and 
failed to divide following extended culture.  Despite repeated attempts using different media 
(EpiLife, EpiGro and RPMI with 20% FCS), different culture conditions (low oxygen) and culture 
surfaces (collagen and Matrigel); tumour cells could not be cultured. 
4.2.2 Attempted cell line generation from patient-derived tumour xenograft tissue 
 
Following these initial failures, attempts were then made at culturing cancer cells from PDTXs, 
as they enrich for viable tumour cells and provide a renewable source of tumour tissue, 
thereby allowing repeated attempts at cell line generation.  In total, attempts were made to 
generate cell lines from ten separate PDTX lines.  To digest xenograft tissue, a rapid digestion 
was performed using a combination of both dispase and collagenase over a 45-minute period 
at 37oC.  This method is a modification of the digestion technique published by Civenni et al. 
(2011) and is described in full in section 2.2.3.    Following digestion, cells were filtered through 
a 40µm filter in order to produce a single cell suspension.  Overall cell yield was further 
increased through the use of a commercially available mechanical tissue chopper, 
manufactured by McIlwain (Surrey, UK).  This tissue chopper is specifically designed to prepare 
sections of tissue while at the same time minimising damage to cell structure.  Despite trialling 
all of the same techniques that were used for the attempted generation of primary cell lines, 
including different types of media, a low oxygen environment and coated culture surfaces, 
xenograft derived tumour cells could not be cultured in vitro.  The only cells that could be 




4.2.3 Attempted cell line generation from FACS sorted xenograft-derived cells 
 
In an attempt to separate the epithelial from the stromal cells, digested PDTXs were sorted 
by flow cytometry.  For this technique to be successful, a cell surface marker needed to be 
selected that is specific for human cells.  The two cell surface markers that were assessed for 
this purpose were human leucocyte antigen (HLA) and human EpCAM.  It was hypothesized 
that HLA would positively select for all human cells, including both epithelial and stromal cells, 
whereas EpCAM would only select for human epithelial cells.  In order to test this, following 
FACS sorting, cytospin preparations of both HLA and EpCAM positive populations were 
assessed for the IHC expression of both human mitochondria and the pancytokeratin AE1:AE3 
(Figure  4-2).  Results revealed that whilst EpCAM and HLA were both able to positively sort 
for human cells, EpCAM was able to sort for a higher proportion of epithelial cells.  Given this, 




Figure  4-2 A comparison between FACS sorted xenograft derived cells based on HLA 
versus EpCAM surface markers 
Cytospin preparations were generated following FACS sorting of xenograft derived cells based 
on either the HLA (panel a) or EpCAM (panel b).  In order to determine the proportion of both 
human and epithelial cells within the sorted cells, cytospin slides were then stained for either 
human mitochondrial antibody or the pan cytokeratin AE1/AE3 and counter stained with DAB.  
Scale bars represent 100μm. 
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Unfortunately, FACS sorted EpCAM positive cells were still unable to be successfully cultured.  
This is despite twelve repeated attempts and trialling a number of additional techniques to 
encourage the growth of epithelial cells, including the use of HISC media designed to prevent 
anoikis (a form of programmed cell death that occurs once anchorage dependent cells are 
detached form the extra-cellular matrix) (Sato, Stange, Ferrante, Vries, Van Es et al., 2011).  
Other techniques included the centrifugation of cellular suspensions following sorting in order 
to facilitate the attachment of anchorage dependent cells to cell culture flasks and the use of 
sphere forming or stem cell assays in an attempt to enrich for cells with the potential for self-
renewal.  Centrifugation was performed at low g-force (250 r.p.m.) for 5 minutes using a 
swinging bucket rotor.  Cells were then cultured at 37oC and 5% oxygen.  Unfortunately, 
following these techniques, only cellular debris was evident. 
4.2.4 Cell line generation using the explant technique 
 
The next technique trialled was a modification of the explant technique of Giard et al. (1973).  
In this technique, xenografts underwent a process of mechanical dissociation followed by 
enzymatic digestion, as previously described in section 2.2.3.  However, rather than passing 
the solution through a 40μm filter in order to yield solution comprised of single cells, the 
entire solution was centrifuged at 1,500 rpm for 5 minutes and the pellet (consisting of 
individual cells, cell clumps and small tissue pieces) re-suspended in RPMI supplemented with 
20% FCS.  This solution was then plated into a T75 flask. After plating, cell clumps and small 
tissue pieces soon became adherent, forming explants.  These were left undisturbed for three 
days whilst being incubated at 37oC and 5% CO2.  Following this, half of the media was then 
refreshed, taking care not to dislodge any of the adherent explants.   
 
Over a period of a few days, fibroblasts started to grow out from these explants.  Following 
this, rounded tumour-like cells began growing on the bed of fibroblasts.  Explants were then 
left in culture for periods of up to six-months.  During this period, media was changed twice 
weekly and fibroblasts removed using a process of selective trypsinisation as they became 
confluent (typically once per week).  During trypsinisation fibroblasts were found to lift after 
only a very short exposure to trypsin (approximately 30 seconds), whereas the tumour cells 
required a prolonged exposure (between 5 to 10 minutes).  After a period of extended culture, 





Figure  4-3 The evolution of an explant in culture 
A series of images detailing the evolution of an explant (Ex) in culture. The explant was derived 
from the rapid digestion of an OAC PDTX and became adherent after only a few days.  Soon 
after becoming adherent, fibroblasts (F) began to grow out.  Over the following weeks (mid 
phase) the explant began to produce epithelial (Ep) cells which became adherent to the bed of 
fibroblasts.  During a period of extended culture, media was changed twice weekly and 
fibroblasts gradually removed using repeated trypsinisation.  Dominant clones began to 
emerge after two to three months (mid phase).  After approximately six months, regions of 
tumour cells emerged that were largely devoid of fibroblasts (late phase).  Blue line marks the 
demarcation between epithelial cells and fibroblasts.  Scale bars represent 100μm. 
 
In order to further enrich for tumour cells, regions of tumour cells were selectively passaged.  
Initially, this led to an outgrowth of both tumour cells and fibroblasts.  However, by continuing 





Figure  4-4 The establishment of a pure cancer cell line through the selective trypsinisation 
of fibroblasts. 
Following passaging, multiple separate colonies of tumour cells would form, separated by 
fibroblasts (a).  Compared to the epithelial cells, fibroblasts would detach after only a short 
exposure to trypsin.  This allowed the fibroblasts to be selectively lifted whilst the epithelial 
cells remained adherent (b).  A magnified view is shown demonstrating that all of the 
fibroblasts have been removed (c).  This process was repeated up to twice weekly until a pure 
epithelial tumour line was established after approximately six months. 
 
Following passaging, tumour cells were also enriched via FACS sorting using human specific 
EpCAM as a surface marker (Figure  4-5).  As these cells had already adapted to in vitro 




Figure  4-5 FACS sorting of explant generated cells based on EpCAM 
A panel of histograms detailing the FACS sorting of explant derived cells originating from the 
OAC PDTX line IS076.  Cells are labelled using an EpCAM antibody conjugated with FITC.  An 
isotype control is initially used to identify a suitable threshold for the identification of 
EpCAM/FITC positive cells (a).  Analysis of the sorted sample reveals a clear population of 
EpCAM/FITC positive cells (b).  Reanalysis of the FITC positive sorted sample confirms that the 




4.2.5 Bona fide oesophageal PDTX-derived cell lines 
 
The explant technique was successful in the generation of four matched xenograft-derived 
cell lines.  These included two OAC lines (TB471 and IS076) and two oesophageal SCC lines 
(ST913 and MA924).  Each xenograft derived cell line took on average six-months to develop 
a purified epithelial cell line that was devoid of fibroblasts and murine cells.  During this 
period, cells were passaged twice weekly.  In the following sections below, the clinical details 
from each original patient are detailed.  ID numbers are also provided which reference back 
to Table 3-2. 
 
4.2.5.1 TB471 (ID 21) 
 
TB471 was a 66-year-old man who presented with a distal OAC arising from a segment of BO.  
This was on background of being anticoagulated for a history of mesenteric ischaemia.  He 
presented with a six-month history of dysphagia and 12 kg loss of weight and was initially 
investigated with a barium swallow that revealed a distal oesophageal tumour.  Endoscopy 
revealed the tumour to be at 34 cm from the incisors and near obstructing.  Staging CT 
demonstrated a hiatus hernia with proximal oesophageal thickening.  No nodal disease was 
evident; however, several pulmonary lesions were identified that were indeterminate in 
nature.  FDG PET revealed an avid tumour of the distal oesophagus (SUVmax of 8) with no 
evidence of locoregional lymph node involvement or distant metastases.  Following the 
insertion of a feeding jejunostomy the patient was commenced on neoadjuvant 
chemotherapy and radiotherapy as per the CROSS protocol (van Hagen et al., 2012).  Repeat 
PET staging demonstrated a complete metabolic response.  The patient then underwent an 
Ivor Lewis oesophagectomy and pathology revealed a complete response with a tumour 
regression grade (TRG) of 1 and with 0 out of 20 lymph nodes involved (Mandard, Dalibard, 
Mandard, Marnay, Henry-Amar et al., 1994).  An area of BO was identified.  In the follow-up 
period the patient subsequently developed both bone and adrenal metastases, which have 
been treated with a combination of resection and stereotactic ablative radiotherapy (SABR). 
 
4.2.5.2 IS076 (ID 22) 
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IS076 was an 83-year-old man with synchronous oesophageal and colonic cancers.  His past 
medical history consisted of atrial fibrillation (for which he was anticoagulated with warfarin), 
hypertension, GORD and hypercholesterolaemia.  He initially presented with a two-month 
history of dysphagia, fatigue, loss of weight (4kg) and iron deficiency anaemia with 
haemoglobin of 68 g/L.  Gastroscopy and colonoscopy revealed a large, ulcerating and 
partially obstructing distal oesophageal tumour in addition to a large, partially obstructing 
mass in the ascending colon.  Histopathology revealed the oesophageal tumour to be a poorly 
differentiated adenocarcinoma and the colonic lesion to be a mucinous carcinoma.  Staging 
FDG PET revealed intensely avid lesions within both the distal oesophagus (SUVmax of 11) and 
ascending colon (SUVmax of 17).  Note was also made of a mesocolic lymph node that was 
possibly involved in addition to a likely right adrenal adenoma.  No other distant metastases 
were identified.  Given the patient’s co-morbidities, the decision was made to proceed directly 
to surgery, as it was thought that he would not tolerate both chemotherapy and radiotherapy.   
He subsequently underwent a combined laparoscopic right hemicolectomy and 
laparoscopically assisted Ivor Lewis oesophagectomy.  Histopathology confirmed that there 
was a 35mm poorly differentiated adenocarcinoma of the distal oesophagus and that the 
margins were clear.  Six out of 30 lymph nodes were invaded with tumour giving an AJCC 
staging of T3N2.  Pathology from the right colon revealed a T3N0 mucinous carcinoma.  
Immunohistochemistry for mismatch repair (MMR) proteins revealed a loss of expression of 
MLH1/PMS2 within the colonic tumour whereas the oesophageal tumour had a full 
expression, thereby demonstrating that the tumours were separate primaries. 
 
4.2.5.3 ST913 (ID 23) 
 
ST913 was a 51-year-old man who presented with a locally advanced SCC of the mid-
oesophagus.  This is on a background of gout, hypertension and hyperlipidaemia.  He 
presented with a three-week history of worsening dysphagia to solids.  He was initially 
investigated with a CT of the chest, which revealed a mid-oesophageal mass and an enlarged 
lymph node in the aorto-pulmonary window.  Subsequent endoscopy revealed a partially 
obstructing mass situated between 26 to 31cm from the incisors.  Biopsy confirmed this to 
be a SCC.  Staging FDG PET revealed an intensely avid mid-oesophageal tumour with some 
low-grade uptake in one aorto-pulmonary lymph node.  ST913 underwent neoadjuvant 
chemotherapy and radiotherapy as per the CROSS protocol.  A feeding jejunostomy was 
placed to facilitate pre-operative nutrition.  During the period of neoadjuvant treatment, 
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ST913 required an ICU admission for management of an altered conscious state that was 
thought to be due to a combination of hyper-osmolar non-ketotic coma and subdural 
haematoma.  He subsequently recovered and a re-staging PET demonstrated that he had had 
a complete metabolic response.  He proceeded to have a laparoscopically assisted Ivor Lewis 
oesophagectomy and histopathology confirmed a complete pathological response with 
associated trans-mural scar formation and 0 out of 10 lymph nodes involved. 
4.2.5.4 MA924 (ID 24) 
  
MA924 was a 77-year-old lady who presented with an oesophageal SCC.  Her past medical 
history consisted of having a stroke secondary to carotid stenosis (which was treated with 
endarterectomy) and hypertension.  She was a non-smoker.  She initially presented with a 
two-month history of dysphagia and odynophagia and subsequent endoscopy demonstrated 
an oesophageal mass situated 30cm from the incisors.  Biopsy revealed a SCC.  Staging 
consisted on a FDG/PET and CT of the chest, abdomen and pelvis.  FDG PET revealed an 
intensely avid lesion within the distal oesophagus over a length of approximately 4.2cm.  
Nodal disease was not evident.  CT revealed a bulky tumour of the distal oesophagus with no 
distant metastases.  Findings were consistent with a locally advanced SCC.  MA924 underwent 
neoadjuvant therapy as per the CROSS protocol.  Re-staging demonstrated evidence of a 
complete metabolic response, as the previous avidity within the distal oesophagus was no 
longer apparent.  MA924 subsequently underwent preconditioning before having a 
laparoscopically assisted Ivor Lewis oesophagectomy.  Histopathology demonstrated a 
complete pathological response with no residual SCC detected, consistent with the findings 
of her re-staging PET.  In the initial post-operative period, MA924 noticed a perineal lesion, 
the biopsy of which confirmed SCC.  This was initially treated with curettage.  A subsequent 
formal excision did not reveal any residual tumour consistent with a TRG of 1.  Two years post 
oesophagectomy, MA924 was progressing well and had no signs of disease recurrence. 
   
 




4.2.6 Generation of the IS076 ascites-derived sub clone 
 
Unique to the IS076 xenograft line is a metastatic sub clone.  This was discovered at the second 
generation of passaging, when two mice harbouring tumours derived from one first 
generation xenograft developed widespread metastases whilst mice harbouring xenografts 
from the other first-generation xenograft remained free from metastases (Figure  4-6).   
 
 
Figure  4-6 The evolution of both metastatic and non-metastatic IS076 sub clones 
A phylogenetic tree detailing the evolution of both metastatic and non-metastatic clones from 
the IS076 PDTX line.  The original patient tumour was divided and implanted intramuscularly 
into two mice. This led to the successful establishment of two separate PDTX lines.  At the first 
passage, one line developed widespread metastases whilst the other line remained non-
metastatic (up until the fifth generation of PDTX).  The metastatic phenotype was maintained 
following a period of cryopreservation. The original patient tumour is represented by multiple 
different colours, each representing a different clone.  The evolution of these clones through 
serial passaging is then shown, demonstrating one theory by which daughter xenografts can 
form with different phenotypes. 
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The metastases first became evident when mice developed rapid onset malignant ascites and 
required culling (Figure  4-7).  In order to obtain a sterile sample of the malignant ascites, 
culled mice had their skin shaved and prepared with alcoholic iodine.  Malignant ascites was 
then aspirated under aseptic conditions using a sterile 21-gauge needle attached to a 10ml 
syringe.  The aspirate was then centrifuged and 1500 r.p.m. for 5 minutes and the pellet re-
suspended in RPMI supplemented with 20% FCS and antibiotics (penicillin and streptomycin).  
The cell suspension was then plated into a T25 flask and left undisturbed for a period of 72 
hours whilst being incubated at 37oC and 5% CO2.  Media was changed twice weekly over a 
period of six months.  A cell line was successfully cultured using this technique and was termed 
IS076–A (for ascites).  The original explant derived cell line was subsequently named IS076–P 
(for primary) in order to differentiate between the two sub clones.  STR analysis confirmed 
that both IS076-A and IS076-P represent separate clones from the same original patient.   
 
 
Figure  4-7 Evidence of metastasis formation within the PDTX model 
Metastases from the IS076 metastatic sub clone were largely confined to the peritoneal cavity.  
At autopsy there was clear evidence of malignant, blood-stained ascites (a).  There was also 
evidence of metastasis formation within the liver and surrounding diaphragmatic surface (b) 





Having separate metastatic and non-metastatic clones form the same patient presents a 
unique opportunity to study the metastatic process in OAC, especially given the limited 
availability of preclinical models that spontaneously metastasise.  However, prior to using the 
models for the study of metastasis formation, it is essential that they undergo a thorough 
characterisation.  Initial efforts to characterise these cell lines have involved performing both 
migration assays and western blots for known markers of epithelial to mesenchymal transition 
(EMT).  Preliminary results demonstrated that the IS076-A was able to migrate much more 
readily in vitro compared to the IS076-P cell line.  This effect was further heightened with the 
use of concentrated fibroblast conditioned media as the chemoattractant (Figure  4-8).  This 
is in keeping with the preliminary results from a western blot analysis which revealed evidence 
of increased vimentin expression, a key regulator of EMT (Liu, Lin, Tang, & Wang, 2015), in the 
IS076-A cell line compared to the IS076-P cell line (Figure  4-9).  However, given that these are 






Figure  4-8 A comparison of cell lines IS076-A and IS076-P using an in vitro transwell 
migration assay  
A transwell migration assay was used to assess the migratory ability of the metastatic (IS076-
A) and non-metastatic (IS076-P) cell lines in vitro.  5×104 cells were pipetted into inserts 
containing an 8"m porous membrane. Lower chambers were filled with 150" l of varying 
chemoattractants (serum free media, media containing 20% FCS and both NAF and CAF 
conditioned media containing 20% FCS).   Following 24 hours of incubation, the cells on the 
undersurface of the membrane were stained using calcein and imaged using a fluorescent 
reader.  Cell numbers were determined from a standard curve of cell number to relative 
fluorescent unit.  Cell migration is presented as a percentage based on the number of cells 




Figure  4-9 Western blot analyses of EMT 
A western blots analysis comparing the EMT characteristics of cell lines IS076-A and IS076-P.  
Proteins are labelled alongside their associated densitometric analysis (normalised to GADPH). 
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4.2.7 In vitro morphology and growth characteristics 
 
IS076-P, TB471, MA924 and ST913 all assumed an epithelial morphology in vitro.  With the 
exception of the IS076-A cell line, they tended to form large cells that grew in colonies and 
were densely adherent, giving a cobblestone-like appearance (Figure  4-10).  They initially 
grew as a monolayer, however, would start to grow in multiple layers once they became too 
dense.  IS076-A, on the other hand, grew as smaller cells that were less adherent.  Once 
established, cells became confluent every three to four days following a 1:4 split.  All cell lines 
were initially cultured with RPMI supplemented with 20% FCS and antibiotics (penicillin and 
streptomycin).  However, once established, media was transitioned to RPMI containing only 
10% FCS and antibiotics. 
 
 
Figure  4-10 In vitro morphology of established xenograft-derived cell lines 
The OAC lines TB471 and IS076-P both demonstrate a typical cobblestone appearance with 
cells growing closely together.  In contrast, the IS076-A cells are much smaller and well-
rounded in appearance.  The SCC cell lines ST913 and MA924 both form a dense monolayer; 
however, the cells exhibit a more spindle-shaped appearance when compared to the 
adenocarcinoma cell lines. 
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4.2.8 Tumorigenic assay 
 
Cell injection xenografts were successfully established from the OAC cell lines IS076-P, IS076-
A and TB471 when injected subcutaneously into NSG mice.  Whilst validation confirmed that 
tissue architecture was maintained between the original patient tumour and first-generation 
PDTX of IS076, the corresponding cell injection xenografts IS076-P and IS076-A failed to 
recapitulate the same degree of differentiation.  However, IHC staining for the pancytokeratin 
AE1/AE3 demonstrated that both IS076-P and IS076-A cell injection xenografts were epithelial 
in origin (Figure  4-11).   
 
Figure  4-11 A comparison between the original patient tumour, first generation PDTX and 
cell injection xenografts of IS076 
H&E staining of FFPE tissue comparing the original IS076 patient tumour to a first generation 
PDTX demonstrates maintenance of tissue architecture (a).  IHC staining against the pan 
cytokeratin AE1/AE3 demonstrates that the cell injection xenografts derived from both IS076-




The TB471 cell injection xenograft, on the other hand, formed well-differentiated glandular 
structures that were filled with mucin (Figure  4-12).  This was following 181 days of in vitro 
culture in order to establish a purified epithelial cell line and 98 days of in vivo culture 
following the injection of 5x106 cell subcutaneously into an NSG mouse.  This is consistent 
with the 226 days that it took to establish the first generation PDTX.  This extended period of 
culture may be due to the fact the tumour was so well differentiated.  In comparison, mice 
inoculated with the same amount of IS076 cells would form tumours much more rapidly, 




Figure  4-12 A comparison between the original patient tumour and cell injection 
xenograft of TB471 
H&E staining of FFPE tissue comparing the original patient tumour TB471 (a) to a 
corresponding cell injection xenograft that had been in culture for eight weeks (b), 
demonstrating that tissue architecture is maintained.  Both original tumour and cell injection 
xenograft display evidence of glandular formation and mucus production.  Scale bars represent 
100μm. 
 
Given the metastatic tendency of the IS076 line, both the ascites and primary lines were 
transduced with eGFP / luciferase prior to injection, in order to assess for metastases.  Results 
revealed that the IS076-A cell line maintained the metastatic phenotype of the parent PDTX 
and consistently formed metastases whilst the IS076-P cell line remained non-metastatic.  
Metastases predominately occurred in the liver, lung, gastroesophageal junction and 









Figure  4-13 Assessing the metastatic burden from a cell injection xenograft derived from 
the IS076-A line 
Individual organs have been displayed following the necropsy of a mouse harbouring a cell 
injection xenograft derived from the IS076-A cell line transduced with eGFP / luciferase (a).  Ex 
vivo bioluminescence imaging confirms the presence of metastases (b). 
4.2.9 Validation of xenograft-derived cell lines 
 
STR analysis confirmed that all PDTXs and established cell lines originated from their 
corresponding original tumours and that no contamination had occurred (Table 4-2).  
Targeted sequencing using a panel of known oncogenes (Table 2-10) confirmed that the 
majority of mutations and variants are maintained across the range of PDTX and cell lines 
compared to the original patient tumour (Table 4-3).  However, there is evidence that 
mutations can accumulate through the successive passage of xenografts, as seen with the 
acquisition of KRAS variants in the PDTXs of TB471, MA924 and ST913.  Another example of 
accumulation is seen with the ST913 cell line that demonstrates evidence of a KIT variant that 
is not evident in the original tumour.  There is also evidence that some cell lines fail to 
demonstrate all the mutations seen within the original patient tumour, such as in IS076-P with 
the loss of the CDKN2A mutation.  This may be due to the fact that the cell line was derived 















Table 4-3 The mutation profiles of the original patient tumours (F0), PDTXs (Fx) and derived cell lines from IS076, TB471, MA924 and ST913 
HGSVg, genomic sequence variation. 
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Additional IHC staining was also performed on the IS076 lines to ensure that they were derived 
from the original patient’s oesophageal cancer and not the synchronous colorectal cancer.  
This was performed using MLH1 and PMS2 in order to differentiate between the two tumours 
based on their microsatellite instability profile, as these proteins were the only ones to be 
differentially expressed between the two tumours (Table 4-4). Results revealed that both the 
metastatic and non-metastatic clones from the IS076 line PDTX both express the proteins 
MLH1 and PMS2, which were absent in the synchronous colorectal cancer (Figure  4-14).   
 
Table 4-4 A comparison between the MMR protein expression of the original colon cancer 
versus the original OAC of patient IS076 
- 
protein not expressed; + protein expressed. 
N.B. As the colonic cancer was unavailable for research purposes these results are based on 
the clinical pathology report.  
COLON CANCER OAC 
MLH1 - MLH1+ 





Figure  4-14 IHC profile of key MMR proteins within cell injection xenografts derived from 
cell lines IS076-A and IS076-P 
The expression of both MLH1 and PMS2 within cell injection xenografts derived from both 
IS076-A and IS076-P matches the profile of the original OAC and not the synchronous colon 
cancer (image not shown). Scale bars represent 100μm.  
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4.2.10 In vitro assessment of putative stem cell markers 
 
The cell line TB471 was also assessed in vitro for the presence of the putative CSC markers 
CD44, CD133 and Lgr5.  The results from this analysis revealed a broad expression of both 
CD44 and Lgr5 across the entire cell population, with CD44 (Figure  4-15) being expressed 
almost uniformly amongst all of the cells whilst Lgr5 (Figure  4-16) was expressed by 
approximately 50% of the cells.  In comparison, CD133 (Figure  4-17) appeared to be more 
specific, as it was expressed by only a minority of cells, in keeping with a potential CSC 
population (Kemper, Prasetyanti, De Lau, Rodermond, Clevers et al., 2012). 
 
 
Figure  4-15 In vitro expression of the putative CSC marker CD44 
Indirect immunofluorescence micrographs of the TB471 cell line following standard 2-
dimensional in vitro culture. Nuclei have been stained with DAPI and are shown in blue.  CD44 
positive cells have been labelled using an anti-CD44 antibody and subsequently stained using 
a fluorescently labelled secondary antibody. Scale bars represent 50μm.  Image courtesy of A. 




Figure  4-16 In vitro expression of the putative CSC marker Lgr5 
Indirect immunofluorescence micrographs of the TB471 cell line following standard 2-
dimensional in vitro culture. Nuclei have been stained with DAPI and are shown in blue.  Lgr5 
positive cells have been labelled using an anti-Lgr5 antibody and subsequently stained using a 
fluorescently labelled secondary antibody. Scale bars represent 50μm.  Image courtesy of A. 
Farley, Pera Laboratory, The University of Melbourne. 
 
 
Figure  4-17 In vitro expression of the putative CSC marker CD133 
Indirect immunofluorescence micrographs of the TB471 cell line following standard 2-
dimensional in vitro culture. Nuclei have been stained with DAPI and are shown in blue.  CD133 
positive cells have been labelled using an anti-CD133 antibody and subsequently stained using 
a fluorescently labelled secondary antibody. Scale bars represent 50μm.  Image courtesy of A. 
Farley, Pera Laboratory, The University of Melbourne. 
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4.2.11 Discovery of a lymphoma-derived cell line 
 
One of the first cell lines to be successfully generated using the explant technique was derived 
from patient RF226.  Unfortunately, as was highlighted in section 3.5, validation of this line 
confirmed that the PDTX from which it had originated had transformed into a human B-cell 
lymphoma whilst being cultured in an immunodeficient setting.  As a result of this 
transformation, the RF226 cell line grew as spheres in suspension, in keeping with a lymphoma 
cell line (Figure  4-18).  This is in contrast to the other oesophageal cancer cell lines that were 
generated, which were all attachment dependent.  The cells within these spheres 
demonstrated rapid proliferation and a tendency to fuse with each other. 
 
 
Figure  4-18 In vitro morphology of a lymphoma derived cell line 
A sequence of time lapse images captured over a 12-hour period detailing the formation of 
spheres in a lymphoma derived cell line (panels a and b).  Individual tumour cells initially divide 
and clump together in order to form small spheres.  Once established, small spheres then fuse 
with other spheres in order to form larger spheres (images c to f). 
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4.2.12 Application of the cell line model for the preclinical assessment of a novel 
therapeutic target 
 
One of the main applications of the cell line model is as a preclinical tool for the evaluation of 
novel therapeutic targets.  As a proof of concept, the IS076-A cell line was used to test the 
effect of BMP inhibition in the management of OAC.  This is based on evidence suggesting that 
activation of the BMP pathway is required for the development of both BO and OAC (Clemons 
et al., 2013; Milano et al., 2007).  Through a collaboration with Professor Krishnadath, from 
the Academic Medical Center (AMC) in Amsterdam, a pilot experiment was performed in 
order to assess the effect of BMP inhibition in cell injection xenografts with high BMP 
expression, using newly generated anti-BMP llama-derived antibodies (Calpe et al., 2016; 
Calpe et al., 2015).  The results from this experiment were extremely encouraging.  When BMP 
inhibitors were administered as a single agent, tumour growth inhibition was similar that to 
that observed with standard chemotherapy.  When both treatments were combined, this 
effect was further increased (Figure  4-19).  In a subsequent experiment, the effect of BMP 
inhibition alone and in combination with cisplatin was also tested on a cell line lacking BMP 
expression.  These results revealed that BMP inhibition had no effect on tumour growth (data 
not shown).  However, in order to determine the significance of these preliminary findings, 
these experiments need to be repeated using additional models in order to determine if the 
results are reproducible.  Complementing these in vivo studies, in vitro studies may also be 
required to determine the mechanisms responsible for any observed effects.  These results 





Figure  4-19 Assessing the effect of BMP 2 and 4 inhibition in combination with cisplatin on 
a PDTX with high BMP expression 
Four separate cohorts of mice bearing cell injection xenografts (five per cohort) were 
established following the subcutaneous injection of 1×106 IS076-A cells.  Once tumours 
reached a volume of 100mm3 mice were randomised to receive either 2mg/kg of cisplatin 
weekly or 100 "g daily of combined BMP 2/4 inhibitor each via intraperitoneal injection.  
Tumour growth is shown in panel a and mean body weight as a surrogate marker of toxicity 
in panel b. Results represent a single experiment. Error bars = SEM. 
4.2.13 Summary 
 
In total, attempts at cell line generation were made using ten out of the 24 different patient 
lines (or their associated xenografts).  These are summarised in Table 4-5.  The first two 
attempts (ID 1 and ID 2) were based on the digestion of primary tissue and were both 
unsuccessful.  Following this, multiple unsuccessful attempts were also made at establishing 
cell lines from FACS sorted xenograft derived cells (ID 8, 10 and 18).  The remaining attempts 
were all based on the explant technique using PDTXs as the source of tissue (ID 14, 21, 22, 23 
and 24).  These attempts were all associated with the successful generation of cell lines.  In 
the case of IDs 21, 23 and 24, these PDTXs were all derived from treatment naïve endoscopic 
biopsies at the time of diagnosis.  Unfortunately, validation confirmed that ID 14 had 
undergone lymphomagenic transformation.  Within this series, the selection of tissue for cell 
line generation (either primary tumour or PDTX) was simply determined based on tissue 
availability.  The type of technique for the generation of an in vitro cell line continued to evolve 
until a cell line was successfully generated.  Once the explant technique proved to be 
successful, all subsequent lines were derived using this technique.  In total, cell line generation 
was attempted from ten different lines using the multiple different techniques previously 
described.  The explant technique using PDTX tissue proved to be the most robust, with four 
of the five attempted lines yielding an epithelial cell line following validation.  
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Table 4-5 Attempted cell line generation and success rate for each individual patient line 
 
 
Abbreviations:  IM, intramuscular; SC, subcutaneous; GOJ, gastro-oesophageal junction; PM, peritoneal metastasis; AC, adenocarcinoma; NET, neuroendocrine 
tumour; SCC, squamous cell carcinoma; CT, chemotherapy; RT, radiotherapy; Y, yes; N, no; no entry, not attempted.  Colours: Green, successful; Yellow, 
lymphomagenic transformation; Red, unsuccessful. * Mixed epithelial component # Transformation occurred at second passage.  Entries in bold represent 




Drawing on the success of the IM PDTX technique (Read et al., 2016), this chapter highlights 
the development of a robust technique for the establishment of xenograft-derived cell lines.  
This has culminated in the development of four matched PDTX and cell line models, one of 
which having both metastatic and non-metastatic clones.  Such a development is a significant 
advancement, particularly in the field of OAC, which has been limited by a paucity of well-
validated cell lines. The successful generation of cell lines in this series is based upon two key 
principles.  The first is the use of the PDTX to enrich for viable tumour cells and provide a 
renewable source of tumour tissue.  The second is the use of the explant technique.  By 
providing an initial bed of fibroblasts, this technique appears to be much more robust and 
reproducible compared to the use of single cell suspensions.  The explant technique itself has 
long been used in the development of cell lines (Giard et al., 1973). 
Historically, OAC cell lines have been extremely difficult to generate.  This is thought to be due 
to the limited availability of treatment naïve tissue, which is usually obtained at the time of 
diagnosis in the form of small endoscopic biopsies that contain varying amounts of viable 
tumour.  For instance, biopsies taken from the centre of a tumour, may potentially contain 
necrotic tissue (as the centre of tumours are frequently necrotic).  Biopsies taken from the 
periphery of the tumour also have the potential to contain surrounding non-malignant tissue.  
In both of these instances the proportion of viable tumour cells available for cell line 
generation is diminished. Obtaining tumour tissue from surgical resection specimens also has 
its limitation, as tumours have typically been treated with neoadjuvant therapy 
(chemotherapy +/- radiotherapy).  As up to 82% of tumours have been reported to exhibit 
either a complete or partial response to neoadjuvant treatment (van Hagen et al., 2012), this 
can also have a significant effect on the proportion of viable tumour cells within a specimen.   
Within this series, three of the four patients from which cell lines were generated underwent 
a complete pathological response to neoadjuvant therapy.  This highlights the importance of 
being able to use treatment naïve tissue for the generation of both PDTXs and subsequent cell 
lines.  Given that IM PDTXs are more easily established from primary tissue than primary cell 
lines (14/19 vs 0/2), it seems logical to use the IM PDTX model to ensure the ongoing culture 
of tumour cells (Read et al., 2016).  This may be due to the fact that the cells remain in an in 
vivo environment and do not have to adapt to the stress of in vitro culture.  Drawing on the 
ability of the PDTX model to enrich for viable tumour cells, I have demonstrated that it is much 
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more efficient to produce cell lines from PDTX material than from primary tumour tissue.  This 
finding is consistent with the generation of cancer cell lines from other cancers such as 
colorectal cancer (Dangles-Marie, Pocard, Richon, Weiswald, Assayag et al., 2007).   
 
In this chapter, multiple different techniques for the generation of xenograft-derived cell lines 
were trialled.  However, all of the techniques that were based on the generation of a single 
cell suspension were unsuccessful.  This is likely due to the fact that epithelial cells are 
dependent on neighbouring cells, including the stroma.  Trying to grow such cells in isolation 
requires highly augmented conditions.  As such, the success of the explant technique may be 
related to the presence of fibroblasts.  From observation, it was evident that tumour cells 
required a bed of fibroblasts in the early stages of culture to facilitate attachment.  However, 
it is not clear from this study if this was due to secreted factors from the fibroblasts or a 
contact dependent phenomenon.  It was only after an extended period of adaptation, of up 
to six months, that tumour cells were able to grow on their own.   
 
Having matched PDTX and xenograft-derived cell lines provides an extremely powerful tool as 
it harnesses the strengths of both models.  Compared to cell lines, which tend to be clonal, 
PDTX recapitulate the heterogeneity of the original tumour to a much greater degree.  Early 
passage xenografts also maintain original stromal elements, which are known to play a key 
role in tumour biology (Tentler et al., 2012).  However, cell lines have the advantage of being 
much more manipulable and conducive to mechanistic studies.  
 
This study also provides an additional metastatic model, which is rare in the field of OAC.  This 
is despite the fact that oesophageal cancer readily metastasises in the patient, and that the 
majority of deaths related to oesophageal cancer are due to metastatic disease.  This may be 
due to a number of reasons.  Firstly, tumour tissue collected for research purposes is usually 
collected from the primary tumour in patients being treated with curative intent as opposed 
to metastatic deposits, as those patients are typically being treated with palliative intent.  
Therefore, the tumour may not have evolved sufficiently to metastasise.  Secondly, the 
metastatic potential of a cell line may be influenced by the microenvironment at the site of 
injection (typically subcutaneously).  Finally, metastasis formation may be a function of time 




The only other truly metastatic cell line is a sub clone of FLO-1 (Liu, Hoefnagel, et al., 2016).  
Other metastatic models, such as that published by Gros et al. (2010), simply represent 
pseudo-metastatic models, as tumour cells are directly injected into the tail veins of mice and 
disseminate immediately.  This enables metastases to form without cells having to undergo 
the initial process of EMT.  Like Liu et al. (2016), we have been able to isolate a clone that has 
increased metastatic potential, and which demonstrates progression through EMT.  Of 
particular note, the metastases that form recapitulate what we see in the patient, despite the 
heterotopic injection site.  Metastases form in the liver, lung, peritoneal cavity and around 
the GOJ nodes.  Having two clones from the same patient, one being reproducibly metastatic 
and the other not, provides a very powerful tool to investigate tumour biology with regards 
to metastasis formation.   
 
This study also highlights the importance of validation of both PDTX and xenograft-derived 
cell lines, as one of the PDTXs from which a cell line was generated in this series had 
undergone lymphomagenic transformation.  This is a phenomenon that we recently reported 
and has been reported to occur in up to 68% in some xenograft series (Read et al., 2016).  This 
is of particular importance in the field of OAC, where the availability of suitable preclinical 
models is limited.  Recent studies have also revealed that misidentification or contamination, 
especially when occurring at the source laboratory, can have significant downstream 
consequences (Alvarez et al., 2008).  In the case of OAC, data from the use of misidentified 
cell lines has been used in over 100 publications and 11 patents and formed the basis of a 
number of clinical trials (Boonstra et al., 2010).  Fortunately, validation of the remaining cell 
lines established in this study confirms that they are of epithelial origin and originate from 
their respective patients.   
 
The diverse mutational profile that exists within OAC has proven to be a major barrier to 
research.  In addition, OAC is characterised by both intra and inter-tumour heterogeneity.  As 
a result, the few cell lines that are available to researchers fail to model the entire genetic 
landscape. It is therefore essential that we generate additional cells lines, each with their 





In summary, we have successfully generated and validated four additional esophageal cancer 
cell lines (two adenocarcinoma and two SCC) with matched PDTXs, creating powerful tools for 
cancer research.  Of note, we have also generated corresponding metastatic and non-
metastatic cell line clones from a single xenograft line.  The combination of these models 
provides a significant advance to the types of preclinical models available for oesophageal 
cancer, in particular adenocarcinoma.  It is hoped that these models will aid in the study of 
cancer biology and the development of novel treatments.   
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Chapter 5 The development & validation of preclinical models 
of both normal human oesophageal epithelium and BO 
5.1 Introduction 
 
Current evidence suggests that BO develops as a result of a complex interplay between 
molecular genetics, cellular interactions and environmental exposures (Krishnadath et al., 
2015).  Due to these complexities, researchers have been unable to develop the ideal model 
system with which to study the disease process (Nakagawa, Whelan, & Lynch, 2015).  As 
previously stated, the ideal model system should produce a 3-dimensional epithelial layer, be 
both reproducible and manipulable, and allow for environmental exposures.  Most 
importantly, however, it needs to contain all of the essential cellular elements required for 
the development of metaplasia (Read et al., 2018).  This is extremely challenging given that 
the Barrett’s cell of origin has not yet been identified (Rhee & Wang, 2018).  Two models, 
however, have the potential to fulfil a number of these prerequisites.   
 
The first is an in vivo tissue reconstitution system known as the hat chamber model.  In this 
model, a culture system is implanted onto the dorsal fascia of an immunocompromised mouse 
(Figure  5-1).  The hat chamber model was originally used for the study of epidermal 
regeneration (Maas-Szabowski, Fusenig, & Stark, 2005; Worst, Mackenzie, & Fusenig, 1982).  
It was later optimized for the study of oesophageal epithelium (Croagh, 2006).  In theory, it 
enables the establishment of a 3-dimensional epithelial layer, is manipulable and allows for 
environmental exposures.  In a series of experiments, epithelium was reconstituted from 
suspensions of oesophageal keratinocytes that were obtained from the digestion of fresh 
oesophageal tissue (Figure  5-2).  Like the original human tissue, the reconstituted epithelium 
formed a three-dimensional stratified squamous epithelium that contained both basal, and 
papillary regions and expressed the same IHC profile.  Staining against human mitochondria 
also confirmed that the tissue was of human origin (Figure  5-3).  However, unlike the native 
tissue, the reconstituted epithelium also contained a keratinized layer.  Whilst preliminary 
experiments demonstrated the model’s feasibility, its application was limited due to issues 
with chamber fixation and cell containment, leading to an overall success rate of less than 






Figure  5-1 A diagrammatic representation of the silicone hat chamber model 
The lower component is initially placed on the dorsal fascia of a mouse before the upper 
component (or hat) is fitted.  The skin is then closed over the device leaving a small aperture 





Figure  5-2 A comparison between normal human oesophageal squamous epithelium and 
epithelium cultured within the hat chamber system 
H&E staining of normal human oesophageal squamous epithelium (a) versus squamous 
epithelium cultured within the hat chamber system (b).  Both specimens consist of stratified 
squamous epithelium (Sq) comprised of both basal (B) and papillary (P) regions.  The tissue 
cultured within the hat chamber also consists of a keratinised (K) layer. Epithelium cultured 
within the hat chamber also demonstrates similar IHC profiles for antibodies against both CK4 
and involucrin, a marker of terminal differentiation.  Image c represents staining against CK4 
of normal human oesophageal squamous epithelium which is compared to epithelium cultured 
within the hat chamber in image d. Image e represents staining against involucrin of normal 
human oesophageal squamous epithelium compared to epithelium cultured within the hat 




Figure  5-3 Epithelium cultured within the hat chamber system is of human origin 
Staining against human mitochondria demonstrating the demarcation (represented by the 
dashed red line) between cultured human tissue (positive staining) versus host murine tissue 
(negative staining).  Scale bar represents 100μm (Modified from Croagh, 2006). 
 
 
Another model that has the potential to fulfil a number of the prerequisites of the ‘ideal 
model’ is the xenograft model.  Although historically, the xenograft model has almost 
exclusively been used for the generation of tumour xenografts, it has also been used to culture 
normal human tissue.  In an early example, Verstijen et al. (1988) implanted normal human 
colonic mucosa subcutaneously into nude mice and cultured it for up to five weeks in order 
to assess epithelial proliferation and differentiation.  Results revealed the successful 
engraftment and ongoing culture of epithelial tissue, with the implanted tissue forming both 
crypt regions and more differentiated cystic structures lined by columnar epithelium (Figure  
5-4).  Given the similarities between colonic mucosa and BO, such as the presence of columnar 
epithelium and mucus producing goblet cells, this model provides a premise for a xenograft 
model of BO.  The key advantage of using the xenograft model for the study of BO is that it 
has the potential to produce a 3-dimensional structure and does not rely on the digestion of 
tissue into single cells.  Transplanted tissue pieces are also more likely to contain the full 
complement of cell types seen in the various stages of the development of BO such as 
squamous cells, columnar cells, goblet cells and stromal cells.  Whole tissue pieces also have 
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the advantage of including cells from the different epithelial regions such as the luminal 
surface, basal layers, ducts and SMGs.  As such, there is a greater chance that the Barrett’s 
cell of origin will be contained within the model. 
 
 
Figure  5-4 Normal human colonic xenografts two weeks post implantation. 
Xenografts consist of both crypt regions and more differentiated cystic structures lined by 
columnar cells (a).  HIDAB staining demonstrating the presence of mucus producing goblet 
cells (b) (Verstijnen et al., 1988. Image reproduced with permission). 
 
The aim of this chapter was to develop an improved preclinical model that can culture both 
normal human oesophageal epithelium and BO.  In order to achieve this the first objective 
was to optimise the hat chamber model by (1) improving chamber fixation and cell 
containment, and (2) demonstrating the successful generation of a Barrett’s-like epithelium.  
The second objective was to draw on the success of the IM xenograft model by adapting the 








5.2.1 Optimisation of the hat chamber culture system 
 
In an attempt to improve the fixation of the hat chamber culture system to the dorsal fascia 
of the mouse, which was identified as major limitation in previous experiments performed by 
Croagh (2006), a piece of ProGripTM mesh was secured to the base of the hat chamber system 
using a non-absorbable suture prior to implantation (Figure  5-5).  A biological collagen mesh 
known as PermacolTM was also considered for this purpose, however, this was considered to 
be unsuitable as it does not permit tissue ingrowth. 
 
Figure  5-5 A diagrammatic representation of the modified silicone hat chamber model. 
In order to facilitate better fixation, a piece of ProGripTM polyester mesh (inset) was sutured to 
the lower component. 
 
In order to implant the hat chamber culture system, immunodeficient mice were first 
anaesthetised and their dorsum prepared with alcoholic iodine.   A dorsal incision was then 
made and stay sutures placed on the skin edges.  Skin flaps were then raised in order to 
accommodate the culture system.  The lower component of the culture system, with mesh 
attached, was then placed on the dorsal fascia of the mouse.  A 100μl cellular suspension, 
consisting of either freshly isolated epithelial cells or cultured cells, was then delivered into 
the system before the upper component (hat) was fitted.  The skin was then closed over the 
hat chamber system using absorbable suture.  A small aperture was left in the wound in order 
to access the chamber.  Mice were then recovered on a heat pad overnight and observed for 
any signs of suffering.  Bile and gastric fluid were then injected into the culture system as 
required, in order to simulate the reflux of acid and bile into the lower oesophagus.  Tissue 
cultured within the hat chamber was then harvested at predetermined time frame (typically 





Figure  5-6 Methodology for the establishment and implantation of the modified hat 
chamber system 
Both upper and lower components of the silicone hat chamber system can be seen in image a.  
Image b demonstrates the modified hat chamber system with the addition of a disc of 
ProGripTM mesh to the base.  In this image a layer of Matrigel has also been incorporated into 
the system prior to implantation.  After placing stay sutures in the dorsal skin and raising skin 
flaps, the lower component (complete with mesh) is securely placed on the dorsal fascia of the 
host mouse (c). A cellular suspension is then delivered into the system (d) before the upper 
component is fitted (e).  The skin is then closed over the hat chamber system leaving a small 
aperture for access (f).  Bile and gastric fluid are then injected into the system as required (g).  
Cultured tissue is then harvested (h).  In this image, tissue ingrowth into the ProGripTM mesh is 




In total, eight separate experiments were performed using the hat chamber culture system.  
Given that two mice were used per experiment, this equated to a total of 16 implantations.  
The addition of ProGripTM mesh to the chamber base plate successfully prevented chamber 
dislodgement.  This was due to the complete incorporation of host tissue into the mesh, which 
created an extremely stable platform (Figure  5-7).  Despite adequate chamber fixation, cell 
containment remained a problem.  When cells were either injected or pipetted into the 
chamber in their associated media, the cell suspension soon dispersed below the chamber.  
This was prevented with the addition of Matrigel to the cell suspension at a ratio of 1:1, which, 
due to its viscosity, contained the cellular suspension within the chamber.  In order to assess 
the effectiveness of this cellular containment; OE33 cells (an established oesophageal cancer 
cell line) were injected into the system.  This led to the formation of a tumour xenograft 
completely within the confines of the chamber (Figure  5-7a).  A similar appearance could also 
be observed from the culture of human oesophageal keratinocytes (Figure  5-7b).  
Unfortunately, an established epithelial structure could not be found within this specimen.  It 
is hypothesized that this tissue growth may simply be the result of growth factors present 
within the Matrigel.  In an attempt to further optimize the model, numerous other variables 
were tested without success.  These included the strain of host mouse (Scid versus NOD-scid), 
cell number (3×105 vs 5×105), timing of cell injection, co-injection with fibroblasts as a form of 
feeder cell and the injection of freshly isolated versus cultured keratinocytes.  Another 
variable that was tested was the effect of immediate cell inoculation versus after one week, 
as this would allow tissue ingrowth into the mesh at the base of the chamber.  This could have 
the potential to further enable cell containment and provide a more vascularised environment 





Figure  5-7 Tissue harvested from the chamber culture system 
Tissue harvested from the hat chamber system following four weeks of culture.  A cell injection 
xenograft derived from OE33 cells is seen in panel a.  Tissue cultured from normal oesophageal 
keratinocytes seeded in Matrigel is seen in panel b.  In both instances the ProGripTM mesh has 
been completely incorporated with tissue.  
 
5.2.2 The establishment of xenograft model capable of culturing both normal human 
oesophageal squamous epithelium and BO 
 
The second aim of this chapter involved the development of a xenograft model capable of 
culturing both normal human oesophageal epithelium and BO.  In order to achieve this, the 
IM transplantation technique was adopted.  Firstly, tissue was obtained from either 
endoscopic biopsy or surgical resection specimen.  In the case of surgical resection specimens, 
once they were received, they were opened longitudinally and carefully inspected for regions 
of normal epithelium, BO and OAC (Figure  5-8).  This was either performed by an anatomical 
pathologist or by the surgical team in theatre.  Pieces of epithelium, approximately 2mm3 is 
size, were then biopsied.  Following collection, tissue pieces then underwent ex vivo imaging 





Figure  5-8 Identification of normal squamous epithelium, BO and OAC from a surgical 
resection specimen 
A photo of a surgical resection specimen of the lower oesophagus and gastroesophageal 
junction that has been opened longitudinally (a) in order to demonstrate a region of BO 
(outlined in blue), normal squamous epithelium (black) and a corresponding adenocarcinoma 
(outlined in green).  Representative H&E sections from all separate regions are shown 
alongside the main image.  Scale bars represent 100μm.  Representative pieces of both normal 
squamous epithelium (b) and BO (c) have then been sampled and imaged using a dissecting 
microscope in order to confirm their origin.  Squamous epithelium is composed of flat sheets 
of epithelium whereas BO demonstrates a villous morphology.  
 
Following collection, tissue was placed in Matrigel and kept on ice until transplanted.  Tissue 
pieces were then transplanted as previously described in section 3.3.  However, after closing 
the IM pocket, a non-absorbable 4/0 suture was then placed at the site of transplantation in 
order to help identify the site at time of retrieval.  Xenografts were then cultured for periods 





Figure  5-9 Establishment and harvesting of both normal oesophageal and BO xenografts 
A small piece of epithelial tissue (obtained from either surgical resection specimen or 
endoscopic biopsy) is implanted into an IM pocket on the dorsum of a mouse in order to 
generate a xenograft (a).  At a pre-determined time point (in this case three-months) the 
mouse is culled and the xenograft retrieved.  The site of dissection is determined from a non-
absorbable marking suture (region of interest in image b) and a muscle flap is raised revealing 
the xenograft (region of interest in image c).  A xenograft of approximately two to three 
millimetres in dimension is dissected (d). 
 
5.2.3 Results from the culture of normal oesophageal epithelium 
 
In total, normal oesophageal epithelium was collected from four separate patients and 
implanted into a total of nine mice using the IM transplantation technique.  Culture periods 
ranged from one to two months.  Squamous xenografts were successfully harvested from six 
of the nine implanted specimens.  All successfully generated xenografts were derived from 
oesophagectomy resection specimens, with normal tissue being harvested from the surgical 
margin, as far away as possible from regions of BO or cancer.  Post harvesting, two distinct 
regions were evident within the squamous xenografts.  These included a cystic region and a 
germinal region (Figure  5-10).  The ‘cystic region’ is lined by differentiated, non-keratinising 
squamous cells organized into four or five layers, with the cyst containing cellular debris and 
keratin.  In contrast, the ‘germinal region’, is composed of a mass of cells that appear less well 
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differentiated and less well organised (Figure  5-10a).  Within this region there is evidence of 
hyperkeratinisation with the formation of keratin islands.  The outer layer of the xenograft 
represents the basal layer, whilst the inner layer represents the luminal surface.  IHC analysis 
revealed that the xenografts were strongly positive for the squamous markers cytokeratin 5 
and p63.  Staining against cleaved caspase-3 revealed that there was only a scant amount of 
cell death (Figure  5-10). 
 
In order to determine the levels of cellular proliferation within the model, a 
bromodeoxyuridine (BrdU) pulse-chase experiment was performed.  As BrdU is an analogue 
of the DNA nucleoside thymidine, it becomes incorporated into cells as they replicate.  By 
administering BrdU to mice harbouring xenografts over a certain timeframe (pulse phase), it 
is possible to determine the cells that have replicated over this period.  Following 
administration, BrdU is then gradually lost with subsequent replications.  The period between 
the cessation of administration and harvesting of tissue is denoted as the ‘chase’ phase.  Cells 
that retain BrdU label at the end of an extended chase period are termed label retaining cells 
and represent slow cycling cells.  Following a five-day BrdU pulse period in conjunction with a 
one-month chase period, BrdU positive cells were identified in the terminally differentiated 
layers of the stratified squamous epithelium (Figure  5-10f).  It is most likely that these cells 




Figure  5-10 Validation and characterisation of the oesophageal squamous xenograft model 
In this experiment, a five-day BrdU pulse period commenced two-weeks post the transplantation of normal oesophageal epithelium.  Following this, the 
xenograft was serially passaged into another mouse and cultured for a further four weeks (chase phase).  The xenograft was then harvested, fixed in formalin 
and embedded in paraffin for histological analysis.  H&E staining demonstrates the formation of a stratified squamous epithelium (a).  A magnified region of 
interest is shown (b).  For the purpose of validation, IHC stains against p63 (c) and CK5 (d) are shown.  In order to asses cellular viability and proliferation 
within the xenograft, staining against cleaved caspase-3 (e) and BrdU (f) is also shown.  Counterstaining was performed using haematoxylin.  Scale bars 
represent 100μm. 
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5.2.4 Development and validation of the Barrett’s xenograft model 
 
As per the squamous xenograft model, BO xenografts were established from tissue obtained 
from either endoscopic biopsy or surgical resection.  In total, xenografts were successfully 
derived from eight out of 14 patient samples and were cultured for periods ranging from one 
to six months.  Early xenografts typically contained both glandular and villous regions in 
addition to a more differentiated cystic structure lined by an intestinal type of epithelium 
(Figure  5-11).  The xenograft lumen contained both cellular debris and secreted mucus that 
was produced by a functioning epithelium.  Following extended culture, the columnar cells 
began to flatten and take on a cuboidal appearance.  The number of glandular regions also 
diminished.   Validation confirmed that the epithelium lining the xenograft is representative 
of the original human tissue (Figure  5-12).  Staining against human mitochondria also confirms 
that the xenograft is of human origin.  Further validation confirms that BO xenografts express 
markers of intestinal differentiation such as CDX2, MUC2, MUC5AC and Alcian blue.  Ki67 
positivity provides evidence of cellular proliferation within the xenograft, which, in mature 






Figure  5-11 BO xenografts across a range of time points 
H&E sections from a range of BO xenografts harvested at separate time points (a=42 days, 
b=42 days, c=92 days, d=97 days, e=104 and f=167 days).  Xenografts are lined by a single 
layer of columnar epithelium and display varying amounts of goblet cells.  The lumen consists 
of secreted mucin and cellular debris.  Crypt and glandular regions are also evident within 
xenografts in c and d. Glandular regions are identified by arrows. Scale bars represent 100μm. 
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Figure  5-12 Validation and characterisation of the BO xenograft model 
Barrett’s xenografts recapitulate an intestinal phenotype, are of human origin and express 
markers of intestinal differentiation and proliferation.  The above panels demonstrate H&E 
staining of a representative piece of original patient tissue prior to implantation (a) and the 
H&E staining of the corresponding xenograft following 92 days in culture (b).  IHC staining 
against human mitochondria confirms that this xenograft is of human origin (c) and staining 
against the transcription factor CDX2 confirms an intestinal phenotype (d).  Ki67 staining 
confirms ongoing evidence of cellular proliferation following 92 days in culture.  Alcian blue 
staining was performed to assess for the presence of goblet cells and mucin production (f).  
This was performed on a separate xenograft that was derived from the same patient that had 
been in culture for 167 days.  Goblet cells are indicated by arrows.  Scale bars represent 100μm. 
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5.2.5 Attempted passaging of Barrett’s xenografts 
 
Two attempts were made at passaging Barrett’s xenografts.  The first attempt was 
unsuccessful, as the passaged xenograft (F2) had undergone lymphomagenic transformation.  
In the second attempt, a xenograft was passaged after only two weeks as part of a label 
retaining experiment.  Following a five-day pulse period, the xenograft was passaged and 
cultured for one month (chase period).  Unfortunately, the section of tissue that was collected 
at the time of passage lacked any evidence of an epithelial structure.  It is most likely that this 
represented a sampling error as only murine tissue was evident in the sample.  Following the 
chase period, the harvested tissue revealed evidence of a squamous epithelial structure 
(Figure  5-10).  This most likely represents the misidentification of tissue at the time of 




5.2.6 Culturing the SCJ within the xenograft model 
 
On two separate occasions xenografts were cultured that contained both stratified squamous 
and columnar epithelium (Figure  5-14).  Within these xenografts a clearly defined SCJ 
separated both squamous and columnar regions. It is possible that these xenografts represent 
the ongoing culture of both squamous and columnar tissue collected from the native SCJ in 
the patient.  Alternatively, it may have formed de novo from resident progenitor cells.  On the 
first occasion, the xenograft was harvested from the same first-generation cohort that was 
used as part of the passaging experiment that was previously described in section 5.2.5 (Figure  
5-13).  As previously stated, this passaged xenograft contained only squamous features.  This 
transition zone was extensively characterized by means of IHC analysis, as seen in the second 
example (Figure  5-14).  Results indicated that columnar cells exclusively expressed CDX2, a 
marker of intestinal differentiation.  The columnar epithelium also contained the occasional 
cell expressing MUC5AC.  Within squamous regions, p63 was expressed in both basal and 
suprabasal regions.  In contrast, staining against cytokeratin 5 demonstrated a more even 
distribution throughout the squamous regions.  Interestingly, a layer of cells expressing both 
CK5 and p63 were evident below the layer of columnar epithelium immediately adjacent to 
the SCJ.  Such an arrangement is consistent with the transitional epithelium recently identified 
by Jiang et al. (2017).  Label retaining cells are also identified following a 32-day chase period, 
also residing below the columnar epithelium immediately adjacent to the SCJ (Figure  5-14h). 
 
 
Figure  5-13 Evidence of a SCJ within the xenograft model 
IHC staining against p63 (panel a) and CK5 (panel b) highlights the squamous regions that have 
been cultured within the xenograft.  Staining against the columnar marker, MUC5AC, is shown 
in panel c.  Within the magnified region of interest (panel c), the SCJ has been highlighted with 






Figure  5-14 IHC characterisation of the SCJ within the xenograft model 
Individual xenografts have the ability to support both stratified squamous and columnar epithelium simultaneously, as seen in panel a (H&E staining).  The 
marked region of interest, demonstrating the junction between stratified squamous and columnar epithelium is shown in panel b (H&E staining).  A panel of 
IHC stains have been performed to further characterise this region.  These include MUC5AC (c), CDX2 (d), CK7 (e), CK5 (f) and p63(g).  In addition, this xenograft 
has also been labelled with BrdU over period of five days.  This was then followed by 32-day chase period.  Staining against BrdU can be seen in panel h.  Scale 
bars represent 100μm. 
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5.2.7 Evidence of lymphomagenic transformation within the Barrett’s xenograft model 
 
Just like the oesophageal cancer xenograft model (Section 3.5), the Barrett’s xenograft model 
was also prone to lymphomagenic transformation.  In keeping with the cancer xenograft 
model, these mice also developed splenomegaly with associated tumour formation.  In total, 
this occurred on two separate occasions.  Both of these cases occurred when the original 
tissue had been collected from patients with concurrent adenocarcinomas, resulting in a 
conversion rate of 2/8 (25%).  In contrast, none of the six Barrett’s xenografts that were 
implanted from patients without cancer developed lymphomas.   
 
5.2.8 Characterisation of the xenograft model at early versus late time points 
 
In an attempt to understand how the xenografts form, xenografts were harvested and 
analysed at both early (Figure  5-15) and late (Figure  5-16) time points.  By analysing 
xenografts harvested at an early time point (day 19) by means of IHC staining against cleaved 
caspase-3, a marker of cell death, it is evident that the transplanted tissue maintains its 
viability (Figure  5-15).  The only evidence of cellular death is from within the xenograft lumen 
(which is expected as it is filled with cellular debris) as well as the occasional differentiated 
cell from the luminal surface of the xenograft.  Rudimentary structures, identified by the 
absence of a lumen, contain minimal evidence of cell death.  In addition, results from a label-
retaining assay performed on these same xenografts demonstrate that the rudimentary 
structures, when compared to the more differentiated structures, contain many more cells 
with BrdU incorporation.  As BrdU becomes incorporated during DNA replication, this implies 
that the cells in these regions are cycling more actively.  In this experiment, a five-day pulse 
period of BrdU was performed commencing one-week post implantation.  A one-week chase 








Figure  5-15 Assessment of cellular viability and proliferation within the early xenografts 
A five-day BrdU pulse period commenced one week after the implantation of Barrett’s tissue taken from a surgical resection specimen. This was followed by 
a seven-day chase period.  All images represent different regions from within a single xenograft.   IHC staining for cleaved caspase-3 (a, b, c and d) and BrdU 
(e, f, g and h) is shown.  Top and bottom panels are matched.  Scale bars represent 100μm. 
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In order to assess the proliferative regions of more mature xenografts, a five-day BrdU pulse 
was performed on BO xenografts that had been in culture for up to 3.5 months (Figure  5-16).  
Results from this experiment revealed that the majority of cellular replication within more 
mature xenografts takes place within the glandular regions.  However, an area of cellular 
proliferation was also identified within a more differentiated region of the same xenograft.  In 
the centre of this region was a single cell without any evidence of BrdU uptake, suggesting 
that this cell is cycling more slowly than the surrounding cells.  Further flanking this region 




Figure  5-16 Labelling of cells within BO xenografts 
Xenografts derived from endoscopic biopsies of two separate patients were cultured for 3 (a) 
and 3.5 months (b).  Mice were then administered BrdU daily for 5 days.  Both xenografts were 
harvested 12-hours following the last dose of BrdU. IHC staining against BrdU is shown.  Scale 
bars represent 100μm.  
 
From these results there is evidence that xenografts harvested at early time points contain 
many more ‘rudimentary’ structures that lack a lumen.  It is highly probable that the more 
differentiated xenografts, characterized by cystic structures lined by a functional epithelium, 




5.2.9 Analysis of cell cycling within the Barrett’s xenograft model 
 
In order to analyse cell cycling within the xenograft model over an extended period of time, a 
series of label retaining experiments were performed on a cohort of mice bearing Barrett’s 
xenografts.  In this experiment, a 5-day pulse period was followed by chase periods of varying 
durations (Figure  5-17).  Following the 5-day pulse phase, the majority of cells from within 
the xenograft were labelled with BrdU, indicating that the majority of the cells replicate within 
a 5-day period.  Over the varying chase periods the proportion of BrdU positive cells gradually 
decreases.   This is because the cells gradually lose their BrdU label with subsequent divisions.  
Within regions of stratified squamous epithelium, the migration of cells from the basal region 
to the luminal surface can be observed.  Following an extended chase period of 42 days, only 
two label retaining cells can be identified residing immediately below the columnar epithelial 





Figure  5-17 Label retention assay of BO xenografts across a range of time points 
Endoscopic biopsies of BO were obtained from one individual patient and implanted into five 
separate mice in order to generate a cohort harbouring xenografts derived from the same 
patient.  After a two-week period to allow for engraftment, host mice were administered BrdU 
daily for five days (pulse phase) in order to label the majority of cells.  Following this, mice were 
then harvested at separate time points (chase period) in order to identify label retaining 
(slower cycling) cells.  The following chase periods were used; two days (panels a, b and c), six 
days (panels d, e and f), 22 days (panels g, h and i), 32 days (panels j, k and l) and 42 days 
(panels m & n).  IHC staining is shown against BrdU.  Scale bars represent 100μm. 
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5.2.10 In vivo culturing of SMGs 
 
Given the importance of the oesophageal submucosal gland as a potential stem cell niche, an 
attempt was made to both harvest and culture these structures using the IM xenograft 
technique.  The aim of this pilot experiment was to firstly assess the feasibility of this approach 
and, secondly, to determine the type of epithelium that is able to be produced by the SMG.  
In order to do this, submucosal tissue was dissected from the proximal margin of a surgical 
resection specimen.  The dissected region was from a region of normal squamous epithelium 
and clear of any BO and cancer.  A representative piece of tissue was taken in order to confirm 
the presence of SMGs from within the specimen (Figure  5-18a).  Results revealed the 
successful formation of xenografts following 53 days of in vivo culture.  However, unlike the 
xenografts of both normal human oesophagus and BO, these xenografts failed to form a 
spherical or cyst-like structure (Figure  5-18b).  Instead, they were predominantly composed 
of solid tissue containing multiple small, incompletely formed structures (Figure  5-18c).  
Rudimentary structures, lacking any noticeable lumen, were also present.  The cultured tissue 
stained positively for the squamous markers cytokeratin 5 and p63 as well as cytokeratin 7 (a 
marker of ductal or transitional epithelium (Mohammed, Streutker, & Riddell, 2002) and 
lacked expression of the intestinal makers MUC5AC and MUC2 (Figure  5-18).  Given that this 
experiment only yielded rudimentary structures, future experiments should be performed 
over longer culture periods to determine if the xenografts become more differentiated.  
Attempts should also be made to both passage these xenografts and perform pulse-chase 






Figure  5-18 Generation of xenografts from oesophageal SMGs 
SMGs were harvested from fresh surgical resection specimens.  A representative piece of tissue 
was formalin fixed and paraffin embedded and stained with H&E in order to confirm that SMGs 
were present (a).  Xenografts were harvested at 53 days post implantation (b).  H&E staining 
revealed multiple epithelial structures (c).  Two areas of interest have been marked.  The solid 
square is shown in panels d, f, h and k whilst the dashed square is shown in panels e and g.  
IHC staining against CK5 (e and f), p63 (g and h), MUC5AC (i), MUC2 (j) and CK7 (k and l) was 








This chapter highlights the successful generation of an improved preclinical model capable of 
culturing both normal human oesophageal epithelium and BO.  This was achieved by adapting 
the IM xenograft technique in order to generate xenografts of both normal human 
oesophageal mucosa and BO, as the initial objective of ‘optimising the hat chamber culture 
system’ ultimately proved to be unsuccessful. 
 
Although initial efforts focusing on improving both hat chamber fixation and cell containment 
within the model were successful, an epithelial layer was unable to be cultured.  This is in 
contrast to the previous successful results published by Croagh (2006) and may be due to the 
fact that immortalised cell lines were used (rather than freshly derived cells) .  In this series of 
experiments, It is most likely that the tissue cultured within the chamber simply represents a 
reaction to the growth factors contained within the Matrigel, as has previously been reported 
(Kawaguchi, Toriyama, Nicodemou-Lena, Inou, Torii et al., 1998).  In the study by Kawaguchi 
et al. (1998) fat pads developed following the subcutaneous injection of Matrigel, 
supplemented with growth factors, into 6-week old mice.  This was shown to be due to a 
process of neovascularisation followed by the migration of adipose precursor cells.  
 
In order to further optimise the hat chamber culture system, numerous variables needed to 
be considered.   Examples of these variables include cell type (fresh vs cultured), tissue 
digestion technique, both the timing and number of cells seeded, presence of feeder cells and 
the addition of Matrigel.  Given the number of potential variables to be tested and the limited 
availability of fresh normal oesophageal and Barrett’s tissue, further optimisation of this 
model was deemed to be both resource intensive and low yield.  As a result, efforts shifted to 
the second objective, which was to adapt the IM xenograft technique in order to generate 
xenografts of both normal human oesophageal mucosa and BO. 
 
Fortunately, the IM xenograft technique led to the successful generation of xenografts from 
both normal human oesophageal tissue and BO, representing the first known in vivo model of 
human oesophageal epithelium and BO.  Through a series of pulse chase experiments and IHC 
analysis assessing for evidence of apoptosis, results have revealed that the xenograft model 
permits the ongoing culture of tissue over an extended period.  However, unlike cancer 
xenografts which continue to increase in size, xenografts formed from normal tissue seem to 
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be limited to a diameter of only two to three millimetres.  The xenografts cultured using the 
IM technique also share a striking resemblance to the ‘organoid’ model (Sato et al., 2011).   In 
fact, when in vitro derived organoids are transplanted in vivo, they also have the ability to 
form 3-dimensional structures that recapitulate the cellular organization of the original tissue, 
much like the Barrett’s xenografts in this chapter (Figure  5-19) (Watson, Mahe, Munera, 




Figure  5-19 The in vitro and in vivo appearance of human intestinal organoids 
A human intestinal organoid following both in vitro culture (a) and renal capsule xenografting 
(b) (Watson et al., 2014. Image reproduced with permission). 
 
The implantation of normal oesophageal tissue led to successful xenograft formation in six 
out of the nine implantations.  Interestingly, xenografts were only established following the 
implantation of tissue from surgical resection specimens and not endoscopic biopsies.  This is 
likely due to the fact that the resection specimen contains cells from deeper within the 
epithelium, including the basal layer, whereas the endoscopic biopsies tend to be more 
superficial and contain a greater proportion of terminally differentiated cells.  This is in 
keeping with the observation that squamous progenitor cells reside in the basal regions 
(Croagh, Phillips, Redvers, Thomas, & Kaur, 2007).   
 
The implantation of Barrett’s tissue led to successful xenograft formation from eight out of 
the 14 patients from which samples were obtained.  Unlike the squamous xenografts, it was 
possible to derive Barrett’s xenografts from both endoscopic biopsy and tissue pieces 
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obtained from surgical resection specimens.  This is likely due to the fact that the luminal 
surface of BO contains cells that maintain the ability to proliferate, in contrast to the luminal 
surface of stratified squamous epithelium that only contains terminally differentiated cells.  
The results of validation confirmed that the xenografts are representative of the original 
human tissue and that the cells not only maintain viability but continue to proliferate.  Using 
this technique, it was even possible to culture both squamous and columnar epithelium within 
individual xenografts.  This property increases the power of the model, as it enables the study 
of the transition zone at the SCJ, one of the proposed locations of the Barrett’s cell of origin.  
 
As with the PDTX model (Section 3.5), validation also confirmed that two of the xenografts 
derived from Barrett’s tissue had also undergone lymphomagenic transformation.  In both of 
these occasions, the patients from whom the tissues were harvested had an undergone 
neoadjuvant therapy prior to surgery for their OAC.  This phenomenon is in keeping with the 
theory that EBV infected B cells become activated following culture in an immunodeficient 
state, such as during chemotherapy and when tissue is cultured in vivo using immunodeficient 
hosts.  Such a process has also been reported with the xenografting of non-cancerous gastric 
mucosa with associated gastritis into NOD SCID mice, with a transformation rate of 50% (2/4) 
(Zhang, Liu, Wang, Tang, Li et al., 2015). 
 
Given that the xenograft model enables the ongoing culture of human tissue for extended 
periods, it has the potential to be used for a number of different applications.  These could 
include the testing of novel drug therapies or investigating different aspects of the disease 
biology, such as the role of the SMG and the identification of potential stem cells.  Such issues 
have proven to be difficult to investigate and have been the source of great controversy. 
 
In an recently published attempt to identify a Barrett’s stem cell, Pan et al (2013) conducted 
a series of label retaining assays on patients undergoing treatment for Barrett’s 
adenocarcinomas as part of the stem cell assessment in neoplastic tissue (SAINT) trial.  
Subsequent analysis of the tissue revealed the location of the slowest cycling cells to be in the 
base of the SMGs (Figure  5-20) (Pan et al., 2013).   
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Figure  5-20 Overview and results from the Stem Cell Assessment In Neoplastic Tissue 
(SAINT) Trial 
Four patients undergoing treatment for oesophageal cancer received a single intravenous 
infusion of IdU followed by either oesophagectomy alone (patients a to c) or endoscopic 
mucosal resection followed by oesophagectomy (patient d).  This created five separate chase 
points for analysis.  IHC staining against IdU reveals the presence of label retaining cells (LRC).  
Arrows indicate the location of LRCs at day 7. * indicates the location of a single LRC at day 






Unfortunately, further conclusions could not be drawn from this study as it was never 
repeated and there was only limited tissue available for analysis.  However, using the 
xenograft model, a similar analysis of human tissue has been performed.  Results from this 
assay revealed that the bulk of cellular activity within Barrett’s tissue occurs within the crypt 
and glandular regions and that a population of label retaining cells reside below the columnar 
cells at the SCJ junction (Figure  5-14).  IHC analysis revealed that the label retaining cells share 
the same location as p63 positive squamous cells.   
 
Coincidentally, a similar population of p63 positive cells have also been identified from within 
human Barrett’s tissue from a group led by Prof Krishnadath from the AMC in Amsterdam 
(Figure  5-21).  This group were attempting to therapeutically target these potential stem cells 
through the use of a novel inhibitor of both BMP2 and BMP4 that they had developed (Calpe 
et al., 2015).  Such inhibition is thought to be required for squamous differentiation to occur 
(Jiang, Ku, Zhou, Dellon, Falk et al., 2015).  This led to a collaborative effort in which mice 
harbouring Barrett’s xenografts were treated with this novel inhibitor. Results revealed that 
treated organoids tended to produce a more squamous-like phenotype and had fewer goblet 




Figure  5-21 Presence of p63 cells within biopsies of BO 
IHC staining against p63 reveals the presence of isolated p63 positive cells within a piece of BO 





In summary, the Barrett’s xenograft model represents a significant improvement in the field 
of preclinical models for the study of BO.  As already highlighted, it has great potential to be 
used as a tool to investigate different aspects disease biology such as the identification of 
stem cells and the role of the SMG.  It has also proven to be a robust model and transferable 
to other laboratories where it has been used as a tool to investigate the effect of a novel 




Chapter 6 Summary and future directions 
6.1 Introduction 
 
Oesophageal cancer is the eighth most common cause of cancer death worldwide (Ferlay et 
al., 2010).  In developing countries, this is largely driven by oesophageal SCC.  However, in 
developed countries, the incidence of adenocarcinoma has now surpassed that of SCC (Pohl 
et al., 2005).  This change has been linked to the rising obesity epidemic (Thrift, Pandeya, et 
al., 2012).  Unfortunately, the majority of patients that present with OAC have advanced 
disease and cannot be cured.  However, even in those patients who present with local disease 
and are treated with curative intent, the 5-year survival is only 45% (Howlader et al., 2015).  
This is despite a number of recent advances over the last two decades such as the introduction 
of neoadjuvant chemotherapy and radiotherapy, the development of improved endoscopic 
techniques for both the detection and management of early cancers, the development of 
minimally invasive surgical techniques and the improved management of post-operative 
complications (Thursfield et al., 2012).  These measures have only led to an incremental 
improvement of 6% in the 5-year survival for all patients, over this time period (Thursfield et 
al., 2012). 
 
It is clear that novel therapies are needed if we are to make any additional impact to the 
current 5-year survival.  Given that the majority of OAC related death are due to the 
development of metastatic disease, research efforts aimed at improving patient survival need 
to focus on the treatment of systemic disease.  Unfortunately, continued advances in this field 
have been limited by a lack of suitable preclinical models (Contino et al., 2016).  For example, 
there are only six bona fide OAC cell lines that are widely available.  This has been attributed 
to the limited availability of treatment naïve tissue and the difficulties associated with 
establishing OAC cell lines (Liu, Duong, et al., 2016).  Another frequently used model, the 
PDTX, is also associated with low engraftment rates (Read et al., 2016).  There is also no 
preclinical model for BO, the only known precursor lesion for OAC (Read et al., 2018).  The aim 
of this thesis, therefore, was to develop improved preclinical models for the study of both 





6.2 Summary of major findings 
 
Central to this thesis is the development of an improved technique for the establishment of 
oesophageal PDTXs.  Through the use of an IM transplantation technique, rather than the 
standard subcutaneous approach, the engraftment rate has more than doubled (Read et al., 
2016).  Validation has also confirmed that the PDTX model recapitulates the original tumour 
with respect to degree of differentiation, molecular and genetic profile and tumour biology.  
However, validation also confirmed that 20% of successfully engrafted PDTXs had undergone 
lymphomagenic transformation.  Evidence suggests that this is due to the presence of EBV 
infected B cells within the transplanted tissue being cultured in an immunodeficient 
environment.  This was an extremely important discovery to make as it has significant 
implications for the ongoing use of PDTX models, both in oesophageal and other cancers.  
Prior to these results being published, very few papers had recognised this phenomenon.  By 
publishing these findings, researchers are now becoming cognisant of the potential for 
lymphomagenic transformation in PDTXs (e.g. Choi et al., 2016; Dieter et al., 2017; Kalavska 
et al., 2018).  This will hopefully prevent the mistaken identification of PDTXs in the future 
and, with it, the publication of incorrect results. 
 
Traditionally, the PDTX model has been used as a preclinical tool for drug discovery.  As each 
PDTX line has its own unique mutational profile, the range of potential therapeutic targets 
increases with each additional PDTX line.  Therefore, to fully harness the power of the model 
in this role, repositories, or biobanks, need to be established.  Cohorts of specific PDTX lines 
can then be generated based upon the drug target being tested.  However, for this approach 
to be feasible, PDTXs need to be able to be re-established following cryopreservation.  In 
another major finding of this thesis, a robust and reliable technique for the successful 
cryopreservation and re-establishment of PDTXs was also reported.  Surprisingly, such a 
technique had not previously been reported for oesophageal PDTXs.  The study by Liu et al. 
highlights how an OAC PDTX line from the biobank was successfully re-established following 
cryopreservation and used as a preclinical model for drug development (D. S. Liu et al., 2015).  
Using the same cryopreservation and transplantation techniques, biobanks have been 
successfully established in other cancers, including both melanoma and anal SCC (Alsop et al., 
2016; Bernardi, 2017).  In the case of anal SCC, this represents the first reported biobank.   
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Drawing on the success of the PDTX model, xenografts were used as a perpetual source of 
tumour tissue in order to generate additional cell lines.  In combination with the explant 
technique (Giard et al., 1973), whereby small tissue pieces (explants) were cultured for 
extended periods, a robust technique was established for the generation of xenograft-derived 
cell lines.  In this technique, an extended period of culture of up to six months ensured that 
cells had ample time to adapt to in vitro culture.  During this period, cancer cells were also 
supported by a bed of fibroblasts.  This technique led to the formation of two additional OAC 
cell lines, each with matched PDTX, one of which having both metastatic and non-metastatic 
clones.  Validation confirmed that these xenograft-derived cell lines were tumorigenic and 
shared the same mutational profile as the original patient tumour.  Cell injection xenografts 
also recapitulated the original patient tumour with respect to degree of differentiation and 
molecular profile.    
 
Having matched PDTX and xenograft-derived cell lines creates an extremely powerful 
preclinical tool, as it harnesses the advantages of both models.  Such advantages include the 
presence of human stroma and tumour heterogeneity, as seen within the PDTX model, and 
the ability to perform high throughput in vitro studies, as seen with the cell line model.  This 
power is further enhanced through the development of both metastatic and non-metastatic 
clones, providing a unique opportunity to investigate mechanisms associated with metastasis 
formation as well as potential therapeutic interventions.  This is extremely important for 
research into OAC, as metastasis formation signals treatment failure and is the major cause 
of death in this patient population.  Until now, models to study clinically relevant processes 
such as metastasis formation in OAC have been limited (Liu, Hoefnagel, et al., 2016).   
 
The IM transplantation technique was also successfully used to form xenografts of both 
normal human oesophageal mucosa and BO.  As these xenografts allow the extended in vivo 
culture of both normal and metaplastic oesophageal tissue they have many potential 
applications in the study of Barrett’s carcinogenesis.  The technique has also proven to be 
robust and transferable to other laboratories.  In one of the main applications of the model, 
a series of experiments were performed at the AMC in Amsterdam, in which a novel molecular 
inhibitor was tested as a potential treatment for BO.  The results from a series of repeated 
experiments revealed that inhibition of both BMP2 and 4 led to the formation of a squamous 
phenotype within the xenograft model, compared to vehicle treated xenografts which 
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maintained a Barrett’s-like phenotype.  In addition, the xenograft model has also been used 
to investigate the dynamics of cellular proliferation in BO, revealing that the bulk of cellular 
proliferation occurs within both crypt and glandular regions.  Results also revealed the 
presence of slower cycling cells residing below the columnar epithelium at the SCJ. 
 
The table below summarises the main advantages, disadvantages and potential applications 
of each of these newly established models. 
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Table 6-1 Summary table of the advantages, disadvantages and potential application of each of newly developed model  
Model Advantages Disadvantages Potential Applications 
Cell Line • Reproducible 
• Manipulable 
• Matched metastatic / non-
metastatic clones 
• Robust 
• Able to be cryopreserved in 
order to form a biobank 
• Lowest cost 
• Two-dimensional 
• Lack heterogeneity 
• Not completely representative 
of human tumours 
• Testing of novel therapies 
• Investigate metastatic process 
PDTX • Contains human stroma 
• Maintains heterogeneity 
• Recapitulates the original 
patient tumour 
• Able to be cryopreserved à 
biobank 
• Time required to establish 
• Resources required 
• Potential for lymphomagenic 
transformation 
• Unable to test responsiveness 
to immunotherapies 
• Testing of novel therapies 
• Investigate metastatic process 
• Investigate model of cancer cell 
propagation 





tissue and BO 
• Contain stromal elements 
• Forms 3-D structures. 
• Permits labelling of cells 
• Permits the ongoing culture for 
extended periods 
• Difficult to manipulate 
• Limited ability to passage 
• Lacks environmental exposure 
• Tissue does not expand 
 
• Investigation of stem cell 
biology 
• Investigating the role of the 
SMG 
• Testing of novel therapies 
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6.3 Future Directions 
 
Future directions stemming from this thesis can be divided into two key areas.  The first 
involves identifying additional experiments that are required in order to complete the 
validation of these newly developed models.  The second involves the application of the 
models to clinically relevant areas. 
 
Whilst the PDTX model has already undergone complete validation, both the cell lines and 
xenograft models of normal human oesophagus and BO require further characterisation.  In 
regard to the cell lines, the majority of the validation already performed has focused on 
characterising both the in vitro and in vivo phenotype.  In contrast, aside from the results from 
the targeted sequencing of known oncogenes and a STR analysis, little is known about the 
genotype of the cell lines.  In order to better understand this, I would like to perform whole 
genome sequencing on the newly established lines.  In order to do this, I have donated the 
cell lines to Professor Rebecca Fitzgerald, who is a key researcher in the field.  Professor 
Fitzgerald has previously performed a large sequencing study on the range of OAC cell lines 
that were previously available (Contino et al., 2016).  As part of a follow up study that is soon 
to be published, newly developed cell lines are also being sequenced.  Included in this study 
are the cell lines IS076-A, IS076-P and TB471.  This will ensure a more thorough validation of 
the cell lines and provide researchers with additional information to help with experimental 
design.  Following publication, it is also intended that these newly derived cell lines will be 
placed into a cell line repository, in order to share this valuable resource. 
 
In order to fully characterise the phenotype of the metastatic model, I would like to repeat 
both the migration assays and western blot analysis for the known markers of EMT.  In 
addition, I have also submitted the matched metastatic and non-metastatic cell lines to a 
larger RNA sequencing study that is being conducted by Professor Krishnadath.  This may 
provide greater insights into the metastatic pathways involved in OAC.  It also has the 
potential to identify new therapeutic targets, which is clinically significant given that 
metastasis formation is the main cause of death in this patient population.   
 
With respect to the Barrett’s xenograft model, I would like to perform two additional 
experiments.  Firstly, I would like to have additional attempts at passaging the xenografts, as 
I have only had limited success with this to date.  If successful, this will increase the power of 
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the model by making it more accessible and, potentially, more manipulable.  Secondly, I would 
like to perform a further analysis of the p63 positive cells that were identified below the 
columnar epithelium at the SCJ in the xenograft model.  I believe that this observation is an 
important discovery, and that these cells may represent squamous progenitor cells.  In order 
to confirm this, I would like to co-stain FFPE sections from xenografts that have been labelled 
with BrdU to confirm if the LRC are also the p63 positive cells. 
 
In regard to the potential applications of these models, my first preference would be to 
continue the work that was performed in chapter three, which looked at the role of BMP 
inhibition in OAC.  The preliminary results assessing the effectiveness of a new class of BMP 
inhibitor in the treatment of OAC were extremely encouraging.  Also of interest, is its potential 
role in image directed surgery, as PDTXs with high BMP expression were able to be imaged 
through the use of a labelled form of this drug.   If successful, this could have a significant 
impact in the surgical treatment of OAC.  
 
In conclusion, this thesis describes the development and validation of multiple novel 
preclinical models for the study of Barrett’s carcinogenesis.  These models include an 
improved PDTX model, multiple new cell lines with matched PDTXs, including a subclone that 
spontaneously metastasises and the first xenograft model of both normal human oesophageal 
mucosa and BO.  Given the paucity of pre-existing models that are clinically relevant, the 
development and successful validation of these new models constitutes a significant 
advancement in the field of OAC.  By harnessing the full potential of these models, it is hoped 
that researchers will be able to develop further insights into this devastating disease and be 
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the+stomach)+and+ its+ response+ to+ treatment.+You+have+been+ invited+ to+ take+part+ in+
this+study+because+you+are+having+an+endoscopy,+a+procedure+in+which+your+doctor+
will+ look+ at+ the+ lining+ of+ the+ oesophagus+ and+ take+ biopsies+ (small+ samples)+ for+
diagnostic+purposes.++If+you+agree+to+take+part+in+the+study+we+will+ask+you+to+allow+














we+have+established.+ + In+order+ to+conduct+ this+ research+we+need+to+ look+at+a+ large+
number+ of+ blood+ and+ tissue+ samples.+ + We+ also+ need+ samples+ of+ normal,+ preP
cancerous+ and+ cancerous+ tissue.+ + Therefore,+ even+ if+ you+ don’t+ have+ cancer,+ your+
samples+ will+ be+ valuable+ for+ our+ research.+ + It+ is+ hoped+ that+ the+ results+ generated+




Being+ in+ the+study+will+ involve+giving+permission+ for+your+doctor+ to+take+up+to+ four+
extra+biopsies+and+a+sample+of+blood+(10P20+ml)+for+our+research+at+the+time+of+your+
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During+ endoscopy+ procedures+ we+ often+ collect+ small+ samples+ (biopsies)+ of+ tissue+
from+ the+ lining+of+ the+oesophagus.+These+are+ tested+under+ the+microscope+ for+ the+
diagnosis+of+various+conditions.+ +These+results+are+given+to+you+by+your+doctor+and+
are+used+to+plan+your+care.+
We+are+ seeking+your+permission+ to+ collect+up+ to+ four+extra+biopsies+at+ the+ time+of+





Qualified+medical+ researchers+will+ use+ the+ collected+biopsies+ and+blood+ samples+ in+
order+to+investigate+the+changes+that+occur+within+the+cells+lining+the+oesophagus.++In+
the+ case+of+ cancer+ samples,+we+wish+ to+ know+how+ the+ cancer+ cells+ grow+and+how+
they+respond+to+antiPcancer+therapies.++




developing.+ +We+may+ also+ use+ your+ biopsy+ for+ experiments+ in+which+we+will+ grow+
some+of+ the+ tissue+ in+ the+ laboratory,+ so+ that+we+can+study+how+the+cells+grow+and+
respond+to+potential+therapeutic+agents.+This+could+include+the+development+of+longP
lived+cell+lines.+






One+ of+ the+ more+ serious+ complications+ associated+ with+ having+ an+ upper+
gastrointestinal+ endoscopy+ is+ perforation+ of+ the+ oesophagus.+ + Depending+ on+ the+
case,+ the+ risk+ of+ such+ a+ complication+ occurring+ is+ between+ 1+ in+ 500+ to+ 1+ in+ 5,000+
cases.++We+are+asking+that+your+doctor+take+up+to+four+extra+biopsies+at+the+time+of+
your+ procedure.+ + This+ in+ itself+ adds+minimal+ risk,+ as+ the+ biopsy+ itself+ is+ very+ small.+
However,+ taking+ the+ biopsies+means+ that+ your+ endoscopy+will+ take+ a+ few+minutes+
longer.+When+a+blood+sample+ is+ taken+there+ is+a+chance+that+you+might+experience+







Principal+Investigator:+Prof+Wayne+Phillips         +






to+ protect+ your+ privacy.+ + All+ samples+ will+ be+ labelled+ with+ a+ unique+ number+ and+
stored+ securely.+ + + Only+ a+ small+ number+ of+ senior+members+ of+ the+ study+ team+will+
have+access+to+identifiable+information.++Finally,+no+information+that+could+be+used+to+













Participation+ in+ research+ is+ entirely+ voluntary+ and+ you+ are+ under+ no+ obligation+ to+






a+ long+ time+and+must+use+ tissue+samples+ from+many+people+before+ the+ results+are+
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have+read+the+information+brochure++ + + + + ++ YES+
The+consequences+involved+in+participation+in+this+research+study+have++
been+explained+to+me+and+I+understand+these+ + + + ++++++++++++++++YES++
I+have+had+an+opportunity+to+ask+questions+and+am+satisfied+with+the++




brochure+ + + + + + + +++++++++++++++++++YES+++++++++NO+
(2) Have+the+following+samples+being+collected+and+used+for+laboratory++
analysis+as+described+in+the+information+brochure:++
a. Extra+biopsies+to+be+taken+during+my+endoscopy++ +++++++++++++++ + +++YES+++++++++NO++
b. A+small+(10P20mL)+blood+sample+ + ++ +++++++++++++++++ +++YES+++++++++NO++
(3) Allow+the+researchers+access+to+my+dePidentified+medical,+
oncology+and+pathology+records+(including+material+such+as+
tissue+blocks+and+slides+if+applicable)+ + + +++++++++++++++++++++++++++++ +++YES+++++++++NO+








• There+will+ be+no+ cost,+ nor+ any+ financial+ benefit,+ to+me+ for+participating+ in+ the+ study.+ If+my+
samples+ lead+ to+ the+ development+ of+ a+ commercial+ product+ in+ the+ future+ I+will+ not+ receive+
payment+for+this.+
• The+samples+will+ remain+ the+property+of+The+Peter+MacCallum+Cancer+Centre.+They+will+be+
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You+will+ need+ to+ tell+ the+ person+ you+ contact+ the+ name+ of+ one+ of+ the+ researchers+
responsible+for+the+project.+
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2. The generation of a TMA from the PDTX biobank 
 
In total, twelve separate oesophageal PDTX lines were selected for the TMA.  These included 
seven adenocarcinoma lines and five squamous cell carcinoma lines.  PDTX lines were selected 
that were easy to establish and grew rapidly once implanted.  Once the PDTX lines were 
selected, representative H&E sections were analysed by a pathologist and regions of 
malignant tissue identified and marked.  A TMA was then established from these marked 
regions by staff from the Victorian Cancer Biobank at the Peter MacCallum Cancer Centre.  
Normal human tissue was also included in the TMA for control purposes. 
 
The layout of the TMA including the identification of individual FFPE histology blocks is shown 
in the following table.  
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PDTX Tissue Microarray Map 
 
 
A, A map of the TMA outlining the location of each PDTX line. B, A matched map of the TMA containing the corresponding histopathology block numbers. ID, 
Original patient identification number (as detailed in Table 4-5). F0, original patient tumour. Fx, derived PDTX. NAF, normal associated fibroblasts. CAF, cancer 
associated fibroblasts. METS, metastatic deposits. GOJ, gastro-oesophageal junction.  Red coloured box, oesophageal adenocarcinoma. Blue coloured box, 
oesophageal SCC.  Yellow coloured box, control tissue. 
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3. Clinical details of the patients whose PDTXs underwent 
lymphomagenic transformation 
 
GB975 (ID 4) 
 
GB975 was a 69-year-old man who had a history of hypertension and was a past smoker.  He 
initially presented with dysphagia and 8kg loss of weight that had occurred over a six-week 
period.  Gastroscopy revealed a circumferential tumour of the distal oesophagus that was 5cm 
in length.  There was no extension into the stomach.  Histology revealed a moderately 
differentiated adenocarcinoma with mild chronic lymphoplasmacytic infiltrate.  The tumour 
was HER2 positive as determined by both silver in-situ hybridisation and 
immunohistochemistry.  Staging CT revealed thickening of the distal oesophagus with several 
enlarged mediastinal lymph nodes.  There was no evidence of distant metastases.  PET 
demonstrated extensive avidity within the primary tumour in addition to the mediastinal 
lymph nodes.  The mediastinal lymph nodes were subsequently sampled via a 
mediastinoscopic approach.  Histology confirmed the presence of metastatic carcinoma 
within these lymph nodes.  Interestingly, the deposit was predominantly a high-grade 
neuroendocrine carcinoma, positive for the somatostatin receptor type 2 on 
immunohistochemistry, and only contained focal moderately differentiated adenocarcinoma.  
The Ki67 level within this tumour was reported as 80%.  It was not clear whether this 
represented a form of divergent differentiation from a primary oesophageal carcinoma.  The 
patient was subsequently treated with neoadjuvant chemoradiotherapy in the form of 
carboplatin and etoposide in addition to 50.4Gy radiotherapy over 28 fractions.  A repeat PET 
demonstrated a complete metabolic response.  Unfortunately, multiple medical problems 
prevented surgery and a re-staging PET/CT revealed evidence of both brain and bone 
metastases.  The patient was subsequently managed palliatively by means of oesophageal 
stent and additional radiotherapy for bleeding. 
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AN959 (ID 9) 
 
AN959 was a 63-year-old man with a history of heavy alcohol use and a 50-pack year smoking 
history.  He presented with a three-month history of odynophagia and dysphagia on a 
background of 25kg of weight loss over the preceding year.  He was initially investigated with 
a gastroscopy which revealed a non-obstructing tumour of the lower oesophagus, 6cm in 
length, which extended into the gastric cardia. Histology revealed that this was a moderately 
differentiated adenocarcinoma.  Staging PET / CT revealed high avidity within the primary 
tumour but no evidence of either nodal or distant metastatic disease.  There was, however, 
evidence of pulmonary tuberculosis.  Unfortunately, a repeat CT performed during his work 
up six weeks later revealed new lung and liver lesions.  The patient was subsequently treated 
with palliative chemoradiotherapy in the form of cisplatin and 5-FU in addition to 50Gy of 
radiotherapy. 
 
RF226 (ID 14) 
 
RF226 was a previously well 66-year-old man who presented with a poorly differentiated 
adenocarcinoma at the gastro-oesophageal junction.  This was on a background of having had 
loss of weight and progressive dysphagia over a period of five months.  He also had an episode 
of haematemesis requiring admission to hospital.  Endoscopy confirmed a near obstructing 
tumour extending from 35cm from the incisors to 40cm.  Subsequent staging PET / CT 
confirmed a large para-oesophageal nodal mass posterior to the pericardium in addition to an 
avid left gastric nodal mass.  There was no evidence of distant metastases.  He commenced 
neoadjuvant chemotherapy in the form of epirubicin, cisplatin and 5-FU as per the MAGIC 
protocol (Cunningham et al., 2006).  Restaging PET confirmed a complete metabolic response 
with respect to the nodal disease.  RF subsequently went on to have surgery in the form of a 
totally minimally invasive Ivor Lewis oesophagectomy followed by adjuvant treatment in the 
form of chemoradiotherapy.  Histology confirmed residual poorly differentiated 
adenocarcinoma with 10/15 lymph nodes containing metastatic disease and a close proximal 
margin.  Unfortunately, he developed locoregional recurrence six months post-operatively 





JA227 (ID 16) 
 
JA227 was a previously well 78-year-old man with a known history of Barrett’s oesophagus 
who was found to have an oesophageal adenocarcinoma on surveillance gastroscopy.  
Endoscopic ultrasound confirmed this to be an early tumour (T1b).  Given that the subsequent 
staging PET / CT failed to demonstrate any evidence of either nodal or metastatic disease the 
patient proceeded directly to have an Ivor Lewis oesophagectomy.  Histology revealed this to 
be a moderate to poorly differentiated adenocarcinoma with invasion into the submucosa 
and 1/10 lymph nodes involved with tumour.  His post-operative course was complicated by 
an anastomotic leak.   
 
JB259 (ID 19) 
 
JB259 was a previously well 63-year-old man who presented with a mid to distal oesophageal 
adenocarcinoma.  Endoscopy revealed this to be originating from a segment of Barrett’s 
oesophagus.  Staging FDG PET revealed an avid tumour that was 12cm in length with 
associated avid lymph nodes in the mediastinum and upper abdomen.  The SUVmax of the 
primary tumour was 16.2.  The patient subsequently underwent neoadjuvant chemotherapy 
in the form of three cycles of epirubicin, cisplatin and capecitabine.  Unfortunately, this was 
tolerated poorly, and the patient lost significant weight and became deconditioned.  Restaging 
CT revealed a marked response to the treatment with a significant reduction in tumour size.  
This was confirmed endoscopically and the patient proceeded to have an Ivor Lewis 
oesophagectomy.  Unfortunately, histopathological assessment graded the response to 
treatment as poor (TRG of 3) with viable tumour cells invading the muscularis propria.  The 




4. Inhibition of BMP2 and BMP4 eradicates Barrett’s esophagus and 
enhances the regeneration of squamous epithelium  
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AMC   Academic Medical Center 
ANOVA   Analysis of Variance 
ARIA   Animal Research Institute of the AMC 
BA   Bile and Acids 
BCA   Bicinchoninic Acid 
BMP   Bone Morphogenetic Protein  
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CaCl2   Calcium Chloride 
CDX2   Caudal type homeobox 2 
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EDTA   Ethylenediaminetetraacetic Acid 
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p63   Protein 63 
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PPI   Proton Pump Inhibitor 
pSMAD1/5/8  phospho-SMAD1/5/8 
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SCJ   Squamo-Columnar Junction 
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SHH   Sonic Hedgehog  
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SQ   Squamous 
TBS   Tris-Buffered Saline 
TGF-β   Tumor Growth Factor Beta 
VHH   Highly Specific Llama derived antigen binding fragments 
WNT   Wingless-type MMTV integration site family 






Barrett’s esophagus is an irreversible metaplasia of the lower esophagus and the only known precursor of 
esophageal adenocarcinoma, a highly malignant cancer. Development of Barrett’s metaplasia is driven by 
increased Sonic hedgehog (SHH) and Bone Morphogenetic Protein 4 (BMP4) signaling (Milano 2007, Clemons 
2009, Mari 2014). Here, we provide evidence that the selective inhibition of BMP2 and BMP4 effectively 
eradicates Barrett’s epithelium. The activity of BMP2 and BMP4 signaling was high in Barrett’s biopsies, 
whereas BMP7 and TGF-β pathways were higher in esophageal squamous mucosa. Selective inhibition of 
BMP2 and BMP4 within an in vivo organoid model of Barrett’s esophagus, favored the development of 
squamous cells, rather than the columnar Barrett cells.  In a mouse model, conditional knockout of Noggin, a 
natural antagonist of BMP2, BMP4 and BMP7, induced expansion of Barrett’s like neo-columnar epithelium 
from multi-lineage glands. Conversely, inhibition of BMP2 and BMP4 led to the development of a neo-
squamous lineage. Similarly, in wild type mice, inhibition of BMP2 and BMP4 resulted in the regeneration of 
neo-squamous epithelium after the cryo-ablation of columnar epithelium at the squamo-columnar junction. 
Through lineage tracing it was evident that the neo-squamous mucosa originated from K5+ progenitor 
squamous cells. Together, this work demonstrates that specific inhibition of BMP2 and BMP4 inhibits the 
development of columnar metaplasia, providing a novel potential strategy for the treatment of Barrett’s 






Barrett´s esophagus is an epithelial type of metaplasia which results from inflammatory signals caused by 
chronic duodeno-gastro-esophageal reflux disease (DGERD)1,2. Barrett’s esophagus patients require 
measures to reduce reflux such as acid suppression or fundoplication and periodic surveillance to prevent 
chronic inflammation and reduce cancer risk3,4. The incidence of Barrett’s esophagus and esophageal 
adenocarcinoma are increasing5. At present, molecular therapies to cure Barrett’s esophagus or other 
metaplastic lesions are lacking. In this study, our aim was to investigate if targeting key homeostatic 
pathways would be effective to eradicate Barrett’s esophagus. 
BMP signaling is essential for the homeostasis and differentiation of intestinal cell lineages6. The embryonic 
development of the esophagus is regulated by BMP4 and one of its natural inhibitors Noggin7. Noggin binds 
to the BMP2, BMP4 and to a lesser extent to the BMP7 protein8, preventing them from binding to their 
cognate receptors and activating downstream canonical signaling9. The normal adult esophagus is 
characterized by low levels of BMP2 and BMP4, and high levels of BMP7, especially within the upper basal 
layer, the latter required for the physiological differentiation of the stratified squamous epithelium10,11. 
Upregulation of the SHH mediated canonical BMP4-pSMAD pathway has been identified as a key 
determinant in the shift from the normal squamous cells to the columnar and intestinal type of cells 
characteristic of Barrett’s metaplasia10,12,13. Increased levels of BMP4 are seen in squamous mucosal biopsies 
following exposure to bile acids alone and in the setting of active inflammation caused by DGERD10,14. In 
murine models with induced inflammation of the esophagus through bile reflux, IL1-β or BMP4 
overexpression, activation of the BMP pathway leads to proliferation of neo-columnar epithelium at the 
squamo-columnar junction (SCJ) in the stomach, resembling Barrett’s metaplasia12,15.  
A more comprehensive analysis and validation in a Gene Expression Omnibus dataset (accession number 
GSE26886)16 reveals upregulation of SHH-TGF-β/BMP signaling in Barrett’s mucosal biopsies compared to 
normal squamous mucosa (Fig1A, Extended data Fig1A, B). Ingenuity pathway analysis indicates higher BMP 
signaling, driven by both BMP2 and BMP4 in Barrett’s esophagus compared to normal squamous mucosa, 
the latter having more active TGF-β pathways and BMP7 signaling (Fig1B). IHC analysis of Barrett’s derived 
patient biopsies confirms increased protein expression of BMP2 and BMP4, and their downstream targets 
pSMAD1/5/8, ID1 and ID2 (Fig1C). pSMAD1/5/8 expression in squamous biopsies is the highest in the basal 
layers (Fig1C). By Western blot we confirm higher expression of BMP2, BMP4, BMP5 and BMP6 in human 















Figure 1: SHH-TGF-β/BMP signaling in Barrett’s esophagus and esophageal squamous epithelium. Gene 
expression analysis of human squamous and Barrett’s biopsies and effect of conjugated bile acids on 
epithelial cells. [A] Clustering of expression values of TGF-β/BMP pathway genes in patients derived biopsies 
of Barrett’s esophagus and normal esophageal squamous mucosa. [B] Ingenuity Pathway Analysis of TGF-
β/BMP signaling in Barrett’s esophagus compared to normal squamous tissue (SQ)16. [C] Representative IHC 
for BMP2 and BMP4, and their downstream targets pSMAD1/5/8, ID1 and ID2, in normal squamous and 
Barrett’s biopsies. Hematoxylin is used as a counterstain. (Scale bars: 100µm).  
 
To test the effects of BMP inhibition on human Barrett’s epithelium, we developed a novel in vivo organoid 
model by intramuscular implantation of endoscopic biopsies in NSG mice. This model is able to sustain both 
normal human squamous and Barrett’s epithelia (Fig2, Extended data Fig2A). Expression of the human 
mitochondrial antigen confirmed the human origin of the organoids (not shown). The squamous biopsies 
and corresponding in vivo organoids show multi-layered lining of Alcian Blue-, CDX2-, p63+ and K5+ squamous 
cells with a papillary-resembling region (Fig2B, C). The Barrett’s biopsies and corresponding in vivo organoids 
are lined with a secretory CDX2+ columnar epithelial layer, containing Alcian Blue+ mucus producing goblet 
cells (Fig2D). At the basal side of the mucous cells, a few p63+, K5+ squamous cells can be observed.  
Most of the currently available BMP inhibitors and antagonists are not selective for targeting single family 
members such as BMP2 or BMP48. Recently, we isolated highly specific Llama derived antigen binding 
fragments (VHHs), which selectively inhibit BMP4 (anti-BMP4) or BMP2 and 4 (anti-BMP2/4)17,18. 
Intraperitoneal (i.p.) injections of NSG mice with anti-BMP4 for at least eight weeks, starting one week after 
implantation of the human Barrett’s biopsies (Fig2E), results in an organoid with a mixed epithelial layer 
characterized by a multi-layered squamous epithelium with p63+, K5+ cells and a reduced number of mucous-
producing cells (Fig2F). Treatment with anti-BMP2/4 results in p63+/K5+ multilayered epithelium, weakly 
expressing K19, but with Involucrin+ and Sox2 expressing cells (Fig2F, Extended data Fig3). Mucous producing 
Alcian Blue+ and CDX2+ cells are absent (Fig2F). Compared to the control mice, the number of Ki67+ 
proliferative cells is reduced in the treated Barrett’s organoids (Extended data Fig3). Of interest is that a 
population of remnant p63+ and K5+ squamous cells is also observed in the original Barrett’s biopsy that 
corresponds with the treated Barrett’s implant (Fig2D, Extended data Fig2B). Analysis of patient biopsies 
already indicated that based on expression profiles, Barrett’s esophagus has similarities to both, normal 
squamous and stomach cardia epithelia19. BMP2/4 inhibition also results in a transient loss of goblet cells in 
the colon, which recovers 4 weeks after the end of treatment (Extended data Fig4). All mice presented 
normal weights, stools and behavior during the treatments. Thus, in a novel organoid model that sustains 
Barrett’s and squamous epithelia, inhibition of both BMP2 and BMP4 is required for a selective reduction of 
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all Barrett’s mucous producing goblet cells and favors the proliferation and establishment of squamous 






Figure 2: Effects of BMP2 and BMP2/4 inhibition on Barrett’s esophagus biopsies in an in vivo organoid 
model. [A] A dissected in vivo organoid from the dorsal musculature of an NSG mouse. [B] H&E staining of a 
complete squamous (left side) and Barrett’s (right side) in vivo organoid. [C] H&E, Alcian blue staining and 
IHC for CDX2, K5 and p63 of a squamous biopsy and corresponding organoid, and [D] and of a Barrett’s 
biopsy and corresponding organoid. [E] Experimental set-up of intramuscular implantation of human 
biopsies to obtain in vivo organoids and treatment schemes with the inhibitors. [F] H&E, Alcian blue staining 
and IHC of CDX2, K5 and p63 of Barrett’s in vivo organoids treated with saline, anti-BMP4 or antiBMP2/4. 
Hematoxylin is used as a counterstain. (Scale Bar 200 µm). 
 
In a K14-Bmp4 transgenic model, we have previously observed the development of columnar metaplastic 
glands at the SCJ. The expected effects were modest due to concomitant upregulation of the BMP 
antagonist, Noggin12. Conversely, a Noggin knockout was embryonically lethal, however analysis of the fetal 
tissue showed aberrant columnar cells lining the esophagus20.  
Here, by crossing Rosa26-CreERT2 mice with loxP [Noggin] loxP mice (Fig3A), a novel Noggin knockout 
model representative of columnar metaplasia has been established. Tamoxifen injection at eight weeks 
results in absence of Noggin in the esophagus, forestomach, stomach body, antrum, intestine and colon in 
adult mice (Extended data Fig 5A). After 24 weeks, in line with previous observations20, the Noggin-/- mice 
have maintained expression of BMP4 and pSMAD1/5/8 comparable to the wild type controls (Extended data 
Fig 5B). Also, there are no major differences in morphology and histology of the esophagus, intestine and 
colon (Extended data Fig 5C). However, 4 weeks after deletion of Noggin, we observe expanded multi-
lineage glands at the SCJ of the stomach, characterized by abundant neo-columnar epithelium resembling 
Barrett’s columnar metaplasia12,21(Fig3A). To investigate if BMP2/4 inhibition can inhibit the expansion of the 
neo-columnar epithelium from the multi-lineage glands, or divert the expansion towards neo-squamous 
epithelium, the Noggin-/- mice have been treated with the BMP2/4 inhibitor (Fig3B). Eight weeks of systemic 
treatment with anti-BMP2/4 results in decreased BMP signaling as can be observed by a reduction in 
pSMAD1/5/8 expression (Fig3C). Inhibition of BMP2 and BMP4 results in increased proliferative activity of 
the squamous layer, which seems to originate from the outer layer of the multi-lineage glands. Additionally, 
there is expansion of the multi-layered neo-squamous epithelium and development of papillae-like 
structures (Fig3B). Thus, conditional deletion of Noggin results in the development of a Barrett’s like neo-
columnar epithelium at the SCJ of the stomach of this murine model. Inhibition of BMP2 and BMP4 inhibits 
the neo-columnar lineage and enhances development of a neo-squamous epithelium. Both the neo-









Figure 3: Effects of BMP2/4 inhibition on neo-columnar epithelium development in a conditional Noggin 
knockout Barrett’s model. [A] Rosa26-creERT2 mice have been crossed with loxP [Noggin] loxP mice and 
injected with tamoxifen for 3 days to obtain Noggin-/- mice. H&E of SCJ in the stomach of the Noggin-/- mice 
at 4, 8, 16 and 20 weeks.  [B] Creation of Noggin-/- mice and scheme for treatment by saline or anti-BMP2/4. 
All mice received proton pump inhibitors (PPIs). H&E and IHC staining for K19, K14, K5 and p63 of multi-
lineage glands at the SCJ in the stomach of WT and Noggin-/- mice treated with anti-BMP2/4 or saline. [C] IHC 
for BMP4, pSMAD1/5/8, K7/K5, Ki67/K14 of multi-lineage glands at the SCJ in Noggin-/- mice treated with 
saline or anti-BMP2/4. Hematoxylin was used as a counterstain. (Scale Bar 100 µm) (broken line indicates the 
border of the neo-squamous epithelium). 
 
In wild type CB6F1/Crl mice, cryo-ablation of the columnar mucosa in the forestomach just distal to the SCJ, 
results in the regeneration of normal stomach columnar epithelium and restored architecture of the crypts 
after 21 days (Fig4A-C). In cryo-ablated mice treated with the BMP2/4 inhibitor for 21 days, the ablated 
columnar stomach epithelium has been replaced by a multilayered K5+, p63+ neo-squamous epithelium that 
poorly expresses the columnar marker K19 (Fig4D). 
The repopulation of the esophageal mucosa is further investigated by using a K5-GFP lineage tracing model. 
Using K5-CreERT2 crossed with Rosa26-Tomato-loxP [stop] loxP-GFP mice, tamoxifen injection activates the 
GFP reporter gene in K5+ cells, permanently marking these cells and their progeny as they repopulate the 
mucosa (Fig4E). After cryo-ablation of the columnar epithelium, the re-epithelization of the stomach in the 
K5-GFP mice is comparable to that of the wild type CB6F1/Crl mice (Fig4D, F). Treatment of the K5-GFP mice 
with the BMP2/4 inhibitor for 21 days results in the appearance of a GFP+ neo-squamous epithelium 
replacing the ablated columnar epithelium (Fig 4F). The GFP expression indicates the origin of the neo-






Figure 4: Anti-BMP2/4 treatment and lineage tracing of K5+ progenitor cells in a cryo-ablation model. [A] 
Macroscopic view of a dissected WT CB6F1/Crl mouse stomach, 21 days after ablation of a glandular part of 
the stomach. [B] H&E staining of a normal SCJ including both the forestomach and glandular stomach of WT 
mice. [C] H&E of the SCJ of WT mice after 3, 7, 14 or 21 days of cryo-ablation of the glandular stomach 
epithelium. [D] Cryo-ablation and scheme for treatment with saline or anti-BMP2/4. All mice received PPIs. 
H&E, Alcian blue stainings and IHC for pSMAD1/5/8, K19, K5 and p63, of the SCJ in CB6F1/Crl mice, 21 days 
after cryo-ablation and treatment with saline or anti-BMP2/4. Hematoxylin was used as a counterstain. [E] 
Crossing of K5-cre mice with Rosa26-Tomato-lox-stop-loxGFP mice and injection with Tamoxifen to generate 
K5-GFP lineage tracing mice. Cryo-ablation and scheme for treatment with saline or anti-BMP2/4. [F] GFP 
expressing squamous cells traced in K5-GFP mice after cryo-ablation of the columnar epithelium in the 
proximal stomach at the SCJ (*) in mice treated with saline or anti-BMP2/4. (Scale Bar 200 µm). 
 
In general, metaplastic changes are associated with altered signaling of pathways which are involved in 
embryonic development. Critical are the SHH, TGF-β and BMP pathways22. BMPs seem to be highly 
homologous molecules that signal via their receptors BMPR I and II. Yet, due to interactions with diverse 
transcription and regulatory factors, and through non-canonical signaling, their effects are highly 
pleotropic12. Apart from BMP4, we found that BMP2 was also highly expressed in Barrett’s biopsies10,12, 
while in addition to BMP7 there is high TGF-β activity in the squamous mucosa11. Consistent with these 
findings, the inhibition of both BMP2 and BMP4 within our novel human in vivo organoid model prevented 
the formation of a Barrett’s phenotype. Both, BMP2 and BMP4 are known for their homeostatic functions 
within columnar epithelia. The specific inhibition of BMP4 alone, or in combination with BMP2, was made 
possible using our recently developed BMP inhibitors17,18. Remarkably, in the anti-BMP2/4 treated in vivo 
Barrett’s organoids there was efficient regeneration of stratified squamous epithelium. We presume that the 
remnant K5+, p63+ squamous progenitor cells observed in the corresponding Barrett’s biopsies developed 
into the neo-squamous epithelium. This was most likely possible because the function of BMP7, essential for 
squamous differentiation10, was left intact. In a second model, we were able to develop columnar metaplasia 
resembling Barrett’s by knocking out the natural BMP2,4,7 inhibitor Noggin. In line with the recent model 
developed by Jiang21, the neo-columnar epithelium arose from multi-lineage glands. Within this same model, 
the inhibition of BMP2 and BMP4 decreased the proliferation of columnar cells, whilst the development of a 
neo-squamous epithelium originating from the outer layer of the multi-lineage epithelium was enhanced. To 
further interrogate the effect of BMP2/4 inhibition on the homeostasis of normal columnar tissue and to 
understand the origin of the neo-squamous epithelium at the SCJ, we developed a third model in which the 
columnar epithelium was ablated at the SCJ.  Following ablation, anti-BMP2/4 treatment inhibited the 
regeneration of normal columnar stomach epithelium. Instead, the ablated epithelium was replaced by neo-
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squamous epithelium. Lineage tracing demonstrated that the origin of this neo-squamous epithelium 
originates from K5+ squamous progenitor cells.  
 
In summary, we found that BMP2 and BMP4 signaling are highly active in Barrett’s esophagus, whilst in 
normal squamous mucosa TGF-β pathways and BMP7 are higher. We demonstrated that specific inhibition 
of BMP2 and BMP4 effectively constrained regeneration of stomach columnar epithelium and Barrett’s 
esophagus in multiple models. Because our novel inhibitor is highly specific for BMP2 and BMP4 and has no 
effect on BMP7, the regeneration of normal stratified squamous epithelium was not affected. To our 
knowledge this is the first targeted therapy that can potentially be applied for treatment of a metaplastic 
lesion. In the future such therapy might be implemented as a novel chemo-preventive strategy. If successful, 
this could prevent cancer progression and reduce the burden of costly surveillance programs. 
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MATERIAL AND METHODS: 
 
Ethics  
Use of all human patient material was approved by the institutional Medical Ethical Committee of the 
Academic Medical Center of Amsterdam (AMC). All patients gave informed consent to participate in the 
study before sample collection. Samples were collected during the routine surveillance program at the 
Gastroenterology and Hepatology Department of the AMC. All patients were on long-term proton pump 
inhibition (PPI) therapy. After a confirmed diagnosis of intestinal metaplasia without dysplasia by endoscopy 
and histology, samples were used in our study. All animal research was conducted under protocols approved 
by the Animal Experimental Committee of the AMC in compliance with the Animal Welfare Body (IvD) (in 
vivo organoids model protocol 103046, Noggin -/- model protocol LEX102613 and ablation model protocol 
LEX159). All animals were kept in the Animal Research Institute of the AMC (ARIA), and experiments were 
performed under ARIA standard operating procedures.  
 
RNA extraction and PCR array of human biopsies 
Tissue samples from human specimens from the normal squamous epithelium and Barrett’s epithelium were 
placed in RNAlater® (ThermoFisher Scientific) overnight at 4°C and then stored at -80°C. RNA was isolated 
using the Qiagen RNeasy isolation kit (Qiagen), following the manufacturer's protocol. Purified human tissue 
RNA was analyzed using RT² Profiler PCR Arrays for human TGF-β BMP Signaling Pathway and human 
Hedgehog Signaling pathway (Qiagen), according to manufacturer’s protocol. In short, cDNA was synthesized 
with 1µg of purified RNA using RT2 First Strand Kit (Qiagen). cDNA templates were mixed with the PCR 
master mix, samples were aliquoted in equal volumes to the plates, and real-time PCR cycling programs 
were run. For the Hedgehog Signaling array, the online RT² Profiler PCR Array Data Analysis tool from Qiagen 
was used for normalization and calculation of fold changes and p-values when comparing the two subgroups 
of samples, Barrett’s and squamous tissue. For the BMP/TGF-β array, RNA starting concentrations per 
sample were calculated using the linregPCR tool, and visualized in a heatmap.  
 
Bioinformatics analysis 
Gene expression profiles of Barrett’s esophagus and esophageal squamous epithelium16 were downloaded 
from the Gene Expression Omnibus (accession number GSE26886). Data were generated using Affymetrix 
Human Genome U133 Plus 2.0 Array and already pre-processed by use of the GC-RMA algorithm. In this set, 
gene expression was compared between 20 specimens containing cells from Barrett’s biopsies obtained 
through laser capture microdissection and 19 specimens of squamous epithelium from healthy individuals.  
Chip annotation file GPL570-55999 was used for annotation of the probe sets. First, data was filtered using 
the nsFilter function from the genefilter package25. 62 control probesets and 27307 probesets with low 
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variance were removed. Thereafter, differential expression analysis was performed using the Limma 
package27. Probesets with multiple-test corrected p-value < 0.05, were considered significantly differentially 
expressed. Unannotated and promiscuous probes (probes associated with more than one gene) were 
excluded from further analysis. For genes associated with more than one probeset, we used the arithmetic 
mean of log2 fold changes from these probesets for further analysis in Ingenuity Pathway Analysis (IPA). 
Genes and log2 fold changes were uploaded in IPA, and gene set enrichment analysis for the TGF-
β/BMP/SHH pathways was performed. Overviews of these pathways are shown in figure 1. The TGF-β 
Signaling pathways were visualized using Path Designer. 
A gene-clustered heatmap was drawn for qPCR data from the AMC dataset using the heatmap package, after 
log transformation and calculation of z-scores for all samples per gene.  
A similar gene-clustered heatmap was drawn for the validation (Wang) dataset, displaying those genes that 
were analyzed in the AMC dataset, after calculating z-scores for all samples per gene. In case of multiple 
significantly differentially expressed probesets coding for the same gene, mean expression of these 
probesets was used as expression value of that particular gene.  
 
Western Blot of human biopsies 
After dissecting, tissue biopsies were briefly washed with cold phosphate-buffered saline (PBS) and cut into 
smaller pieces while on ice. Minced tissue was transferred to a homogenizer, and 500 µl of RIPA buffer 
(ThermoFisher Scientific) supplemented with protease inhibitors (ThermoFisher Scientific) was added per 10 
mg of tissue. Samples were carefully homogenized and kept on ice for 30 min while mixing occasionally. 
Subsequently, samples were sonicated for 2-5 minutes and centrifuged at 10,000 x g for 20 minutes at 4°C. 
The supernatant was transferred to a new tube and stored at -20°C until future use. 
Protein concentrations were determined using the PierceTM BCA Protein Assay Kit (Pierce Biotechnology), 
following the manufacturer’s protocol. Lysates were combined with sample buffer (125 mM Tris-HCl, pH 6.8; 
4% SDS; 2% β-mercaptoethanol; 20% glycerol; 1 mg bromophenol blue) and loaded with the equal amount 
of protein (15 µg/lane) on a 12% SDS-polyacrylamide gel and subsequently blotted onto polyvinylidene 
difluoride (PVDF) transfer membranes (Millipore). The membranes were blocked with blocking solution (5% 
Nonfat milk in Tris-buffered saline (TBS) with 1% Tween®20 and afterwards incubated with the appropriate 
primary antibody solution anti-BMP2, Peprotech (#500-P195); anti-BMP4, R&D (#mab757); anti-BMP5, 
Abcam (#ab10858) and anti-BMP6, R&D (#AF507) at a 1:500 dilution in blocking solution overnight at 4⁰C. 
Subsequently, membranes were washed and incubated with secondary antibodies, HRP-anti-Goat (Dako 
(#P0160), HRP-anti-rabbit (Dako (#P0448)) and HRP-anti-mouse (Dako (#P0447)), diluted 1:2000 in blocking 
solution for 1 hour at room temperature. Membranes were incubated with PierceTM enhanced 
chemiluminescent (ECL) substrate (Pierce Biotechnology, Rockford, IL USA) and proteins visualized using 
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ImageQuant LAS 4000 (GE Healthcare Life Science). Densitometry analysis was performed using Image J 
1.45s (Wayne Rasband, National Institutes of Health, USA).  
 
In vivo organoid model 
NOD-scid interleukin-2 (IL2) receptor gamma chain knockout (NSG) mice were purchased from The Jackson 
Laboratory and bred in-house at the Animal Research Institute of the Academic Medical Center of 
Amsterdam (AMC). All mice were maintained in specific pathogen free conditions, given autoclaved standard 
pellet feed and water ad libitum, and housed in ventilated racks.   
Fresh samples were collected endoscopically from the squamous epithelium and Barrett’s segment of four 
different patients. Samples were placed in chilled PBS without Mg2+ and Ca2+ and supplemented with 200 
U/ml of penicillin and 200μg/ml of streptomycin and kept on ice. Each biopsy was divided into approximately 
1 to 2mm3-sized pieces discarding any necrotic areas and blood clots. Representative samples were fixed in 
10% buffered formalin for histological evaluation and the remaining pieces for implantation were placed in 
Matrigel (Corning) and kept on ice until implantation. All biopsies were implanted within 2h of collection. 
A total of 16 NSG mice were used. Mice were anesthetized via an i.p. injection of ketamine (100mg/ml) and 
xylazine (20mg/ml) solution. After weighing, mice were injected with 10μl of the anesthetic solution per 
gram of body weight. The dorsum of each mouse was shaved and prepared with a 2% chlorhexidine 
gluconate/70 % isopropyl alcohol solution. Under aseptic conditions, a 15-mm midline incision was made 
immediately caudal to the dorsal hump at the level of the renal angle. Using blunt dissection, a skin flap was 
raised and the skin retracted laterally in order to expose the implantation site. A superficial stay suture was 
placed in the dorsal musculature immediately caudal to the lowest rib using a 4/0 braided absorbable suture. 
After tenting the muscle fibers, an intramuscular pocket was created using a combination of sharp and blunt 
dissection until it was just large enough to accommodate the Barrett’s biopsy. The Barrett’s biopsy was then 
coated in matrigel and placed in the intramuscular pocket prior to suture closing. One or two separate 
transplantation sites were used per mouse. A 4/0 non-absorbable suture was used to mark the site of 
implantation.  The skin was closed using 3/0 braided absorbable suture. Implants were cultured for a 
maximum period of 12 weeks in order to form the in vivo organoid structures. Commencing one-week post 
implantation and continuing for a total of 12 weeks, mice were treated with either saline (control group), 
anti-BMP4 or anti-BMP2/4 (treatment group) via i.p. injections17. Mice were closely monitored for any sign 
of discomfort and/or stress throughout the experiment.  
At the end of the 12-week treatment period mice were culled using CO2 inhalation. Immediately following 
culling, mice were shaved and their skin was prepared. After identifying the non-absorbable marking suture, 
the muscle was incised around the site of xenograft leaving a 2mm wide margin. Following this, the muscle 
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was retracted medially and the in vivo organoid harvested. Samples were fixed in 10% buffered formalin to 
be assessed both histologically and immunohistochemically. 
 
Noggin knockout (Noggin-/-) mouse model 
Nogtm1.1Rmh/J mice (JAX stock #016117) were crossed with Rosa26-creERT2 mice (JAX stock #008463) 
(Jackson, USA). Tamoxifen (1mg, i.p.) was administrated for three consecutive days to delete Noggin in all 
cells expressing Rosa26-creERT2. Stomach tissues were formalin fixed and paraffin embedded for H&E 
staining and for IHC. 
 
Ablation mouse model 
CB6F1 mice were purchased from Charles River (CB6F1/Crl strain code 176) and housed in the ARIA. 
Experiments were performed using 8 to 10-week-old male mice, with an initial weight above 20g. Before and 
after the procedure, animals received liquid food for three days. Afterwards, normal pellet food and tap 
water were available ad libitum.  
Mice were subjected to inhalation of 2% isoflurane for induction and maintenance of anesthesia. The 
animals were gently fixed to a heating pad (37 °C) and after weighing, the abdomen was shaved and 
prepared with a 2% chlorhexidine gluconate/70 % isopropyl alcohol solution. A single injection of pain-killer 
(5mg/kg, Melovem) was administrated subcutaneously. A 1.5 to 2cm midline laparotomy was then made. 
With the help of atraumatic forceps, the stomach was exteriorized. A small gastrotomy was then made along 
the anterior border of the stomach and crossing the SCJ. Gastric contents were emptied as much as possible 
using atraumatic forceps and cotton swaps. Using a cryo-pen (Cryoalfa LUX), liquid nitrogen was applied to 
the posterior wall of the stomach at the SCJ in order to ablate the epithelium. Liquid nitrogen was applied 
twice in the same location for 10 seconds each time. The stomach was closed with continuous stitches using 
an 8/0 non-absorbable suture. The sutured stomach was placed back inside the peritoneal cavity and the 
abdominal wall and skin were closed separately using a 5/0 vicryl absorbable suture.  
Postoperatively and after recovering from anesthesia, mice received liquid food for three consecutive days, 
wherein on the third day they had available both liquid and normal pellet food. Antibiotic water (400g/ml, 
Baytril 2.5%, Bayer) was also present for the first five days after surgery. Afterwards, autoclaved tap water 
was available ad libitum. The animal cages were kept on a warming blanket for the first 24 postoperative 
hours. Animals were euthanized if they displayed signs of suffering, such as >15% weight loss after surgery. 
Throughout the experiment, mice received daily oral gavage of omeprazole (400mol/kg, Teva) and i.p. 




 lineage tracing mouse model  
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K5-GFP mice were generated by crossing Rosa26-Tomato-loxP [stop] loxP-GFP (JAX stock #007576) 
purchased from the Jackson Lab, with K5-creERT2 mice, kindly donated by Dr. Chen28. Genotyped positive 
K5-GFP mice were housed in +/+ IVC cages in ventilated racks in the ARIA. Experiments were performed on 
12 weeks old mice, both female and male. To induce lineage tracing of K5 cells, mice received i.p. injection of 
tamoxifen (0.25mg/kg) one day before the ablation procedure. The K5-GFP mice stomach was ablated as 
described above. For 14 days, the mice received daily oral gavage of omeprazole (400mol/kg, Teva) and i.p. 
injection of either saline (control group) or anti-BMP2/4(500μg/ml; treatment group)17. 
 
Immunohistochemistry  
Formalin-fixed, paraffin-embedded tissue samples were used for IHC. Slides with 5µm thick sections from 
the paraffin blocks were cut and deparaffinized in xylene and rehydrated in a graded series of ethanol. 
Antigen retrieval was performed in citrate buffer saline (0.01mol/L, pH 6.0) for 20 min at 98 degrees. 
Endogenous peroxidase activity was blocked by incubation of slides in 3% H2O2 for 30 minutes, followed by 
10% normal goat serum for 30 min to block nonspecific bindings. Slides were incubated at room 
temperature for 2h or overnight at 4ᵒC, with primary antibodies as listed in Table S2. Slides were washed in 
TBS + 1%Tween® 20 and incubated with the respective biotin linked secondary reagents from the LSAB™2 
Kits (Dako) following the manufacturer’s protocol. Peroxidase activity was visualized using DAB+ (Dako). 
Finally, sections were counterstained with Mayer’s hematoxylin, dehydrated and mounted. 
 
Table S2: List of the antibodies used in Immunohistochemistry. 
Antibody Clone Dilution Company 
BMP2 - 1:100 Biosciences 
BMP4 - 1:400 Abcam 
CDX2 CDX2-88 1:200 Biogenex 
Human mitochondria - 1:1000 Abcam
Involucrin SY5 1:100 Covalab 
K5 EP1601Y 1:200 Epitomics 
K14 LL002 1:200 Abcam 
K19 - 1:200 Epitomics
Ki67 - 1:200 Thermo Scientific
p63 4A4 1:100 Santa cruz 
pSMAD1/5/8 - 1:100 Millipore 
SOX2 - 1:200 Epitomics 
MUC5AC - 1:100 ThermoFisher Scientific
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Noggin - 1:100 Epitomics
 
Immunofluorescence 
Tissue slides were de-paraffinized and antigen retrieval was performed in citrate buffer pH 6. Slides were 
blocked in 10% goat serum for 10 min and treated with the avidin/biotin blocking kit (Vector lab). Slides 
were incubated with primary antibodies Noggin (1:100 epitomics) and Ki67 (1:100 Thermo Scientific), 
washed with TBS + 1%Tween® 20 and incubated with goat-anti-rabbit-fluor488. Glass slides were mounted 
with DAPI (Roche, Mannheim, Germany)/vectashield (Vector laboratories Inc, Burlingame, CA, USA). Images 




qPCR data was tested for a normal distribution using the Shapiro test. The Mann-Whitney U test was 
performed to investigate differences in expression of each gene between Barrett’s esophagus and normal 
squamous tissue. Genes with a p < 0.05 were considered differentially expressed. 
Statistical differences in protein level were determined using Kruskal-Wallis test in a multiple comparison  
1-way ANOVA. 
Paired t-tests were performed to test statistical differences in mRNA expression of BMP2,4,5,6 and 7 and 
SHH in cells treated with bile acids at different timepoints. Statistical significance was set at p < 0.05. 
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Figure 1: [A] Clustering of RNA expression in biopsies from Barrett’s and squamous tissue 
(Squamous) and from a validation cohort (Wang 2013, GSE26886). [B] qPCR of SHH/WNT pathway 
genes in biopsies from Barrett’s and squamous tissue from AMC patients (left), and from a validation 
cohort (right) (Wang 2013, GSE26886). Genes significantly differentially expressed in Barrett’s 
compared to squamous in the AMC cohort (p < 0.05). [C] Western blot of BMP2, 4, 5 and 6 in Barrett 
patient’s biopsies (left panel). Levels of BMPs in Barrett’s biopsies were quantified and normalized to 
squamous tissue. Data are represented as mean (± SEM) of three independent experiments 
performed in triplicate. Multiple comparison 1 way-ANOVA *p < 0.05 and **: p < 0.01. SEM: Standard 
error of the mean; ns: not significant.  
 
Figure 2: [A] H&E and IHC for CDX2, p63 and K5 of an organoid obtained from a biopsy taken at the 
SCJ from a Barrett’s patient. [B] IHC staining of p63+ remnant cells (arrows) in a Barrett’s biopsy. 




Figure S3: IHC staining of squamous and Barrett’s biopsies in comparison with the corresponding in 
vivo Barrett’s organoid treated with Saline or BMP2/4 inhibitor. IHC staining for pSMAD1/5/8, Ki67, 
K19, SOX2 and Involucrin. Hematoxylin was used as a counterstain. (Scale Bar 200 µm) 
 
 
Figure S4: The effect of anti-BMP2/4 treatment on the intestine of WT mice. [A] H&E staining of the 
small intestine in mice at different time points of anti-BMP4 or anti-BMP2/4 treatment. [B] H&E of 
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the colon 18 and 42 days of treatment with antibmp2/4, and after stopping treatment for 4 weeks. 




Figure S5: Noggin-/- mice injected with Tamoxifen for 3 days (i.p.) and compared to control mice 
(Noggin-/- without Tamoxifen injection) [A] The stomach entrance, forestomach, stomach body, 
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antrum, intestine and colon were stained for Noggin by immunofluorescence and counterstained 
with DAPI. [B] Immunofluorescence for BMP4 and Noggin of the SCJ, 24 weeks after tamoxifen 
injection. Hematoxylin and DAPI were used as counterstain. [C] IHC of p63 and ki67 of the 
forestomach. Alcian Blue staining and IHC for ki67. Hematoxylin or DAPI were used as counterstains. 
(Scale Bar 100 µm) 
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